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1. LIVER CANCER 
1.1. Introduction 
With an average 5 year survival of 17,5%, primary liver cancer poses a major 
health issue(1, 2). Primary liver cancers can be categorised as hepatoblastoma 
(cancer of fetal liver cells or hepatoblasts), angiosarcoma (cancer of the inner lining 
of blood vessels or endothelium), intrahepatic cholangiocarcinoma (iCC, tumour of 
bile duct epithelial cells or cholangiocytes) and hepatocellular carcinoma (HCC, 
tumour of liver epithelial cells or hepatocytes). The latter two, being the most 
common in adults, also occur together as the mixed hepato-cholangiocarcinoma 
(HCC-CC), which could be liver progenitor cell (LPC) derived. HCC, which 
accounts for 80% of all primary liver cancers, is the fifth most common -and the 
second most deadly cancer worldwide (1-3).  
Cancer generally develops in different stages. In short, during tumour initiation, one 
or more cells gather enough pro-oncogenic mutations to initiate neoplastic 
transformation, which allows them to escape normal tissue homeostasis and 
increase their proliferation capacity (4). During tumour progression, the transformed 
cell(s) proliferate and form small neoplastic nodules.  
The increased proliferation rate allows more mutations to build up, causing tumour 
heterogeneity. Continuous exposure to different stressors like oxygen and nutrient 
shortage during further growth leads to a selection process where only the best 
adapted and most resilient tumour cells survive (4).  
Eventually, the tumour can become malignant and cells invade the connective 
tissue and penetrate blood and lymphatic vessels, which leads to local and distant 
metastasis (Figure1) (4). 
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Figure1.Stages of cancer development. 
After tumour initiation, the initiated cell starts dividing so a neoplastic nodule is formed. While 
the tumour grows, cells in the nodule progress by acquiring more mutations, causing tumour 
heterogeneity, indicated by different shapes and colours in the figure, increasing malignancy. 
Eventually cells invade the extracellular matrix and can metastasise through blood and 
lymphatic vessels. 
Over 80% of primary liver tumours develop in a background of chronic liver 
disease, where continuous injury leads to (1) DNA damage, resulting in an 
accumulation of pro- oncogenic mutations and (2) continuous tissue damage and 
repair which is associated with excessive proliferation (3, 5). Furthermore, 
continuous activation of inflammatory and repair pathways help create ideal 
conditions for tumour growth (3, 6, 7). 
1.2. Clinical aspects of hepatocellular carcinoma 
The major cause of HCC in Asia and sub- Saharan Africa is hepatitis B virus 
infection, where carriers may develop HCC with or without development of 
cirrhosis. AflatoxinB1 exposure and alcohol abuse are also major risk factors. In 
Western countries, hepatitis C virus-induced cirrhosis is the most common risk 
factor. Due to the obesity epidemic, non- alcoholic fatty liver disease and non-
alcoholic steatohepatitis-induced HCC incidences are on the rise (7, 8). 
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Ultrasound abdominal scanning is used to screen patients with liver disease, when 
a suspicious nodule is found this is then further characterised using computed 
tomography or magnetic resonance imaging. Diagnosis can then be reinforced 
and/or specified by performing biopsies and blood tests for alpha-fetoprotein (AFP). 
While AFP measurements are inexpensive, simple and a very helpful tool to 
measure therapy response or potential recurrence, increased AFP levels are 
detected in only 40-65% of HCC patients, decreasing its usefulness to detect 
small/new HCC lesions(8).  
Unlike other types of cancers, staging of HCC is not performed through the 
classical TNM (tumour, lymph Nodes and Metastases) system. Since the 
underlying liver disease is a major factor in patient survival and success or failure of 
the treatment, the Child Pugh score, which categorises liver function (Table1), is 
integrated in the evaluation of the tumour stage (3). Several scoring systems have 
been proposed, all integrating both liver and tumour characteristics; the Barcelona 
Clinic Liver Cancer (Figure 2) is most commonly used to determine treatment (7).  
Table 1: Child Pugh Score (adjusted from(3)) 
 
Points 
1 2 3 
Encephalopathy None 
Grade 1-2 
(Or precipitant-induced) 
Grade 3- 4 
(Or chronic) 
Ascites None 
Mild to moderate 
(diuretic responsive) 
Severe 
(diuretica refractory) 
Bilirubin (mg/dl) <2 2 - 3 >3 
Albumin (g/dl) >3,5 2,8 – 3,5 <2,8 
INR <1,7 1,7 – 2,3 >2,3 
Child Pugh class obtained by adding scores for each parameter 
Class A 5 – 6 points Least severe liver disease 
Class B 7 – 9 points Moderately severe liver disease 
Class C 10 – 15 points Most severe liver disease 
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 Figure 2: the Barcelona clinic liver cancer treatment plan. 
Scheme, showing different treatment options depending characteristics of the hepatocellular 
carcinoma, as well as the severity of the underlying disease (7) 
Potentially curative treatment options 
For small lesions with minimal underlying liver disease (Child Pugh A), ablation 
(destruction of tumour cells without physical removal by surgery) or resection 
(surgically removing nodules) are first-in-line treatment strategies. Five-year 
survival rates are however still estimated between 40% and 80% due to high 
recurrence rates (3, 7). For tumours that are within the Milan criteria, defined as a 
single tumour of ≤5 cm in size or up to three nodules of ≤3 cm in size without 
vascular invasion and are not eligible for resection, liver transplantation is the best 
option. Since transplantation cures both hepatocellular carcinoma and the 
underlying liver disease, the Child-Pugh score is not an issue (3, 7, 9).  
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Non- curative treatment options 
Non-curative treatment options are mostly based on depriving the tumour from its 
oxygen and nutrient supply, decreasing tumour growth and increasing patient 
survival time.  
This can be applied locally or systemically. Most of the normal liver’s blood supply 
comes from the portal vein; in contrast, hepatic tumours receive over 80% of their 
blood supply from outgrowths of arterial branches. This provides a unique tool, in 
which chemotherapeutics or radio-active particles can be administered arterially 
and/or embolization of the feeding artery can be performed to cause maximal 
damage (3, 7, 9). The combination of the two strategies is called transarterial 
chemo–embolization (TACE) or trans-arterial radio-embolization respectively.  
The main purpose is to increase the patient’s life expectancy but these treatments 
are also used to suppress tumour growth in patients within the Milan criteria waiting 
for transplantation and can, in some cases, decrease tumour volume to fit the Milan 
criteria (3, 7, 9). Even though the non- tumorous, ‘healthy’ liver is mostly spared, 
some damage still occurs and the remaining liver function has to be sufficient, 
excluding Child-Pugh C patients. 
Over the years, many systemic treatment options have been tested, with very little 
success due to high cytotoxicity and small effects on tumour size and 
characteristics. Up until now, the only approved systemic treatment is the multi-
kinase inhibitor Sorafenib (Nexavar©) (3, 7, 9-11). The effects of Sorafenib are not 
specific, but the most important mode of action related to HCC therapy is blocking 
the vascular endothelial growth factor and platelet derived growth factor beta 
receptors on endothelial cells. This results in inhibition of the formation of new 
blood vessels (angiogenesis) towards the growing tumour, denying tumour cells 
adequate oxygen and nutrient supply and thus decreasing tumour growth. 
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Indeed, Sorafenib treatment was shown inefficient in reducing tumour volume, but 
was capable of reducing the density of tumour vasculature, attributing to the 
increased survival time (11).  
SHARP (sorafenib HCC assessment randomised protocol trial) investigators found 
a mean overall survival of 10,7 months in the sorafenib treated group compared to 
7,9 months in the control population (11) and an Asian- Pacific study observed a 
mean overall survival of 6,5 compared to 4,2 months (10). Unfortunately, beside 
this very mildly increased survival time, sorafenib treatment includes significant 
toxicities (10, 11), and treatment has been shown to induce therapy resistance and 
increased local invasion and distant metastatic capacities (12, 13). 
1.3. Clinical aspects of iCC and mixed phenotype tumours. 
iCC is staged using an adjusted TNM staging system (Table 2) and, depending on 
the stage of the tumour upon diagnosis, average 5 year survival of iCC is 2 – 15%. 
The only curative treatment is full resection of the tumour, which, unfortunately, is 
only an option for very few patients and is still accompanied by a five year survival 
of only 8 – 47 % (5, 6). So far, no benefits have been confirmed for using adjuvant 
radio- and/or chemotherapy. Furthermore, due to high recurrence rates (up to 90% 
within 2 years), liver transplantation for cholangiocarcinoma is contraindicated. 
Palliative treatment is the only option for the majority of patients, with a mean 
overall survival of 3 to 6 months depending on the possibility of biliary drainage (5, 
6, 14). 
HCCs with a cholangiocytic phenotype and HCC-CC tumours, clinically present as 
HCC tumours. However, both tumour phenotypes have to be taken into account for 
treatment, decreasing treatment options and survival rates compared to single 
phenotype tumours. Mixed phenotype tumours can occur in different “subtypes” 
depending on the interaction between the HCC and iCC compartment.  
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Firstly, HCC and iCC can present at different locations in the same liver. Secondly, 
tumours can present next to each other, intermingling only at the site of overlap. 
Lastly, one tumour can carry histological features of both HCC and iCC.  
It is unclear which of these tumours originate from hepatocytes/cholangiocytes and 
alter their phenotype throughout disease progression to adapt to environmental 
stresses, and which HCC-CC tumours arise from a common liver progenitor cell 
(LPC), able to differentiate towards both a hepatocytic and a cholangiocytic 
phenotype (15-17).  
Table 2: TNM and AJCC/UICC staging systems for intrahepatic CCA (5) 
TNM stage Criteria 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Solitary tumour without vascular invasion 
T2a Solitary tumour with vascular invasion 
T2b Multiple tumours with or without vascular invasion 
T3 
Tumour perforating the visceral peritoneum or 
Tumour involving local extrahepatic structures by direct invasion 
T4 Tumour with periductal invasion 
N0 No regional lymph node involvement 
N1 Regional lymph node metastases 
M0 No distant metastases 
M1 Distant metastases 
Stage Tumour Node Metastasis 
0 Tis N0 M0 
I T1 N0 M0 
II T2 N0 M0 
III T3 N0 M0 
IVa 
T4 
Any T 
N0 
N1 
M0 
M0 
IVb Any T Any N M1 
Currently, research is focusing on predicting prognosis and therapy response 
through identification of specific characteristics, like stem/progenitor cell markers, 
or activation specific pathways, like hypoxia or Notch signalling, which could be 
used as markers to predict prognosis and response to therapy(15, 18-21).  
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Therapeutic options for advanced liver cancer are mostly based on depriving the 
tumour of its nutrient and oxygen supply, which can lead to activation of the hypoxic 
adaptive response and result in increased expression of liver progenitor cells, both 
linked to therapy resistance and poor prognosis (13, 22-28). Further research, 
investigating the effect of hypoxic conditions on disease progression and the 
expression ofliver progenitor cell characteristics in HCC is necessary to unravel the 
interplay between these tumour characteristics. 
1.4. Mouse models for Liver Cancer 
Carcinogenesis evolves from a multitude of genetic alterations and mutations that 
eventually lead to the transformation of cells, enabling them to bypass the immune 
response and cell death and increase their proliferative capacity (4). The different 
kinds of mouse models that are being used to study hepatocarcinogenesis can be 
classified into genetic, carcinogen-induced and xenograft models. 
Indeed, several mouse models have been established, to mimic the most common 
genetic alterations (genetic models), allowing the investigation of 
hepatocarcinogenesis which evolves from multiple “at random” hits (carcinogen-
induced), or attempting to study the behaviour of tumour cells in vivo, dissociated 
from normal progression from liver disease to liver cancer (xenograft models) (29). 
Genetic models 
Inducing a mutation, which is commonly observed in HCC, allows researchers to 
study its effect and importance in the induction of specific pathways, tumour 
growth, progression and therapy response.  
However, inducing one specific mutation is not entirely representative of human 
disease, where a plethora of interactions and underlying disease precede 
tumourigenesis. 
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Constitutive gene expression (target gene is expressed or deleted in all cells) can 
be used for non- lethal mutations, that only affect the organ or cell-type of interest. 
For liver cancer this method has been used to replicate hepatitis B virusand 
hepatitis C virus–mediated carcinogenesis by inserting constructs coding for viral 
particles involved in the induction of HCC (30, 31). Tumourigenesis can be 
activated by overexpressing (proto)oncogenesor reducing the expression of tumour 
suppressor genes, a short overview of mutations used for HCC induction, are 
provided in table 3. Since constitutive over/under expression of these genes can be 
lethal, interfere with embryonic development or induce random tumours in different 
organs, several cell-specific (conditional) gene expression systems were 
developed, of which we will describe the Cre-lox system as it was used in this work. 
In the Cre-Lox system, expression of the site specific Cre-recombinase 
(Bacteriophage P1 derived) is controlled by a specific promoter sequence, resulting 
in tissue/cell specific inversion, deletion or translocation of sequences flanked by 
constitutively inserted LoxP sequences (32-34). 
LoxP sites that are oriented in the same direction result in Cre-mediated excision of 
the loxP flanked gene/sequence, however, if LoxP sites are oriented in opposite 
directions, Cre activity results in an inversion of the sequence between the lox-
sites, and loxP sites on different chromosomes will induce a Cre-mediated 
translocation (Figure 3A) (32). The development of these systems has allowed 
researchers to investigate the effect of (proto) oncogenes and tumour suppressor 
genes on specific cell populations in the liver. Most commonly used liver specific 
promoters are albumin (Alb, expressed by mature hepatocytes) and Afp  (targeting 
all hepatoblast derived cells: hepatocytes, cholangiocytes and LPCs) (33, 34). 
Sox9, hepatocyte nuclear factor 1 beta (Hnf1-b) and Osteopontin (Opn) promoters 
have been used to examine the effect of gene expression in the biliary line 
(cholangiocytes and LPCs) (34, 41-45). 
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Table 3: Genetically induced liver tumours (adjusted from (35))  
Type Gene 
Liver 
specific 
Tumour 
type 
Time to 
induction 
Ref 
(P
ro
to
) 
o
n
co
ge
n
es
 
o
ve
re
xp
re
ss
io
n
 
TGF alpha Yes HCC 9 -15 months (35, 
36) c-Myc + TGF alpha Yes HCC 8 months 
Beta Catenin+ H-RAS No HCC 6 months 
(35) 
PDGF No HCC 12 months 
c- Met No HCC 12 months 
HBV large envelope 
polypeptide 
No HCC 18 – 21 months 
HBx No HCC 11- 15 months 
HCV core protein No HCC 16 – 19 months 
NRAS and AKT1 Yes HCC 6 months (37) 
Notch1 intracellular 
domain 
Yes 
HCC /  
HCC-CC 
8 - 12 months 
(38, 
39) 
Notch2 intracellular 
domain 
yes HCC 12 months (40) 
Tu
m
o
u
r 
su
p
p
re
ss
o
r 
K
n
o
ck
 o
u
ts
 
PTEN Yes HCC 18 months 
(35) 
MDR2 No HCC 16 months 
TAK2 Yes HCC 4 – 8 months 
Nemo Yes HCC 12 months 
CYLD No HCC 10 – 12 months 
TSC1 Yes HCC 9 – 10 months 
Mcl1 Yes HCC 18 months 
BCL-xL Yes HCC 18 months 
APC Yes HCC 8 – 9 months 
P53 Yes HCC-CC 5 months 
The Cre- lox system was further improved by fusing the Cre protein with the 
tamoxifen sensitive domain of the estrogen receptor (ERT or ERT2 systems) 
resulting in a Cre protein that is cytosol bound until the administration of tamoxifen, 
allowing migration to the nucleus and lox excision (Figure 3C) (46, 47). This iCre is 
only activated while tamoxifen is present, so only cells expressing iCre at the time 
of tamoxifen induction, and their direct progeny, will present with the mutation after 
tamoxifen is cleared (46, 47).  
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Figure 3: Models for site specific recombinase 
A. LoxP sites that are oriented in the same direction result in Cre-mediated excision of the loxP 
flanked gene/sequence, however, if LoxP sites are oriented in opposite directions, Cre activity 
results in an inversion of the sequence between the lox-sites, and loxP sites on different 
chromosomes will induce a Cre-mediated translocation B. Cre activity is restricted to cells 
expressing the Cre protein C. iCre- lox system: The fusion of the Cre protein with the tamoxifen 
sensitive domain of the estrogen receptor (ERT) ensures that Cre activity occurs only in cells 
expressing a specific promoter sequence after tamoxifen is administered. 
For a cell specific knockout, the Lox sequences are placed before and after (a 
crucial intron of) the gene of interest (also called “floxing”), resulting in gene 
inactivation upon Cre-mediated Lox excision (Figure 3B,C) (32). The Rosa26 
promoter, which has been shown to be ubiquitously expressed in all cell types, 
followed by a lox flanked stop codon and the gene of interest is used for tissue 
specific gene induction. Here, the stop codon inhibits expression of the inserted 
gene in all non-Cre expressing cells (Figure 3B,C)(48).  
C B 
 
A 
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Chemically induced HCC 
Introducing mutagenic toxins to the liver allows researchers to follow the entire 
process of carcinogenesis, starting with the induction of DNA damage and 
inflammation, resulting in continuous activation of damage and repair mechanisms, 
eventually leading to neoplastic transformation and carcinogenesis.  
Commonly used carcinogens to induce liver cancer are Aflatoxine, thioacetamine 
and, most commonly used, diethylnitrosamine (or N-nitrosodiethylamine; DEN) (30, 
31, 49). 
The downside to using chemicals to induce liver cancer is that due to the 
unpredictability of the mutations, there is a high variability between animals. 
However, these variations are a better representation of the human population 
which is of interest for drug testing studies.  
Since we used DEN to induce HCC in our studies, we will shortly discuss this 
compound. Upon liver uptake, DEN is first hydroxylated into ɑ-hydroxylnitrosamine 
by the cytochrome P450 enzyme-system, after which the acetaldehyde group is 
cleaved, and the highly reactive, electrophilic ethyldiazonium ion is formed. 
Culmination ofDNA damage-induced by ethyldiazonium and reactive oxygen 
species, formed by the cytochrome P450, results in dose-dependent DNA damage, 
resulting in mutations and eventually tumour initiation.  
DEN mostly induces activation of the proto- oncogene H-RAS, which is also seen in 
human HCC with poor prognosis(50). The effects of DEN are dose, interval, age, 
sex and strain related (30, 49, 51, 52). All mice strains can develop HCC, however, 
there appears to be a delay of several months between highly resistant (like 
C57Bl6) and very susceptible strains (like C3H). In younger mice, the enzymatic 
competence rises to reach a peak at 7 to 15 days of age, at this time susceptibility 
to hepatocarcinogenesis is at a maximum for both male and female mice. Next, the 
metabolic capacity decreases, and does so faster in females than males (52).  
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In our lab, we have previously validated a protocol in which male sv129 mice are 
injected with 35mg/kg of DEN at a weekly base, starting from 5 weeks of age. In 
this model, neoplastic lesions are observed from 15 weeks onwards and mice 
develop HCC with 100% penetrance from 25 weeks onwards (29). In this model, 
we can observe HCC lesions in a background of minor fibrosis (metavir score F1 – 
F2) (29).  
Xenograft models 
Axenograft is defined as the transplantation of cells or tissues from one species to 
another. In cancer research, human cancer cell lines are often used to test the 
response of cancer cells to therapeutic regimens or conditions. To investigate the 
effects in an in vivo situation, these cancer cells can also be injected 
subcutaneously or orthotopically (in the organ in which the original tumour 
originated) in immunodeficient mice (30, 31, 49).  
Severely compromised immunodeficient or nude athymic mice are mostly used 
since the lack of T-cell response in these mice ensures that cancer cells will not be 
cleared by the adaptive immune response. The major advantage of using a 
xenograft model is that the process of tumour formation is fast(2-6 weeks) 
compared to orthotopic models. These models are also excellent for preclinical 
cytotoxicity, pharmacological and pharmacokinetic drug tests (53).  
A major downside to using established cancer cells is that each cell line has 
specific, characteristics, which cannot always be correlated to heterogeneous 
tumours observed in the clinic (53). Furthermore, interaction between the immune 
system and the cancer cells is by definition lacking, further decreasing 
transferability to the clinic (53).  
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One way around this is the use of a syngeneic model, like Hepa1-6 mouse 
hepatoma cells originating from C57/Bl6 and transplanting these cells in the liver of 
C57/Bl6 mice. Since these mice are frequently used to study liver damage, this 
allows injection of tumour cells in a diseased liver, permitting researchers to 
investigate the role of the underlying chronic liver disease in tumour growth and 
progression. Next, cells can be extracted from human tumours, and directly used in 
xenograft models, to evaluate the response of the tumour to specific treatment 
regimens (54). Optimisation of this technique can prove to be a valuable clinical 
tool and will open a window for personalised treatment.  
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2. LIVER PROGENITOR CELLS 
2.1. Introduction 
Microscopically, the liver is made up of many hexagonal structures, which are each 
comprised of a central vein, which will eventually debouch into the vena cava 
inferior, surrounded by several portal triades, consisting of tracts from the portal 
vein, hepatic artery and a bile canaliculus (Figure 4A). 
The two main epithelial cell populations in the liver are hepatocytes (or liver cells) 
and cholangiocytes (or bile- duct cells). Hepatocytes are responsible for the major 
part of liver function, including elimination of toxins and regulation of the 
carbohydrate and lipid metabolism. Hepatocytes are arranged in cords called 
hepatic plates (Figure 4B), stretching from a portal triad to a central vein. On one 
side, at the basal surface, a plate is lined by liver sinusoidal endothelial cells 
(Figure 4B), guiding blood flow from the portal tract to the central vein, generously 
allowing diffusion of oxygen, nutrients and toxins along the way. Apically, bile is 
excreted from hepatocytes, where it flows in the canals of Hering (bile canaliculus), 
which are lined by neighbouring hepatocytes (Figure 4B), towards the portal triad. 
At the portal triad the canals of Hering evolve into bile canaliculi, creating a junction 
between cholangiocytes and hepatocytes (Figure 4B), where LPCs can be found. 
In healthy liver, hepatic stellate cells (HSC, liver specific fibroblasts) and Kupffer 
cells (liver resident macrophages) can be found intrasinusoidally (Figure 4B). 
During liver injury, this non-parenchymal fraction is enriched by infiltrating portal 
myofibroblasts and inflammatory macrophages which play an important role in 
disease progression and resolution by contributing to the inflammatory response 
and fibrogenesis(55, 56). Moreover, liver macrophages and myofibroblasts were 
shown to play a major role in the regulation of LPC- cell fate (57). 
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Figure 4: Microscopic structure of the liver 
A. Hexagonal structure of liver plates showing the location of the central vein and the portal 
triade. B. Microscopic structure of the liver showing the location of different cell types. 
Histologically, hepatocytes are defined as large cells that represent the bulk of the 
liver mass (Figure 5). Bile ducts are lined by cubical cholangiocytes that are easily 
distinguished from endothelial cells on haematoxylin-eosin (H&E) stained sections 
(Figure 5A). Biliary structures, including bile ducts and LPCs, can further be 
distinguished from other cell types in the liver by performing a cytokeratin 19 
(KRT19) staining (Figure 5B). 
A 
B 
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Figure 5: Histology of the Liver 
A. H&E and B. cytokeratin 19 (KRT19) stained sections of normal liver, showing biliary structures 
(including LPCs) in brown.C. KRT19 stained sections of mouse liver after receiving the 3,5-
diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet for biliary damage-induced LPC response. D. 
the choline deficient ethionine supplemented (CDE) diet for hepatocellular damage-induced LPC 
response. Scalebars: 20µm for A,B,D and 200µm for C 
2.2. Regulation of LPC differentiation 
Due to the immense self- replicative capacity of hepatocytes and cholangiocytes, it 
is believed that LPCs have little to no function in normal physiological conditions. 
However, upon severe acute or chronic injury, when hepatocytes and 
cholangiocytes can no longer restore liver function by self-replication alone, LPCs 
are activated. LPCs are bipotential stem cells that can differentiate towards 
hepatocytes and cholangiocytes and are most commonly believed to reside in the 
junction between both cell types in the canals of Hering(22, 44, 59). 
Portal Venule 
B A 
Bile Duct 
C D 
KRT19 
KRT19 
KRT19 
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 While interest in the role of LPCs in liver injury, disease and carcinogenesis has 
been massively expanding in the last decade, the exact role for LPCs in liver 
pathology has not yet been determined(60). Upon activation, LPCs proliferate and 
migrate to the site of injury: dispersed throughout the liver lobules to the site(s) of 
hepatocellular damage (Figure 5C) or around the portal triad in case of biliary 
damage (Figure 5D) (42, 44, 59).  
The Notch signalling pathway plays a pivotal role in the regulation of the cell fate of 
LPCs, which hasthoroughlybeen described by Boulter et al. (57). Cholangiocyte 
damage attracts portal myofibroblasts carrying jagged1 (JAG1) ligands, which 
activate the NOTCH signalling pathway in LPCs, resulting in biliary 
differentiation(57). However, during hepatocyte damage, macrophage-produced 
WNT, induced by phagocytosis of hepatocytic debris, inhibits cholangiocellular 
differentiation and drives LPCs towards the hepatocellular lineage (Figure 6)(57).It 
is howeverhypothesised that when these mechanisms fail to adequately repair cell 
damage, a ductular reaction, consisting of cholangiocytes, inflammatory cells, 
stellate cells and LPCs, is formed (pathological repair), which contributes to 
fibrogenesis and  further liver damage(57, 61).Further investigating the exact 
triggers for hepatocyte debris-mediated, macrophage-derived Wnt signalling and 
cholangiocyte damage-induced NOTCH ligand expression could allow the 
identification of new therapeutic targets to inhibit or ameliorate the response in 
pathological conditions. 
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2.3. Liver progenitor cell characteristics in liver cancer 
LPCs are a heterogenous cell population characterised by the expression of stem 
cell characteristics, cholangiocyte markers and early hepatocyte features, each to a 
variable extent (22, 44, 59). This heterogenousity severely complicates LPC 
research, different groups use different markers for characterisation and isolation 
studies, making it unclear whether results can be extrapolated or if we are even 
investigating the abilities of the same cell population (22, 44, 59, 62).  
 
Figure 6: Notch is a crucial factor in LPC cell fate decisions 
In biliary regeneration, the interaction of LPC with myofibroblasts attracted by biliary injury 
results in jagged 1 mediated activation of the Notch signalling pathway in LPCs, leading to 
biliary specification During hepatocellular regeneration macrophage derived Wnt signalling 
activates the Wnt- pathway through interaction with Frizzled receptors in LPCs which results in 
differentiation towards a hepatocellular phenotype 
Cell populations exhibiting LPC characteristics have been called “ductular 
hepatocytes”, “atypical ductal cells”, “intermediate hepatobiliary cells”, “hepatic 
progenitor/stem cells” and “oval cells”, and the same general set of characteristics 
are expressed by so- called side population cells (which are isolated from other 
tumour cells by their ability to efflux Hoechst 33342, caused by the expression of 
multi drug resistance proteins) and to define the “cancer stem cell” (CSC) (22, 44, 
59).  
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Throughout this work, we will define LPC as single KRT19 positive cells (in contrast 
to KRT19+ cholangiocytes that are part of a canalicular structure) residing around 
the portal tract and “cells with (increased) expression of LPC characteristics” for 
cells of which the cellular ontogeny is unclear, i.e. in liver cancer. Several studies 
have demonstrated that cells with LPC characteristics are part of the tumour niche 
in primary liver tumours (19, 63, 64) and increased expression of LPC markers like 
KRT19, prominin1 (PROM1), epithelial cell adhesion molecule (EPCAM) and AFP 
have been shown to be related to poor prognosis in HCC (19-21, 65-68).  
The predisposition of primary liver tumours to develop in a background of chronic 
liver disease in which there is an increased proliferation of progenitor cells (27, 69), 
increases the likelihood of progenitor cells accumulating and stabilizing enough 
mutations to obtain a cancerous phenotype. It may thus be possible for LPCs to 
transform into (hepatic) cancer stem cells and grow into primary liver tumours (70, 
71). It has been shown that HCC-CCs can be progenitor cell derived, however, 
there is a broad range of tumours that carry both phenotypes that are not 
necessarily LPC derived (17). In HCCs with cholangiocellular or LPC features for 
example, these characteristics can be gathered over time, during tumour 
progression. Researchers have demonstrated that HCC-cells and hepatocytes can, 
in certain conditions, de- or transdifferentiate towards a more cholangiocyte or 
LPC- like phenotype, characterised by expression of biliary markers like KRT19, 
EPCAM and SOX9(72-74). This suggests that HCC-CC tumours could also arise 
through de- or transdifferentiation of HCC-cells. In the mouse models used 
throughout this thesis, HCC with increased LPC or cholangiocellular characteristics 
will be defined by coexistence of (pre)neoplastic hepatocellular lesions and biliary 
neoplastic lesions in the same liver and/or increased expression of biliary and LPC 
markers like KRT19, EPCAM, SOX9 and PROM1. 
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Many different factors are believed to be involved in the regulation of the 
expression of LPC characteristics in HCC, some of which have been extensively 
described in our review entitled “the roles of transforming growth factor – beta, 
WNT, NOTCH and hypoxia on liver progenitor cells in hepatocellular carcinoma” 
(22). For the purposes of this thesis, we will only focus on hypoxic and Notch 
signalling in the next section. 
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3. HYPOXIA AND NOTCH SIGNALLING 
3.1. Molecular factors in the hypoxic response 
When the oxygenation of cells or tissues is insufficient, they become hypoxic. 
Hypoxia can result from reduced oxygen tension in the blood flow or from an 
insufficient blood supply to affected cells. Cellular adaptation to hypoxic conditions 
is mainly regulated by the hypoxia inducible factor (HIF) pathway, which is mostly 
regulated by prolyl hydroxylase domain (PHD) proteins that serve as oxygen 
sensors: in normoxic conditions, they use available O2 to hydroxylate the 
continuously produced hypoxia inducible factors 1 and 2 alpha (HIFα), resulting in 
ubiquitination and HIFα – degradation (Figure 7) (75-78). When the oxygen supply 
is low, PHDs can no longer hydroxylate HIFα, resulting in stabilisation and 
migration to the nucleus. Here, HIFαdimerises with the hypoxia inducible factor 1 
beta subunit, and binds DNA, where the complex acts as a transcriptional regulator. 
Altered gene expression then changes the cell’s metabolic state by, firstly ensuring 
survival, proliferation and adequate energy production in anaerobe conditions (like 
glucose transporter 1, GLUT1; phospho-fructokinase, PFK) and secondly, several 
pro–angiogenic (like VEGFA) and erythropoiesis stimulating cytokines (like 
Erythropoietin) increase oxygen supply (27, 75, 79, 80). This reaction to hypoxic 
conditions is called the ‘hypoxic adaptive response’ (Figure 6) (75-77, 79).  
There are three main mammalian PHD homologs: PHD1, PHD2 and PHD3 and 
while their regulation and function is mostly similar, some discrepancies do exist. 
While PHD1 and 3 are believed to hydroxylate HIF2α more efficiently, PHD2 is 
more abundant and has a strong preference for the hydroxylation of the hypoxia 
inducible factor HIF1α subunit over HIF2α(81).  
This explains why PHD2 deletion cannot be overcome, while other PHDs can 
compensate for the loss of PHD1 or 3.  
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Moreover, expression of PHD2 and 3is upregulated upon increased HIF signaling, 
a negative feedback loop that ensures rapid HIFα degradation upon 
reoxygenation(81). PHDs can also hydroxylate other substrates, like the IκB kinase 
(IκK), inactivating its activity(81, 82). In hypoxic conditions, unhydroxylated IκK is 
able to phosphorlylate the nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor alpha resulting in transcriptional activation of nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB), inducingpro-survival, anti- 
apoptotic and pro-inflammatory signaling. Moreover reports have shown that NF-κB 
signaling is essential for activation of the HIF signaling pathway (82, 83).  
In physiological conditions, this system prevents massive cell death during 
organogenesis, wound healing and decreased oxygen intake. However, the same 
mechanism is also activated in pathological conditions coinciding with reduced 
oxygen tension, like chronic liver disease and cancer (25, 27, 28, 79, 80, 84). In this 
case promoting cell survival and inducing angiogenesis contributes to disease 
progression. 
 
Figure 7. General schematic 
of the activation of the 
hypoxic adaptive response. 
In normoxic conditions (high 
O2) the prolyl hydroxylase 
domains (PHD) can hydrox-
ylate the hypoxia inducible 
factor alpha (HIFɑ) resulting in 
its degradation. In hypoxic 
conditions (low O2) PHD can 
no longer utilize oxygen for 
HIFɑ hydroxylation, causing 
stabilisation and migration of 
the HIFɑ protein to the 
nucleus. Here the HIF complex 
acts as a trans-activator for 
pro- survival genes. 
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3.2. Molecular factors in NOTCH signalling 
The Notch pathway is important in stem cell self-renewal, and plays a special role 
in the control of many binary cell fate choices in embryonic and adult cells (85). 
Notch signalling is also involved in several fundamental cell regulatory processes 
such as proliferation, apoptosis and epithelial to mesenchymal transition (EMT)(85). 
There are 4 NOTCH receptors and 2 types of ligands described in mammals: the 
NOTCH 1, NOTCH 2, NOTCH 3 and NOTCH 4 receptors, and the jagged and 
Delta ligands. Ligand binding to the N- terminal extracellular domain of the receptor 
triggers cleavage of the C- terminal NOTCH intracellular domain (NICD) (Figure 8) 
(34, 85-89). NICD cleavage is a two-step process, the second step, mediated by 
the presenilin-gamma-secretasecomplex, which is composed of 5 subunits: 
presenilin 1 and 2, nicastrin, presenilin enhancer 2, and anterior pharynx-defective 
1(85, 89). Upon its release into the cytoplasm NICD migrates to the nucleus, binds 
toCSL (CBF1/Su(H)/Lag-1), and recruits co-activators, such as mastermind–like, to 
induce NOTCH-dependent gene transcription (Figure 8).  
The two major targets are the Hairy and HES-related repressor protein families of 
transcription factors (HES and HEY) and the MYC transcription factor (85, 89). The 
list of target genes and role in different physiological and pathological events are 
both cell type and receptor specific (89-91). 
3.3. Hypoxia in primary liver cancer 
Chronic liver disease is characterised by inflammation which, amongst others, 
causes an increased metabolic rate, oxygen need and NF-kB activation, leading to 
activation of the hypoxic adaptive response(83). Moreover, the accompanying 
fibrogenesis results in increasing rigidity of the organ, which causes portal 
hypertension and reduced blood flow to the liver. Together this indicates that, in 
tumours arising in a background of chronic liver disease, the hypoxic adaptive 
response can already be activated at tumour initiation. 
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Figure 8: Mechanism of 
NOTCH pathway activation 
Ligand binding induces 
gamma secretase-mediated 
cleavage of the NOTCH 
intracellular domain (NICD). 
NICD then migrates to the 
nucleus were it transactivates 
genes involved in several cell- 
regulatory processes. 
During progression, oxygen deprivation is further accomplished by inadequate 
blood supply to growing tumours (29, 92). In addition, treatment strategies for 
advanced HCC, like TACE and Sorafenib are based on depriving the tumour from 
its oxygen supply to reduce tumour growth, however, this could also result in 
activation of the hypoxic adaptive response, which stimulates survival and pushes 
the environment to increase oxygen delivery, which can severely aggravate tumour 
growth and survival and certainly influence progression (79).  
Increased expression/stabilisation of HIFα has independently been correlated with 
poor prognosis (25, 79, 93, 94) but has also been shown to induce therapy 
resistance (12, 23, 26, 95), metastasis (13, 28, 96) and expression of 
stem/progenitor cell characteristics (24, 97, 98) in several cancers, including HCC. 
Furthermore, in tumours recurring in HCC patients that underwent TACE treatment 
followed by transplantation, the more aggressive HCC-CC phenotype was 
observed in recurring tumours (99, 100). This phenotypic switch was accompanied 
by increased expression of LPC characteristics, which was also observed after 
tumour resection (24, 101).  
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While little is known concerning the role of PHD1 and 3 in HCC, previous studies in 
our lab have shown that in DEN-mediated HCC induction in PHD2 haplodeficient 
mice also results in the development of a mixed HCC-CC phenotype with increased 
expression of LPC characteristics (27). 
A HepG2 xenograft study has also shown an increased amount of side population 
cells after laminin treatment (16), showing the potential of HCC- cells to 
dedifferentiate, and an in vitro study has shown that this de- or transdifferentiation 
can also be induced by exposure of HCC cells to reduced oxygen tension (74). 
 In addition, it was also shown that hepatocyte transdifferentiation is reversible in 
vitro(102, 103). Together, these data show that increased hypoxic signalling can 
induce de- or transdifferentiation of HCC cells, but also that the original phenotype 
could be restored. A better understanding of the mechanisms involved in the 
increased expression of LPC characteristics by HCC cells, could lead to the 
discovery of new therapeutic targets that could inhibit the observed hypoxia-
induced phenotypic changes. 
3.4. NOTCH signalling in primary liver tumours 
Aberrant NOTCH signalling is well described in many different kinds of cancer, 
such as breast, lung, colorectal, pancreatic and hepatic cancer (24, 63) and has 
been described as both oncogenic and tumour suppressive, depending on tissue 
type and circumstances (63-65). The role of NOTCH signalling is now also being 
extensively studied in hepatocellular carcinoma(34). 
 Liver specific overexpression of NICD1 (using both Afp:Cre and Alb:Cre mice) has 
been shown to induce liver tumours with biliary features (38, 39), which were also 
observed in livers with hepatocyte- specific NICD2 overexpression (104).  
NOTCH2 overexpression in hepatocytes was shown to rapidly induce hepatocyte 
dedifferentiation (104), which indicates a role for NOTCH signalling in the 
dedifferentiation of hepatocytes.  
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The gamma secretase complex is not only an essential factor in NOTCH cleavage, 
it is involved in the intramembranous cleavage of several proteins like E-Cadherin, 
N-Cadherin, CD44 and the amyloid precursor protein (105), which is important in 
the pathogenesis of Alzheimer. This resulted in the development of many 
compounds to inhibit this complex, gamma secretase inhibitors (GSIs), to decrease 
amyloid plaque formation in the progression of Alzheimer’s disease (105). 
However, due to the overlapping function, these GSIs have also been shown 
effective in inhibiting NOTCH signalling pathways (106, 107). Because of the 
importance of NOTCH signalling during development, in proliferation and cell fate, it 
is not surprising that NOTCH inhibitors, like GSIs could be therapeutic in neoplastic 
malignancies (107, 108). 
Since increased NOTCH signalling induces HCC with the same LPC-like 
phenotype as observed after hypoxic stimuli, and activation of both pathways has 
been shown during hepatocarcinogenesis, it is likely that the NOTCH pathway and 
hypoxic signalling pathways are interconnected in the establishment of the tumour’s 
phenotype in HCC. Indeed, hypoxia has also been shown to induce or maintain a 
dedifferentiated phenotype in different neuronal and myofibroblast-derived cell 
lines, coinciding with increased expression of NOTCH ligands and downstream 
targets (109, 110),administration of a GSI was able to inhibit these effects 
(109).Moreover, using GSI’s in hypoxic conditions, the NOTCH signalling pathway 
has been shown crucial for hypoxia-induced EMT, cell motility and invasiveness 
(111, 112). Interestingly, activation of the HIF signalling pathway was also shown to 
increase the expression of NOTCH ligands and downstream targets (109, 111, 
112) and HIFα has also been shown to induce increased gamma secretase 
activity(113, 114) and/or to bind NICD, augmenting it’s stability. 
Chapter 1 
30 
GSI’s could prove interesting tools to investigate the crosstalk between the HIF and 
NOTCH pathways in hepatocellular carcinoma. However, GSI’s inhibit the four 
NOTCH receptors, and while NICD1 and NICD2 have been shown to be 
functionally equivalent (115), specific NOTCH receptor inhibition had distinct 
outcomes in hepatocarcinogenesis (90).  
Interestingly, NOTCH1 inhibition was shown to have a beneficial effect on HCC but 
drastically increased the iCC burden, while NOTCH2 inhibition positively affected 
HCC load (90). The latter indicates that, while sharing hepatocyte-related effects, 
both receptors possibly have distinct effects on the biliary compartment. Using a 
HNF4:Cre mouse, researchers demonstrated that NOTCH2 overexpression in the 
biliary compartment induces severe ductular reactions (104). In vitro, NOTCH2 and 
4 have been shown essential for LPC proliferation, while NOTCH3 was shown to 
induce hepatocytic differentiation, and no clear NOTCH1 mediated effects were 
described (91). The discrepancies between NOTCH1 and NOTCH2 inhibition in 
HCC could be caused by cell specific effects of inhibiting different receptors. It 
would therefore be important to investigate the effect of NOTCH1 upregulation in 
the biliary compartment.  
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5.1. Abstract 
Primary liver tumours have a high incidence and mortality. The most important 
forms are hepatocellular carcinoma and intrahepatic cholangiocarcinoma, both can 
occur together in the mixed phenotype hepatocellular-cholangiocarcinoma. Liver 
progenitor cells (LPCs) are bipotential stem cells activated in case of severe liver 
damage and are capable of forming both cholangiocytes and hepatocytes. 
Possibly, alterations in Wnt, Transforming growth factor-β, Notch and hypoxia 
pathways in these LPCs can cause them to give rise to cancer stem cells, capable 
of driving tumourigenesis. In this review we summarize and discuss current 
knowledge on the role of these pathways in LPC activation and differentiation 
during hepatocarcinogenesis.  
5.2. Introduction 
Liver cancer is one of the most frequently diagnosed cancers worldwide. Despite 
efforts made, these tumours are often detected in an advanced stage, making liver 
cancer the 3rd most deadly cancer worldwide (1). The most important types of 
primary liver cancer are hepatocellular carcinoma (HCC) and intrahepatic 
cholangiocarcinoma (ICC). HCC often develops in a background of chronic liver 
disease caused by chronic alcohol abuse, viral hepatitis or non-alcoholic 
steatohepatitis, while less is known on potential risk factors for ICC. Both primary 
tumours can be found together in combined hepatocellular–cholangiocarcinoma 
(CHC), which is characterised by a worse prognosis than HCC or ICC (2, 3).  
There are several curative therapeutic options for primary liver tumours including 
resection, transplantation and radiofrequency ablation.  
However, more often than not, these tumours are detected in late stages. At this 
point, existing therapies like anti-angiogenic compounds such as sorafenib and 
transarterial chemoembolisation (TACE) (4), mainly aim to slow down tumour 
growth and increase survival.  
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Unfortunately, these treatment strategies still hold various serious adverse effects 
and therapy resistance, relapse and metastasis remain a real threat (4-6). 
Importantly, anti-angiogenic treatment also sometimes causes increased local 
invasion and metastasis, worsening tumour progression (5). Finally, a phenotypic 
switch from HCC to CHC has been reported after both TACE and increased 
hypoxia inducible factor alpha (HIFα) stabilisation in a mouse model for HCC (6, 7).  
Cancer stem cells (CSC) are cancer cells that possess stem cell characteristics 
such as the ability to differentiate to all cell types found in a particular cancer 
sample and are associated with relapse and metastasis (8, 9). Recently, interest 
has grown in the existence of liver CSC with a liver progenitor cell (LPC) gene 
signature.LPCs are triggered during severe acute or chronic liver injury, during 
which proliferation of mature hepatocytes is inhibited (10). LPC-progeny can 
express hepatocyte- or cholangiocyte-specific lineage markers and experimentally 
have been proven to differentiate into either of these cell types (11-13).  
Possibly, adverse effects often seen following treatment could be caused by 
survival and adaptation of LPC derived CSC.  
This would indicate that LPCs could not only play a role in tumour initiation, but also 
in progression and therapy resistance (14-17). This review will briefly summarize 
the current knowledge on signalling pathways acting in primary liver tumour 
biology, specifically their involvement in LPC activation and proliferation, as well as 
a possible relation between LPCs and CSCs. 
5.3. Liver progenitor cells 
In case of severe hepatic damage, like in elaborate chronic liver injury, when 
proliferation of hepatocytes and/or cholangiocytes alone is insufficient to restore the 
liver mass and function, liver progenitor cells (LPCs) are stimulated to proliferate 
and replace the damaged cell types (12). 
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 Even though LPCs can most commonly be found in the canals of Hering (18, 19), 
several other possible locations have been described: intralobular bile ducts, peri-
ductal cells and peri-biliary hepatocytes (20). Possibly, the LPC niche also consists 
of other actors in liver damage, such as hepatic stellate cells and Kupffer cells (21-
23). Differential interaction with these cells could account for the different 
observations concerning LPC location and factors involved in their activation in 
various models of liver injury (19, 22, 23).The most commonly used markers for 
identification of LPCs, or determination of cells with LPC like characteristics are 
Prominin 1 (CD133), epithelial cell adhesion molecule (EpCAM), alfa-fetoprotein 
(AFP), and (cyto-) keratin 19 (CK19). However, many other stem cell, hepatic and 
cholangiocytic markers are used to characterize LPCs (Table I:selection of LPC 
markers and their potential role in hepatocarcinogenesis) (24-26). Although the 
existence of LPCs and their role in liver injury is generally accepted, and a broad 
range of markers is being used to identify and/or isolate these cells from livers (13, 
19, 27-29), researchers have not yet agreed on a precise set of markers defining 
the LPC population, therefore filtering out the identity of the “true progenitor cell”, 
remains a challenge.  
5.4. Liver progenitor cells in hepatic carcinogenesis 
Several studies have shown that cells with LPC characteristics are part of the 
tumour niche in primary liver tumours (30-32). Because of their multipotent 
characteristics there probably is a role for LPCs in HCC and ICC formation, 
however, due to the dual hepatocytic and cholangiocytic origin, it is CHC that is 
generally presumed to be a progenitor derived tumour (30, 33). 
Currently, there are two major hypotheses on how stem cells influence tumour 
formation. Firstly, the clonal evolution model, which presumes that a single cell 
acquires random mutations and gives rise to a group of identical tumour cells, each 
with equal potential to generate a tumour.  
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Secondly, the cancer stem cell theory proposes that a tumour consists of a 
heterozygous cell population, where only certain cells are able to self–renew and 
differentiate (9).Over the years, CSC have been shown to play a role in the 
development of certain forms of leukaemia and glioblastoma, as well as in several 
solid tumours such as breast, gastric and colon cancer (15, 24, 34) and are now 
being extensively studied in hepatocarcinogenesis (15, 24).The predisposition of 
primary liver tumours to develop in a background of chronic liver disease in which 
there is an increased proliferation of progenitor cells (2, 7) increases the likelihood 
of progenitor cells accumulating and stabilizing enough mutations to obtain a 
cancerous phenotype. It may thus be possible for LPCs to transform into (hepatic) 
cancer stem cells and grow into primary liver tumours(15, 24). So far, several 
pathways have been shown to mediate LPC activation, proliferation and/or 
differentiation. The balance between Wnt and Notch signalling has been proposed 
to be crucial for determination of the LPC cell fate. Activation of the Notch pathway 
is essential for biliary differentiation, as shown by several in vivo and in vitro 
experiments (35, 36). Moreover, in case of hepatocyte injury, activation of the 
canonical Wnt pathway probably prevents activation of the Notch pathway, thus 
pushing LPC differentiation towards hepatocytes (35, 36). Also, interaction between 
tumour cells and the extracellular matrix (ECM) is shown to be essential for tumour 
progression, invasion and metastasis, transforming growth factor-β (TGF-β) 
mediated epithelial mesenchymal transition (EMT) plays an important role in this 
interaction (37). Recently TGF-β signalling has also been linked to the presence of 
LPCs in hepatocarcinogenesis (38). 
The Notch, Wnt and TGF-β pathways are also well known to be involved in many 
tumorigenic processes. For this review we will focus on these three pathways and 
discuss their role in hepatocarcinogenesis, with special attention to their potential 
involvement in LPC and/or CSC–mediated tumour initiation and progression (Figure 
1).  
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Table I: selection of LPC markers and their potential role in hepatocarcinogenesis. 
Abbreviation Full name Role in HCC and/or CC development 
CK7 (cyto) keratin 7 
Increased expression of these cholangiocytic markers in 
primary liver tumours indicate poor prognosis (16, 42). 
CK19 (cyto) keratin 19 
ALB Albumin 
Hepatocyte-specific marker, up-regulated in ICC, compared to 
other cholangiocellular tumours like extrahepatic 
cholangiocarcinoma (43, 44). 
OPN Osteopontin 
restricted to cholangiocytes lining the canals of Hering,  
good LPC marker for lineage studies (12). 
OCT4/ 
Pou5f1 
Octamere binding 
transcription factor/ 
Pou domain class 5, 
transcription factor 1 
Embryonic transcription factor involved in stem cell self – 
renewal. 
Possible prognostic marker for HCC, and up-regulated in 
chemoresistant liver cancer cells (45). 
AFP Alfa – feto - protein 
Fetal serum protein, often but not always re – expressed in 
HCC and CHC (44, 46) 
LIF 
Leukemia inhibitory 
factor 
Cells are pushed to differentiate during decreased LIF levels. 
LIF is elevated in LPCs and known to induce acute phase 
proteins in hepatocytes (47). 
Sox 9 
SRY-related HMG box 
transcription factor 9 
Transcription factor involved in cholangiocyte-specific 
development (48). 
CD133 Prominin1 
Cancer stem cell marker, up-regulated in most primary liver 
cancers. Associated with more aggressive phenotype and 
therapy resistance (49-51). 
CD34 CD34 antigen 
Cancer cell marker mainly expressed in early hematopoietic 
cells 
CD44 CD44 antigen 
Up-regulated in most primary liver cancers, regulation 
associated with more aggressive phenotype and treatment 
resistance (51). 
CD56/ 
NCAM 
Neural cell adhesion 
molecule 
Shift from E- cadherin to NCAM expression indicates epithelial 
mesenchymal transition 
CD117 c-KIT 
Proto oncogene, up-regulation due to mutation occurs in many 
tumours. C-Kit inhibition is also reported to slow LPC expansion 
and tumour formation in rodents (52). 
5.5. Wnt/β- catenin pathway 
The canonical Wnt signalling pathway directs essential cell regulatory mechanisms 
such as cell proliferation and cell polarity, but also plays an important role during 
embryonic development (39-41). 
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A key player in the canonical Wnt signalling pathway is β-Catenin, which also plays 
a crucial role in intracellular junctions by forming a receptor complex with epithelial 
cadherin (E -cadherin) (39).Upon binding of Wnt to its receptor Frizzled, β-catenin 
switches from being part of a destruction complex to the formation of a “Wnt-
signalosome” that prevents β-catenin degradation. This allows the latter to migrate 
to the nucleus where it binds to the T-cell factor/lymphoid enhancer factor and 
induces transcriptional activation of Wnt-responsive genes (39, 53). This β-catenin 
signalling has been shown to be necessary for mouse LPC activation upon injury in 
rodents (54) and to regulate the hepatocytic specification of LPCs (35). 
In HCC cell lines, activation of the Wnt/β-catenin signalling pathway not only 
increases EpCAM accumulation in both the cytoplasm and the nucleus (53), but 
also increases the EpCAM+AFP+ and the Oval Cell marker 6 (OV6)+ population. 
These represent cell populations with strong LPC features which also demonstrate 
tumorigenic and invasive capacities (41, 55).  
Canonical signalling probably also plays a role in chemoresistance, which is 
strongly linked to LPC proliferation (56, 57), as shown by the increased EpCAM 
expression in patients with reduced sensibility to interferon α/5-fluorouracil 
combination therapy (57). In addition, blocking the Wnt/β-catenin pathway not only 
inhibits HCC cell growth (53), but also diminishes chemoresistant OV6+ colonies 
(41). Interestingly, canonical and non-canonical Wnt pathways seem to have 
opposing effects on tumour growth (58-60).  
The canonical pathway (mediated by Wnt1-3) mediates growth and regeneration 
and is reported activated in well differentiated HCC cells while it is repressed in 
poorly differentiated HCC cell lines (41, 54, 60). 
Oppositely, activating the non-canonical pathway (including Wnt 5a and 11) has 
been shown to inhibit HCC and ICC growth (58-60), possibly by antagonizing the 
canonical pathway, and promoting cell motility and invasion (60).  
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This could indicate an important role in the growth and migration pattern of the 
tumour, caused by interaction between these two pathways during 
hepatocarcinogenesis. 
5.6. Transforming growth factor-β pathway 
TGF-β is involved in various cellular functions, such as cell growth, differentiation 
and apoptosis, in adult as well as in embryonic stages (61). Binding of TGF-β to its 
receptor results in phosphorylation of the receptor eventually followed by the 
translocation of Smad proteins (SMAD2/3) to the nucleus in a complex with SMAD4 
(coSMAD), where they can regulate transcription by binding to Smad-binding 
elements in co-operation with a plethora of Smad interacting proteins (62, 63). 
However, TGF-β also uses non-Smad signaling pathways such as the 
phosphoinositide 3-kinase/Akt/mTOR pathway, the p38 and Jun N-terminal kinase / 
mitogen-activated protein kinase pathway to transduce its signals (64). 
In addition to these non-canonical pathways, TGF-β signalling is regulated at many 
levels by processes such as endocytosis of the receptor complex, or by molecules 
like inhibitory Smads6/7 and the bio-activity of the ligands through proteolytic 
cleavage by their protease (mainly furin) (62). 
Like its regulation, the role of TGF-β in tumour formation is rather complicated. In 
healthy tissue, it acts as a tumour suppressor controlling the cell cycle, inducing 
apoptosis and regulating autophagy. During tumourigenesis, cells switch their 
response to TGF-β, making it a potent inducer of cell motility, invasion and 
metastasis, as well as guardian of stem cell maintenance (65). In liver 
carcinogenesis, TGF-β has been shown to have both tumour suppressing and 
promoting effects (24, 61) and its expression is decreased in early, while increased 
in later stages of tumourigenesis (24, 66, 67).  
TGF-β signalling is also a master regulator of initiating and maintaining EMT, the 
process directing cancer cells towards invasion and metastasis (37). 
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 In HCC cells, inhibition of TGF-β has been reported to upregulate E-Cadherin and 
thereby lower migration and invasion potential (68). However, in human fetal 
hepatocytes (cells carrying progenitor cell features, like EpCAM and CK19 as well 
as hepatoblast features like AFP), TGF-β even induces apoptotic, growth inhibitory 
signals, as well as pro-invasive, mesenchymal characteristics such as neuronal 
Cadherin, Snail and Vimentin (68). What is more, during EMT, TGF-β signalling 
results in dissociation of β-catenin from the E-Cadherin/β-catenin membrane 
complex resulting in cytoplasmatic and nuclear accumulation of β-catenin and 
subsequent activation of the Wnt pathway (69). Possibly, this upregulation of the 
Wnt pathway, due to TGF-β dysregulation causes a larger population of activated 
LPCs in HCC patients (70) and in mice following partial hepatectomy (71). 
Furthermore, in patients, high nuclear β-catenin accumulation is correlated with 
higher vascular invasion grades and increased recurrence after transplantation 
(70).  
These data suggest an important, but contradictory role for TGF-β signalling in 
hepatocarcinogenesis, possibly regulating the activation and differentiation of 
LPCs, through regulation of the Wnt- signalling pathway. Because of the important 
role of TGF-β in EMT, its regulation is decisive for the tumours invasive and 
metastatic potential.  
5.7. Notch pathway 
The Notch pathway is important in stem cell self-renewal, differentiation, and plays 
a special role in the control of many binary cell fate choices in embryonic and adult 
cells (72). In the liver, notch signalling promotes differentiation of LPCs towards the 
cholangiocytic lineage rather than to hepatocytes (73). Furthermore, Notch is 
involved in several fundamental cell regulatory processes such as proliferation, 
apoptosis and EMT (72).  
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Binding of Delta or Jagged ligand to the Notch receptor, causes cleavage of the 
extracellular C-terminal peptide. Notch intracellular domain (NICD) is then cleaved 
by γ-secretase, releasing it into the cytoplasm so it can migrate to the nucleus, bind 
to CSL, recruit co-activators such as mastermind–like, and induce Notch-dependent 
gene transcription. The two major targets are the Hairy and Hes-related repressor 
protein families of transcription factors (72, 74).  
Like the Wnt and TGF-β pathway, aberrant Notch signalling is well described in 
many different kinds of cancer, such as breast, lung, colorectal, pancreatic and 
hepatic cancer (24, 74). However, deregulation of the Notch pathway has been 
described as both oncogenic and tumour suppressive, depending on tissue type 
and circumstances (74-76).For example, the effect of Notch signalling on 
hepatocarcinogenesis can be determined by its effect on several players in cell 
cycle control such as p53 (76), cyclin-A, -D1 and -E (75).  
Induction of p53 in HepG2 cells, leads to an increased expression of NICD and 
downregulation of the cells proliferative capacity, but not the other way around. 
Moreover, in cells expressing mutant p53, not able to induce NICD up-regulation, 
administration of recombinant NICD protein did cause reduced proliferation (76). 
In a different HCC cell line, SMMC7721, NICD over-expression by retroviral 
transfection did cause increased p53 levels, as well as decreased levels of proteins 
involved in cell cycle control, like phosphorylated forms of the retinoblastoma 
protein, thus also causing inhibition of growth and proliferation (75). Unfortunately 
neither of these studies investigated the LPC properties of the used cells, before 
nor after p53 or NICD induction. 
In accordance, Notch pathway inhibition by DAPT (γ-secretase inhibitor) in adult 
mice after conditional deletion of retinoblastoma protein family genes in the liver, 
which causes proliferation of the progenitor compartment, resulted in an increased 
number of HCC nodules (77).  
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Also, over-activation of NICD inhibits cell proliferation in tumour cell lines derived 
from these retinoblastoma-deficient mice, but not in HepG2 cells (77). These data 
suggest a differential role for the Notch pathway in progenitor cells compared to 
hepatocytes, further supported by recent findings of hepatocyte-specific NICD 
overexpression causing development of HCC with 100% penetrance after 12 
months (78) and ICC after partial hepatectomy (79).  
Finally, Notch signalisation has also been related to therapy resistance; delta-like 
ligand-induced activation of the Notch pathway seems to mediate tumour 
resistance to anti-angiogenic therapy by activating escape mechanisms in the 
tumour causing the formation of new vessels circumnavigating the therapy-induced 
blockage (80, 81). 
5.8. Role of hypoxia in hepatic carcinogenesis and progenitor cell 
activation 
In the presence of oxygen, HIFα is quickly hydroxylated by prolyl hydroxylase 
domain proteins, causing degradation. However, in hypoxic conditions, shortage of 
hydroxyl–groups leads to HIFα stabilisation and migration to the nucleus where it 
regulates processes supporting cell survival under hypoxic conditions, for example 
by increasing (neo) angiogenesis (82). Primary liver tumours, especially HCC, often 
develop in a background of chronic liver disease, characterised by fibrogenesis, 
eventually leading to cirrhosis. This process is accompanied by increased hypoxia, 
caused by sinusoidal capillarisation and formation of fibrotic septa increasing 
resistance to blood flow and thus decreasing oxygen delivery to liver cells. In 
addition, the fast growing liver tumours quickly outgrow the existing liver 
vascularisation, thus creating hypoxic conditions (7, 83, 84). 
Current treatment strategies for advanced stage liver cancer - such as anti-
angiogenic treatment or TACE - often aim to deprive the tumour from its blood and 
nutrient supply (4). 
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However, therapy resistance to TACE and anti-angiogenic treatment has been 
attributed to induction of hypoxic conditions and activation of HIF (3, 7, 85), by 
adversely increasing cancer cell survival and tumour growth.  
Recently, a significant increase in stem cell marker expression has been seen in 
vitro after exposure of HCC cultures to hypoxia (86). Possibly, the decreased 
oxygen levels in tumour cells stimulate dedifferentiation towards a progenitor 
phenotype. Potentially increased proliferation and altered differentiation of LPCs in 
HCC also cause the phenotypic switch to CHC in prolyl hydroxylase domain 2 
heterozygous mice, which are characterised by increased HIFɑ stabilisation (3, 7) 
and in patients, after receiving TACE treatment(6).  
These findings have raised many questions about the future of these therapies, 
since monotherapies are often insufficient in treatment of HCC and can even 
induce more aggressive disease. It is of vast importance to consider alternative 
therapeutic strategies that prevent this massive hypoxic response. For example, a 
recent study has shown a better outcome in mice with HCC, after treatment with 
anti-placental growth factor, causing vascular normalisation, instead of blocking 
neo angiogenesis, and thus causing less hypoxia (3). Also, administration of EF24, 
could synergistically enhance the antitumor effects of sorafenib, reduce metastasis 
and overcome sorafenib resistance through inhibiting HIFα by sequestering it in the 
cytoplasm and promoting degradation by up-regulating the Von Hippel-Lindau 
tumour suppressor in five different cell lines and in both xenograft and orthotopic 
mouse models for HCC (87). Possibly, HIF-dependent alterations to the Wnt, Notch 
and/or TGF- β pathways are responsible for the observed reaction of tumour tissue 
to hypoxia inducing therapies.  
Both in vitro and in vivo experiments have shown crosstalk between the Wnt and 
HIF pathways, depletion of β- Catenin resulted in more severe hepatic injury in a 
mouse model for liver perfusion while an increased Wnt signalisation resulted in a 
marked decrease of hepatic injury compared to control (88). 
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In this study, Wnt1 overexpression resulted in a significant higher response of HIF 
sensitive genes and HIFα protein levels, Whileβ-Catenin/T-Cell factor target gene 
expression was significantly reduced after ischemia, without a decrease in total β-
Catenin. An observation further supported in HCC cells in vitro, where a direct 
interaction between HIFα and β-Catenin was shown, enhancing HIF signalling and 
driving EMT (89).  
So, in hypoxic conditions, HIFα competes with the lymphoid enhancer factor for 
binding of transcriptional activator β-Catenin thus inhibiting the canonical Wnt 
pathway responsible for hepatocyte proliferation and instead promoting adaptation, 
survival and EMT through HIF signalisation (88, 89). This further demonstrates the 
potency for intratumoural hypoxia to push LPC differentiation towards a more 
aggressive, therapy resistant cancerous offspring. Furthermore, the EMT of 
hepatocytes could also contribute to dedifferentiation of hepatocytes towards a 
stem/progenitor like phenotype as seen in vitro (90). EMT in hypoxic conditions is 
probably accomplished by HIF-mediated activation of the TGF–β pathway (91, 92).  
Next to the β-Catenin-induced intensification, Notch1 signalling has been shown 
not only essential for HIF and snail mediated EMT (93, 94), but also capable of 
inducing EMT in normoxic conditions by directly targeting Snail in breast cancer cell 
lines (94). However, in an HCC cell line a direct interaction between NICD and 
Snail in the cytoplasm has been shown to result in ubiquitinilation and degradation 
of Snail (95), again, showing the complex nature of these cell-type specific 
interactions. 
5.9. Conclusions 
Despite the increase in scientific interest, the role of LPCs in cancer progression is 
still unclear. These bipotential progenitor cells could shift to a cancerous phenotype 
and give rise to HCC, ICC and CHC.  
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These cells could thus not only be involved in regulating tumour initiation and 
growth, but also in the invasive and metastatic potential. Likely, specific interactions 
between several pathways involved in regulation of LPCs can be modulated by 
intrinsic as well as extrinsic factors and is capable of driving tumourigenesis and 
determining its phenotype. 
Of the 3 main liver tumours potentially derived from LPCs, CHC is most suitable to 
study the role of bipotential cells during tumour formation, since it consists of both 
hepatocyte- and cholangiocyte-like cells (96). We discussed a role for altered 
regulation of Notch, Wnt, HIF and TGF–β signalling in primary liver tumour 
development.  
Interactions between these pathways could possibly force a group of progenitor -or 
cancer stem cells to behave differently, causing a tumour to exhibit both HCC and 
ICC like characteristics. 
There also is a potential role for hypoxia in the determination of cell fate in LPCs, 
possibly not only by triggering conversion of its tumourigenic offspring to a more 
malignant, mixed phenotype (6, 7), but also by inducing therapy resistance (80, 97). 
As discussed here, the major target of altered signalisation could be EMT, a major 
process in malignant conversion, provoking hepatocytes to exhibit more 
stem/progenitor- like features and thus increasing the pool of cancer cells with an 
LPC signature. These findings are of particular interest when using therapies 
altering signalisation of one or more of these pathways, triggering changes which 
could potentially lead to more aggressive tumours. More specifically, inhibiting the 
involvement of the Notch, Wnt or TGF-β pathway could be the key to altering the 
massive response to hypoxia and would allow us to reduce the adverse effects so 
often caused by hypoxia-inducing therapy. 
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Figure 1: Schematic representation of the role of Wnt, Notch, TGF-β and Hif-1a signalisation 
on hepatocytes, cholangiocytes and liver progenitor cells in hepatocarcinogenesis. 
This figure shows the cel growth promoting effects of the Wnt and Notch pathways on 
hepatocytes and cholangiocytes respectively, as well as their differential role on liver progenitor 
cells. Also, the complicated dual role of TGF- β as guardian of cell cycle control, as well as its 
tumour promoting and invasion and metastasis inducing potential in all cell types is visualised. 
Finally, the complex interactions between these three pathways, and the possible influence of 
the HIFpathway is visually represented. 
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5.11. Addendum/corrigendum 
Official gene symbols were not consequently used in this manuscript, correct 
nomenclature of used abbreviations is provided in table A1. 
Table A1: gene symbols for used abbreviations 
Gene symbol Short Full 
TGFB1 TGF-β Transforming growth factor beta 
PROM1 CD133 Prominin 1 
EPCAM EpCam Epithelial cell adhesion molecule 
AFP AFP Alpha feto-protein 
KRT19 CK19 (Cyto) keratin 19 
KRT7 CK7 (Cyto) keratin 7 
ALB ALB Albumin 
SPP1 OPN Secreted Phosphoprotein 1 - Osteopontin 
POUF1 OCT4/ Pou5f Pou Class 5 homeobox 1 
LIF LIF Leukemia inhibitory factor 
SOX9 Sox 9 SRY- box 9 
CD34 CD34 CD34 molecule 
CD44 CD44 CD44 molecule 
NCAM1 CD56/NCAM Neural cell adhesion molecule 
KIT CD117/C-Kit KIT proto-oncogene receptor tyrosine kinase 
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1. GENERAL AIMS 
In this thesis, we describe the work performed to further  unravel the role of hypoxia 
in the expression of LPC characteristics in primary liver cancer and to empower our 
hypothesis that the Notch signalling pathway plays a crucial role in hypoxia-
mediated phenotypic changes in hepatocarcinogenesis (Figure 9). We first 
evaluated the effect of increased HIFα stabilisation on tumour phenotype and the 
expression of LPC characteristics at different time points in DEN-induced 
hepatocarcinogenesis. To determine whether increased hypoxic signalling induces 
an early signature, we next evaluated the expression of hypoxic, LPC and Notch 
markers during early DEN-induced hepatocarcinogenesis in PHD2 haplodeficient 
(PHD2+/-) and wild type (WT) mice. To examine a potential therapeutic role for 
Notch inhibition to counter the effects of increased hypoxic signalling in HCC, we 
evaluated tumour growth and expression of LPC characteristics in a xenograft 
mouse model, which was placed in a hypoxic environment and given a GSI or 
placebo. Lastly, we attempted to validate a mouse model for inducible biliary 
specific Notch 1 over-expression; this will allow us to further define the cell and 
receptor specific effects of Notch signalling in liver disease and cancer. 
 
Figure 9: Hypothesis on how the Notch signalling pathway might play a crucial role in hypoxia-
mediated effects on tumour phenotype.  
We hypothesize that activation of the hypoxic adaptive response mediates phenotypic changes 
by activating the Notch Signalling pathway. Possibly, Notch signalling in HCC- cells can cause de- 
or trans differentiation (dotted lines) towards a more LPC- or cholangiocyte – like phenotype. 
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2. SPECIFIC AIMS 
2.1. Determine the impact of prolyl-hydroxylase domain inhibition on the 
expression of liver progenitor cell characteristics in the 
pathogenesis of hepatocellular carcinoma 
In hypoxic conditions, PHDs can no longer hydroxylate HIFα, resulting in 
translocation of HIFα to the nucleus and transactivation of pro-survival genes. In 
primary liver cancer activation of the hypoxic response can occur at different time 
points in hepatocarcinogenesis. Treatment for advanced HCC is mostly based on 
depriving the tumour of its oxygen supply.  
However, in tumours recurring in HCC patients that underwent the hypoxia inducing 
TACE treatment followed by transplantation, the more aggressive HCC-CC 
phenotype, accompanied by increased expression of LPC characteristics, was 
observed in recurring tumours (1, 2). Moreover, an in vitro study has shown that de- 
or transdifferentiation of HCC- cells can be induced by exposure of HCC cells to 
reduced oxygen tension (3). 
Since the activation of the hypoxic adaptive response is linked to increased 
expression of progenitor cell/cancer stem cell characteristics and poor prognosis in 
cancer (4, 5), we aimed to investigate if these effects are time- dependent by 
inducing increased HIFα stabilisation through PHD inhibition at different time points 
in the pathogenesis of HCC. 
We assessed the time-dependent effect of PHD inhibition and increased HIF 
signalling by administering the pan-PHD inhibitor dimethyloxaloylglycine (DMOG) at 
three different time-points in hepatocarcinogenesis: during tumour initiation, during 
tumour growth and during tumour progression. Elucidating the time points at which 
activation of the hypoxic pathway could be safe or has detrimental effects with 
respect to tumour outcome may allow us to anticipate and adapt current hypoxia 
inducing therapeutic strategies.  
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We aimed to address these issues in chapter 3.1 and results were published: E. 
Bogaerts, F. Heindryckx, L. Devisscher, A. Paridaens, Y-P. Vandewynckel, A. Van 
den Bussche, X. Verhelst, L. Libbrecht, L.A. van Grunsven, A. Geerts, H. Van 
Vlierberghe. Time-Dependent Effect of Hypoxia on Tumor Progression and Liver 
Progenitor Cell Markers in Primary Liver Tumors.Plos One (2015;10(3): e0119555) 
(6). 
Interestingly, our lab has previously used PHD2 haplodeficient mice to mimic a 
hypoxic reaction by increasing HIFα stabilisation. Our group has shown that these 
mice also show an increased incidence of cholangiocellular lesions after DEN-
induced hepatocarcinogenesis. This was associated with a higher expression of 
LPC markers in livers of DEN-injected PHD2+/- mice compared to livers of DEN-
treated wild type (WT) mice(7). This phenotype was also observed in human 
tumours recurring after transplantation preceded by hypoxia inducing TACE 
treatment(1). 
As PHD2 is the main oxygen sensor in the liver, we aimed to investigate if the 
effects we observed upon early DMOG treatment could be mediated by PHD2. 
Moreover, elucidating the kinetics of phenotypic changes during tumour initiation 
and early development in PHD haplodeficient livers could reveal critical markers 
and events involved in the observed phenotypic switch at later timepoints.  
We therefore also aimed to determine if the effects of PHD2 haplodeficiency in 
advanced stage hepatocarcinogenesis were preceded by an early LPC 
signature.These issues were addressed in chapter 3.2and results were published: 
Bogaerts E, Paridaens A, Verhelst X, Carmeliet P, Geerts A, Vlierberghe HV, 
Devisscher L. Effect of prolyl hydroxylase domain 2 haplodeficiency on liver 
progenitor cell characteristics early in mouse hepatocarcinogenesis. Excli Journal 
(2016;15:687-698)(8). 
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2.2. Determine the role of the Notch signalling pathway in the hypoxia-
mediated phenotypic switch in hepatocellular carcinoma 
Notch signalling is an important regulator of LPC-differentiation, favouring 
progression towards a cholangiocytic phenotype, and has been shown important 
during hepatocarcinogenesis.  
Several reports have shown that hypoxia-mediated effects on proliferation, 
migration, invasion and therapy resistance in cancer are moderated by interactions 
between HIF and NOTCH signalling (9-11). Moreover, overexpression of NOTCH 
ligands was also shown to induce HCC, high in LPC characteristics, as also 
observed in patients after TACE treatment and in DEN treated PHD2+/- mice. 
To further unravel potential interactions between hypoxic and Notch signalling in 
our mouse models, we first aimed to determine the effect of PHD inhibition on the 
expression of Notch receptors, ligands and downstream targets. We therefore 
examined the mRNA expression of actors of the Notch pathway in DEN mice 
treated with DMOG at different time points, assessed in chapter 3.1and in DEN 
treated PHD2 haplodeficient and WT mice at different time points, described in 
chapter 3.2. 
In these studies, we observed that increased expression of markers for hypoxia 
coincided with an increased expression of LPC and Notch markers. We 
hypothesise that the Notch pathway could be involved in the dedifferentiation of 
HCC towards a LPC or biliary phenotype.  
To further evaluate the role of Notch signalling on hypoxia-induced effects on 
tumour phenotype, we next investigated the effect of Notch inhibition in a xenograft 
mouse model submitted to decreased oxygen tension in chapter 3.3:“Gamma 
secretase inhibition dampens hypoxia-induced tumour growth and decreases the 
expression of liver progenitor cell characteristics”. 
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Here HepG2 xenograft mice were placed in a hypoxic or normoxic environment and 
treated with either a gamma secretase inhibitor or placebo. We determined the 
effect of hypoxic conditions on tumour growth and phenotype and evaluated the 
therapeutic potential of reducing Notch-signalling by inhibiting gamma secretase 
activity on these hypoxia-induced effects (manuscript in preparation). 
2.3. Determine the effect of increased biliary Notch1 signalling in liver 
disease and cancer. 
The Notch signalling pathway is important in cell fate decisions and activation of the 
NOTCH1 pathway has been linked to induction of liver tumours with a biliary 
phenotype. However, Notch 1 upregulation and inhibition studies have led to 
controversial results, which could indicate that the effects of NOTCH1 are cell – 
specific. Possibly, differential effects of Notch1 in the biliary and hepatocytic lineage 
could account for conflicting results between Notch1 upregulation and antibody-
mediated inhibition studies. Therefore, we created a mouse model for Notch1 
upregulation in the biliary compartment.  
Our efforts to validate a mouse model for inducible, biliary specific Notch1 
upregulation and the effects on liver injury are assessed in chapter 
3.4.:“Development of a mouse model for inducible Notch1 over-activation in the 
biliary compartment and the effect on liver injury.” 
For this study we used the tamoxifen inducible osteopontin-CreERT2 mice 
(provided by Prof.Lemaigre, UCL), which we crossed to 
Gt(ROSA)26Sortm1(Notch1)Dam/J mice (Jackson laboratories), to obtain biliary 
specific, inducible Nicd and green fluorescent (GFP) overexpression.To evaluate 
the effect of biliary Nicdoverexpression on LPC-mediated cholangiocyte repair, 
OpnCre+;RosaNicd+/+ and OpnCre-;RosaNicd+/+ mice were submitted to the 3,5-
diethoxycarbonyl-1,4-dihydrocollidine(DDC) diet to induce cholestatic liver injury, 
characterised by a distinct ductular reaction (12). 
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In future experiments, the tamoxifen regimen will be further validated and the effect 
of biliary Notch1 overexpression in LPC-mediated hepatocytic repair, will be 
analysed using the choline deficient ethionine supplemented(CDE) diet. 
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1.1. Abstract 
Background & Aims 
Expression of liver progenitor cell (LPC) characteristics has been proposed as a 
negative prognostic marker in primary liver tumors. Hypoxia has been linked to 
activation of the Notch pathway which is responsible for activation and proliferation 
of LPCs and hypoxia-induced LPC activation has been shown in hepatocellular 
carcinoma. Our aim was to elucidate the time-dependent effects of hypoxia on the 
LPC niche in hepatocellular carcinoma which could aid in determining a safe time 
frame for use of hypoxia inducing therapies. 
Methods 
We used dimethyloxaloylglycine to mimic a hypoxic reaction in mice by stabilizing 
hypoxia-inducible factor 1 alpha at three distinct time points in diethylnitrosamine-
induced hepatocarcinogenesis. LPC, metastasis and Notch pathway markers were 
determined by quantitative PCR and (immune)histochemistry (heamatoxillin-eosin, 
reticulin, Sirius red and cytokeratin 19 staining).  
Results 
Activating the hypoxia inducible pathway early in hepatocarcinogenesis resulted in 
an increased incidence of both cholangioma and hepatocellular lesions, associated 
with high expression of LPC, metastatic and Notch pathway markers.  
Adversely, activating the hypoxic response during tumor development resulted in 
decreased incidence of hepatocellular lesions and increased cholangioma 
incidence, with an unaltered gene expression profile of LPC-, Notch pathway -and 
metastatic markers. A hypoxic insult at advanced stages of hepatocarcinogenesis 
severely increased the expression of LPC characteristics, however without 
increased expression of actors of the Notch pathway and metastatic markers and 
minor changes in incidence of hepatocellular and cholangioma lesions. 
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Conclusion 
Our results indicate that increased hypoxia at the onset of tumor development has 
detrimental effects on tumor progression; patients with HCC developed in a 
background of fibrosis/cirrhosis might therefore represent a more difficult treatment 
group. In contrast, hypoxia during tumor development appears to favor tumor 
outcome, highlighting the importance of early detection. Finally, hypoxia in 
advanced stages resulted in increased expression of LPC characteristics indicating 
poor outcome. 
1.2. Introduction 
Primary liver tumors, especially hepatocellular carcinoma (HCC), often develop in a 
background of chronic liver disease, characterized by fibrosis and eventually 
cirrhosis. This process is accompanied by increased hypoxia, caused by sinusoidal 
capillarization and formation of fibrotic septa, increasing resistance to blood flow 
and thus decreasing oxygen delivery to liver cells (1). 
In addition, fast growing liver tumors quickly outgrow the existing liver 
vascularization and newly formed intra-tumoral vessels are often structurally and 
functionally abnormal (2). Ideally, applied anti-angiogenic treatment inhibits further 
extension of this poorly structured blood supply, depriving tumor cells of oxygen 
resulting in growth arrest (3, 4). However, this intra-tumoral hypoxia, can also result 
in inhibition of prolyl hydroxylase domains (PHD), leading to stabilization of the 
hypoxia inducible factor 1 alpha (HIF-1α) resulting in transactivation of a plethora of 
genes such as the pro-angiogenic vascular endothelial growth factor alpha (Vegfa), 
and members of the glycolytic pathway such as glucose transporter 1 (Glut1) and 
phosphofructokinase (Pfk) aiding tumor cell survival (2, 4). Therapy resistance to 
sorafenib has been linked to increased HIF signalization and anti-angiogenic 
treatment has been identified to cause increased local invasion and metastasis, 
worsening tumor progression (5-8). 
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Liver progenitor cells (LPCs) reside in the canals of Hering and are activated upon 
severe acute or chronic hepatic injury (9). These bipotential progenitor cells 
proliferate and migrate towards the site of injury to replace hepatocytes and/or 
cholangiocytes and restore liver function. 
Interest in the role of LPCs in liver disease pathogenesis has recently expanded (9-
15) and the knowledge that Notch and Wnt signaling drive LPC differentiation 
towards cholangiocytes or hepatocytes respectively has opened new perspectives 
into the regulation of hepatic cell differentiation(10, 15). 
Several other pathways, including the HIF-1α-pathway have been linked to 
differential LPC behavior in liver disease and cancer (14). For example: exposure 
of HCC cells to hypoxia significantly increased stem cell marker expression in vitro 
which could account for the observed dedifferentiation in tumors with low oxygen 
supply (16). Interestingly, PHD2 haplodeficient mice, in which the HIF-dependent 
pathway is continuously activated, show increased cholangiocarcinoma (CC) 
burden, coinciding with increased expression of liver progenitor cell (LPC) markers 
after diethylnitrosamine (DEN)-induced HCC induction (17). Additionally, TACE 
treatment is also able to switch tumor phenotype from HCC to mixed HCC-CC, with 
increased expression of LPC markers, a more aggressive character and worse 
prognosis compared to HCC (18, 19).  
Treatment-induced hypoxia may thus increase the expression of stem/progenitor 
characteristics, which can mediate tumor progression, invasion, metastasis, 
therapy resistance, early post-operative recurrence and induce a phenotypic switch 
(5, 6, 8, 17-24). Elucidating the time points in hepatocarcinogenesis at which 
activation of the hypoxic pathway has detrimental effects with respect to tumor 
outcome may allow us to anticipate and adapt current therapeutic strategies. 
Therefore, we assessed the time dependent consequences of elevated HIF 
signaling on tumor progression and LPC activation by using the PAN-PHD inhibitor 
dimethyloxaloylglycine (DMOG) in an orthotopic HCC mouse model. 
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1.3. Materials and methods 
Primary tumor induction and dimethyloxaloylglycine (DMOG) mediated 
activation of the HIF pathway 
Ethics statement: All experiments were evaluated and approved by the Ghent 
University, faculty of health and medicine’s ethical commission for animal testing 
(ECD 12/57) and all efforts were made to minimize animal discomfort.  
Weekly intraperitoneal (IP) DEN (Sigma –Aldrich, Bornem, Belgium) injections 
(35mg/kg) are known to induce neoplastic regions after 16 weeks, HCC nodules 
after 20 weeks and HCC with 100% penetrance from 25 weeks on (2). For this 
study we administered DEN for 22 weeks in 5-week-old male 129S2/svPasCrl 
mice, control mice received weekly doses of saline equivalent to DEN counterparts.  
Dose and interval of DMOG, which has been shown to induce HIF-1α stabilization 
(25), was first tested for its ability to effectively induce functional HIF-1α by 
measuring the transactivation of Vegfa, Glut1 and Pfk. Mice received a single IP 
DMOG injection (4,8mg/20g) followed by euthanasia after 3 and 7 days. Livers 
were removed and sections were lysed for RNA extraction and qPCR. Results 
showed that biweekly DMOG injections effectively induce HIF activation (Figure 1A) 
and this treatment strategy was further applied.  
DEN -treated mice received DMOG or PBS for five weeks at three different time 
points during tumor development: at early (1-5 weeks), intermediate (Int, 16-22 
weeks) and advanced (Adv, 22-27 weeks) stages.  
For comparability between intermediate and advanced treatment groups and to 
reduce bias by acute DMOG effects, we chose to sacrifice mice from these groups 
7 days after the final DMOG injection. Saline control mice received DMOG from 
week 16 to 22 or from week 22 to 27 and were sacrificed after respectively 22 or 27 
weeks. 
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Sacrification was preceded by anesthesia of the mice with isoflurane (Florene, 
Abbott, Hoofddorp, the Nederlands) in oxygen for weighting and blood sampling 
from the ophthalmic artery. After cervical dislocation, the liver was prelevated and 
weighed. Part of the liver was emerged in RNA later (Ambion, Gent, Belgium) and 
snap frozen, remaining tissue was incubated in 4% phosphate buffered 
formaldehyde (KP4078.9010 Klinipath, Olen, Belgium) and imbedded in paraffin, as 
previously described (1, 2, 7). 
Immunohistological analyses 
Hematoxilin-eosin (H&E) staining was performed as previously described (26) and 
sections were analyzed by a pathologist for general morphology and neoplasticity 
based on the following characteristics: enlarged cells with normal nucleus to 
cytoplasm ratio (n/c), small cells with increased n/c, enlarged pleomorphic nuclei, 
and binucleation.Sirius red staining was performed as routinely described (26) to 
assess fibrosis which allows distinction between areas of ductular proliferation and 
cholangioma characterized by presence of typical cholangiofibrosis (7, 17).Reticulin 
staining was performed to evaluate the presence of HCC nodules (26), which are 
absent for reticulin.  
HIF-1α stabilization was evaluated through immunohistochemistry, using a rabbit 
anti – HIF-1α antibody (sc-10790, 1/400 in PBS, RRID: AB_2116990, Santa Cruz 
biotechnology, INC, California USA).  
Cytokeratin 19 (CK19) staining was performed to visualize structures of the 
cholangiocytic lineage, including LPCs, using monoclonal rabbit anti-CK19 (1/200 
in TBS, ab133496, RRID:AB_11155282, abcam, Cambridge, UK). Epithelial cell 
adhesion molecule (Epcam) expression was examined using a goat polyclonal 
antibody raised against the transcriptionally active intracellular domain of Epcam 
(sc-23788, 1/300 in PBS, RIDD: AB_2098653, Santa Cruz biotechnology, INC, 
California, USA).  
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LSAB-horseradish peroxidase-mediated visualization (K0690, DAKO, Heverlee, 
Belgium) was performed for all protocols. Overall immunoreactivity was calculated 
using Cell D software (Olympus Imaging Solutions, Münster, Germany) to assess 
increased expression of all cells of the cholangiocytic lineage. Since cholangiocytes 
organize in ductular structures and LPCs occur as singular cells, 5 portal areas 
were centred at a magnification of 400 and all CK19+ single cells were counted. 
Quantitative real time PCR (qPCR) 
RNA was extracted from 20 mg of frozen liver tissue preserved in RNA-later, 
according to the manufacturer’s guidelines (Rneasy Mini Kit, Quiagen, Venlo, the 
Nederlands). 
cDNA was obtained from 1µg RNA using the iScript cDNA synthesis kit (Bio-Rad, 
Nazareth-Eke, Belgium) and real time quantitative PCR (RT-qPCR) analyses were 
performed using a SYBR green mix (Sensifast Bioline Reagents Ltd, London, UK). 
Primer sets are listed in Table SI, their efficiency was calculated from the slope of a 
standard curve using the following formula: E=〖10〗^(-1/slope)-1. All reactions 
were run in duplicate and normalized to reference genes that showed stable 
expression in all samples. The comparative Ct method was used to compare gene 
expression between groups. 
Statistics 
Data were analysed using SPSS21 software (IMB corp, Armonk NY, USA). 
Kolmogorov-Smirnov test was used to test for normality. Student’s T-test was then 
performed in case of normality; the Mann-Whitney-U test was used for not normally 
distributed data. P-values ≤0, 05 where considered significant. All data are 
presented as average ±SEM. 
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1.4. Results 
Time dependent effect of HIF-1ɑ stabilization on DEN-induced tumorigenesis 
We first analyzed whether 4,8mg/20g biweekly or weekly DMOG injections are 
required to maintain stable activation of the HIF-pathway in livers, by performing 
qPCR analysis of HIF sensitive genes like Vegfa, Glut1 and Pfk.  
There was an increased expression of HIF sensitive genes, for at least 3 but not 7 
days, significant for Vegfa and Pfk after DMOG induction, compared to PBS control 
(Figure 1A). Further treatment regimes were therefore carried out by biweekly 
DMOG injections.  
To assess the effect of HIF-1ɑ stabilization early on in tumorigenesis, DMOG was 
administered during the first 5 weeks of DEN treatment (Early). Samples were 
taken after 22 weeks, and we observed that early DMOG treatment had no effect 
on relative liver weight (Figure 2A). Sirius red staining revealed cholangioma 
formation in 37,5% and reticulin staining showed premalignant HCC lesions in 
62,5% of mice compared to respectively 0 and 50 % of the mice receiving PBS 
(Figure 2B, C). 
To evaluate the activation of the hypoxic pathway during intermediate stages, 
DMOG was injected from week 16 to week 22 (intermediate, Int.) during DEN 
induction. Samples were taken at the end of week 22, Int. DMOG also did not 
influence relative liver weight (figure 2A). Sirius red and reticulin staining in Int. 
DMOG-treated animals showed cholangioma formation in 50% of DMOG injected 
mice and no HCC lesions, compared to no cholangioma lesions and 50% HCC 
lesions in PBS control mice (Figure 2B, C). 
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Figure 1.Hypoxia inducible factor expression. 
A: Expression of HIF-1α target genes, characteristic for stabilization of HIF-1α, 3 and 7 days after 
single DMOG injection B. Representative images of HIF-1α staining, showing HIF stabilization in 
all DEN groups, mostly located in and around cholangioma and HCC lesions and near portal 
areas. C. mRNA expression of HIF-1α markers .Scale bars: 200µm, *: p<0,05; **p<0,01 
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For the effect of HIF-1ɑ stabilization after the final DEN injection, during tumor 
growth, DMOG (or PBS) was administered from week 22 to 27 (advanced, Adv.) 
and samples were taken after 27 weeks. Adv. DMOG resulted in a significantly 
increased relative liver weight compared to PBS counterparts (Figure 2A). Sirius 
red staining showed cholangioma lesions in 66,7% of DMOG and 50% of PBS 
induced animals and reticulin staining showed HCC lesions in 40% of DMOG and 
50% of PBS treated livers (Figure 2B, C).  
This suggests that, Early Int. and Adv. DMOG result in increased cholangioma 
formation and Early DMOG even increases HCC formation, while Int. DMOG 
inhibits HCC formation. 
Immunohistochemistry and qPCR analysis was then performed to assess HIF-1α 
stabilization and activity after Early, Int. and Adv. DMOG treatment. While HIF-1α 
immunopositivity was limited in saline control livers, in DEN treated livers there was 
some cytoplasmic presence of the HIF-1ɑ protein in hepatocytes and 
cholangiocytes around the portal area, but immunopositivity was mostly observed 
in and around hepatocellular and cholangioma lesions (Figure 1B). 
HIF-1α activity was determined through qPCR analysis for downstream HIF target 
genes. As expected, there was no increased expression in Int. –and Adv. DMOG 
groups compared to their PBS control groups (Figure 1C). Strangely, these DEN 
groups also show no increased or even a decreased expression of HIF-dependent 
genes compared to saline control.  
However, we do see significantly increased mRNA expression of HIF target genes 
Glut1 and Vegfa in DEN livers after Early DMOG treatment compared to all other 
groups (Figure 1C). 
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Figure 2: General parameters. 
A: Liver/ bodyweight ratios for all groupsB: Prevalence of cholangioma and hepatocellular 
lesions, showing percentage of mice showing one or more cholangioma or (premalignant) HCC 
lesionsC: Representative images of Sirius red and reticulin staining showing cholangioma lesions 
in all DMOG groups except for PBS control after 22 weeks, and HCC lesions in all DEN groups 
except for the Int. DMOG group.  
Scale bars: 200µm, *: p<0,05; **p<0,01 
DMOG: dimethyloxaloylglycine; DEN: diethylnitrosamine 
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Time dependent effect of hypoxia on LPC characteristics in DEN treated mice 
Tumor sections were analyzed for overall CK19 immunopositivity, which is a 
marker for biliary epithelial cells, including LPCs. All animals receiving DEN showed 
increased immunopositivity for CK19 after 22 weeks compared to saline controls. 
(Figure 3A and B left graph). Mice treated with DMOG at advanced stages showed 
significantly enhanced CK19 immunopositivity compared to PBS control (Figure 3A 
and B right graph). CK19+ single cells (Figure 3C) were numerous in livers of DEN 
treated groups compared to saline controls at 22 weeks (p<0,05), but no significant 
difference was seen between treatment regimes (Figure 3D upper graph). DMOG 
treatment from week 22-27 did however result in a significant increase in CK19+ 
single cells compared to both PBS and saline control groups (Figure 3D lower 
graph). 
Next, we examined sections for Epcam immunopositivity, which is a marker for 
biliairy epithelial cells, including LPCs(27) as well as tumor cells(28). In saline 
control mice, staining was limited to cholangiocytes and some membranous 
staining of hepatocytes (Figure 4A). In DEN treated mice immunopositivity was 
seen in the cytoplasm of hepatocytes, mostly around portal areas and in regions 
containing cholangioma -and hepatocellular lesions (Figure 4A). These results were 
in line with those of CK19, with a positive trend to increased Epcam expression for 
all DEN mice, significant for all DMOG groups and for mice that received PBS from 
week 22 to 27 compared to saline control (Figure 4B). Futhermore, Adv. DMOG 
treatment also resulted in a significantly increased Epcam immunopositivity 
compared to PBS control after 27 weeks (Figure 4B).  
Since progenitor cell markers have been proposed as markers of poor prognosis in 
HCC, we next examined the mRNA expression of liver progenitor cell markers 
cytokeratin 7 (CK7), CK19, CD44, alpha-fetoprotein (Afp), Epcam and prominin1 
(Prom1).  
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Figure 3.immunohistochemistry for cytokeratin 19. 
A: Representative images of CK19 staining, early DMOG and PBS counterparts show 
cytoplasmatic staining in hepatocytes B: quantified % of overall CK19 staining after 22 and 27 
weeks C: Image of portal area arrowheads point to single cells D: Average number of single cells 
per portal area for each group 
Scale bars: 40µm, *p<0,05, **p<0,01 and#p<0,05, ##p<0,01 compared to all other groups 
In DEN mice receiving DMOG at early stages, there was a non-significant 
increased expression of CK7, CK19, Epcam and Prom1, compared to PBS control, 
which was not seen in mice treated with DMOG at intermediate stages (Figure 5A).  
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Suggesting a protective role for Int. DMOG and a previously unreported effect of 
early hypoxia. Afp expression was significantly increased after both early and 
intermediate DMOG treatment compared to PBS control (Figure 5A). 
 
Figure 4.Epithelial Cell Adhesion Molecule. 
A. representative images of Epcam staining showing presence around cell membranes of 
hepatocytes and in cytoplasm of cholangiocytes in saline control livers (upper left). In DEN 
treated livers, cytoplasmic expression in hepatocytes around portal areas, cholangioma –and 
hepatocellular lesions was increased.B.quantified % of Epcam intracellular domain staining after 
22 and 27 weeks. Scale bars: 40µm *:p<0,05; **p<0,01 
Adv. DMOG resulted in a non-significant increase of all markers, except for CK7 
where a non-significant decreased expression was seen, compared to PBS control. 
Both DEN groups showed increased expression of LPC markers compared to 
saline control (all significant for Adv. DMOG group, significant for Prom1, CK7 and 
CK19 for PBS group), (figure 5B).  
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Figure 5.mRNA expression of LPC markers 
A: mRNA expression of LPC markers after early and Int. DMOG B: mRNA expression of LPC 
markers after Adv. DMOG. *:p<0,05; **p<0,01; ##<0,01 compared toall other groups 
Since Notch signaling is known to be involved in the differentiation of LPCs to 
cholangiocytes, and has also been suggested to mediate hypoxia-induced therapy 
resistance and increased invasion/metastasis (14), we examined mRNA levels of 
Notch 1, Notch 2 and Notch3 receptors, the ligand Jagged1 and main target gene: 
hairy enhancer of split 1 (Hes1); and matrix metalloproteinase 9 (Mmp9) and 
Integrin alpha 5 (ItgaV) as markers for metastasis (4).  
Interestingly, Notch and metastasis markers were only up-regulated in mice that 
received DMOG at early stages (Figure 6). Table 1 summarizes the main findings 
for all groups.  
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Figure 6.mRNA expression of Notch and metastasis markers.  
A: mRNA expression of Notch and metastasis markers after early and Int. DMOG B: mRNA 
expression of Notch and metastasis markers after Adv. DMOG in DEN-induced hepatocellular 
carcinoma. *p<0,05 ; **p<0,01 , ## p<0,01 compared to all other groups 
Table 1. Summary of groups and major findings. 
Timing DMOG 
Early intermediate advanced 
week 1 -5 week 16 -22 week 22 -27 
DEN induction 22 weeks 
Total time 22 weeks 27 weeks 
DEN control group 
22w DEN + 22w DEN + 
PBS (week16-22) PBS (week 22 -27) 
General parameters 
 relative liver weight 
    
 1,039 ± 0,02798 1,167 ± 0,06543 1,321 ± 0,07186
Tumor type 
 
Hepatocellular lesions   
 
Cholangioma   
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Liver progenitor cell markers 
 
CK19+ single cells   
  1,036 ± 0,1279 0,7589 ± 0,1511 4,179 ± 1,012
 
CK19 mRNA   
  2,172 ± 0,9123 0,2844 ± 0,1336 5,711 ± 1,423
 
CK7 mRNA   
  3,020 ± 0,9846 0,3080 ± 0,1281 8,932 ± 2,806
 
Prom1 mRNA   
  2,973 ± 1,044 0,4728 ± 0,1257 1,972 ± 0,4273
 
Epcam mRNA   
  1,337 ± 0,4107 0,5967 ± 0,1828 14,29 ± 3,995
 
CD44 mRNA 
  
 0,8260 ± 0,1985 0,6499 ± 0,08237 4,075 ± 1,909
 
Afp mRNA 
  
 5,978  ± 2,008 1,912 ± 0,5875 2,913 ± 1,338
Notch markers 
 Notch1 mRNA 
  
 2,096 ± 0,02613 1,185 ± 0,08566 1,460 ± 0,2858
 Notch2 mRNA 
  
 1,807 ± 0,2696 0,8063 ± 0,1477 0,8674± 0,05704
 
Notch3 mRNA 
   
 1,543 ± 0,2627 0,9848  ± 0,2933 0,6119  ±0,09868
 
Jagged1 mRNA 
  
 
2,633 ± 0,5159 1,529 ± 0,2996 0,8272 ± 0,2529 
 Hes1 mRNA 
 * 
 0,8795 ± 0,1181 0,4431 ± 0,04125 0,9004 ± 0,2051
Metastatic markers 
 MMP9 mRNA 
  
 2,688 ± 0,8184 0,8170 ± 0,2145 0,8541  ± 0,1239
 
ItgaV mRNA 
  
 
3,063 ± 0,9327 0,9311 ± 0,2445 0,7502 ± 0,3067 
First row: : No change compared to DEN control, : Increase compared to DEN control, : Decrease 
compared to DEN control.  
Second row: fold changes ±Standard deviation, compared to PBS control .
*: p<0,05, **: p<0,01 
1.5. Discussion 
In the present study, we show that pan-PHD inhibition in early and advanced 
stages of hepatocarcinogenesis induces increased expression of LPC 
characteristics, while PHD inhibition in intermediate stages has a tendency to 
decrease the expression of LPC characteristics.  
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Furthermore, the early, but not intermediate or advanced-stage HIF-1α stabilization, 
concurred with increased expression of actors of the Notch pathway and metastatic 
markers. These results indicate an important time-dependent effect of hypoxic 
stimuli in HCC and a previously undescribed detrimental delayed effect of an early 
hypoxic event on tumor development. Currently LPCs are being intensively studied 
for their role in various liver diseases and have recently also been implicated in the 
pathogenesis of primary liver tumors. Increased expression of LPC characteristics 
serves as a marker for poor prognosis (21, 23, 24, 29). Moreover, since LPCs 
highly express multi drug resistance proteins, they are also implicated in therapy 
resistance (31). Furthermore, different studies have shown a phenotypic switch 
from HCC to HCC-CC following hypoxic stimuli, coinciding with increased 
expression of progenitor cell markers (6, 17, 18). Since activation of the hypoxic 
pathway could alter LPC behavior in hepatocellular carcinoma, we studied the 
effect of increased activation of HIF on DEN-induced hepatocarcinogenesis.  
We used DMOG to induce the hypoxic response, aimed at mimicking oxygen 
deprivation at different time points in tumor development. The early HIF-1ɑ 
stabilization reflects patients with chronic liver disease, characterized with fibrotic 
strands and hypoxia prior to tumor development.Additionally, early HIF-1ɑ 
stabilization may also mimic hypoxia-inducing treatment strategies affecting 
recurrent tumor behavior. 
The intermediate DMOG induction relates to patients undergoing anti-angiogenic 
treatment for early stage cancer. Lastly, the group receiving DMOG at advanced 
stages resembles patients receiving treatment for advanced stage HCC.  
Immunohistochemistry for HIF-1α expression showed few hepatocytes expressing 
HIF-1ɑ in saline groups, and cells expressing the HIF-1ɑ protein in DEN groups 
were mostly residing in the portal area, and in and around hepatocellular- and 
cholangioma lesions, coinciding with CK19 and Epcam immunopositive regions.  
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Our aim was not to show HIF-1α stabilization following DMOG at specific time 
points but to evaluate its effect on tumorigenesis and LPC activation on the long 
term. We therefore chose to euthanize mice 7 days after the final DMOG injection, 
which is confronted with an attenuation of HIF-1α stabilization and transcriptional 
activation as shown in by the single DMOG injection experiment. Activation of the 
HIF pathway in DEN groups was examined through qPCR analysis of HIF target 
genes, no difference could be detected between intermediate and advanced 
DMOG and their respective PBS controls, confirming that acute effects of PHD 
inhibition were eliminated by euthanizing animals 7 days after the final DMOG 
injection. 
Strangely, saline groups had an equal Glut1 and Pfk and even an increased Vegfa 
mRNA expression compared to intermediate and advanced DMOG groups and 
their PBS controls. Since saline mice had also received DMOG, possibly a variety 
of feedback loops could be differentially regulated in DEN compared saline mice 
(31, 32), which should be further investigated.  
Interestingly, the DEN group that received DMOG at early stages, did show 
significantly increased expression Vegfa and Glut1 compared to other groups. HIF 
induction early in DEN-induced hepatocarcinogenesis also caused increased 
formation of cholangioma and HCC lesions as well as a massive upregulation of 
LPC features and metastatic markers on the RNA level, compared to groups that 
received DMOG or PBS at intermediate stages.  
This massive delayed effect of hypoxia has not previously been described and 
indicates that early hypoxia could readily prepare cells for later tumor growth and 
growth–induced hypoxia, resulting in tumors with a more aggressive phenotype. 
 Thus, monitoring the extent to which the hypoxic pathway is activated after hypoxic 
treatment for recurring tumors or as a result of inflammation and fibrosis in chronic 
liver disease could have prognostic value when these patients (re)develop HCC 
later on.  
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Indeed, there is evidence of a phenotypic switch in tumors recurring after TACE, 
which induces a massive hypoxic response (18, 19). 
Mice receiving DMOG during tumor development (at intermediate stages) displayed 
no HCC lesions and no altered expression of LPC or metastatic markers compared 
to PBS control mice. While the increased formation of cholangioma lesions should 
be monitored, these benign intrahepatic bile duct adenomas usually do not require 
treatment (33). Taken together, this could point to a safe therapeutic window for 
hypoxia inducing treatment after early detection.  
Administering the pan-PHD inhibitor DMOG in advanced stages of tumor 
development resulted in a significantly increased relative liver weight, a slight 
decrease in HCC and a minor increase in cholangioma lesions coinciding with a 
significantly increased expression of LPC markers and number of CK19+ single 
cells. This observation is in line with previous reports showing that treatment-
induced hypoxia is linked to an increased expression of stem/progenitor 
characteristics (16, 34, 35). However, while this hypoxia-induced LPC signature did 
not coincide with increased expression of metastatic markers, HCC lesions with a 
cholangiocytic signature have been linked to poor prognosis and early recurrence 
(20-24, 30, 36). Furthermore, while the increased relative liver weight compared to 
PBS counterparts is at least partly caused by the increased amount of cholangioma 
and its accompanying cholangiofibrosis, it could also be a sign of increased tumor 
burden. 
Notch signalization is involved in LPC proliferation and pushes LPC differentiation 
towards cholangiocytic structures. Since we observed an increased incidence of 
cholangioma lesions in DEN livers after a hypoxic insult, RNA expression of Notch 
related genes was analyzed. Increased mRNA expression of actors of the Notch 
pathway was seen in livers of mice receiving DMOG early in hepatocarcinogenesis 
coinciding with high expression of LPC- and metastatic markers.  
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This suggests a role for Notch-mediated increased proliferation of LPCs and 
differentiation towards cholangiocytes in the pathogenesis of HCC after early 
hypoxic stimuli, thus contributing to the development or recurrence of aggressive, 
more invasive tumors with a mixed phenotype.  
Indeed, pharmacological inhibition of the Notch pathway has already been proven 
to be effective in reducing the amount of chemo-resistant cancer stem cells in 
breast and colon cancer (37, 38). Surprisingly, DMOG administration at both 
intermediate and advanced stages did not lead to increased expression of actors of 
the Notch pathway.  
While CK19 and CK7 positive liver tumors have been proposed to be progenitor 
cell derived (37), in vitro experiments have shown that HCC cells are capable of 
trans differentiating towards a cholangiocytic phenotype (39, 40). The fact that the 
stem cell marker Prom1 is only marginally up-regulated compared to the 
pronounced cholangiocytic markers CK7 and CK19, and there does not appear to 
be any Notch involvement in tumors undergoing hypoxia at advanced stages, might 
reflect this HCC trans-differentiation rather than LPC involvement. However, while 
whole liver analysis showed no Notch pathway activation, individual cell 
populations should be analyzed for more clarity on Notch involvement.  
The present study underlines that early hypoxic stimuli have detrimental effects on 
tumor progression with an increased expression of poor prognostic markers later 
on.  
Activation of the HIF pathway at advanced stages of tumorigenesis resulted in 
severely increased expression of LPC characteristics without Notch activation. 
Hypoxic treatment at intermediate stages of DEN-induced hepatocarcinogenesis 
appears to have the least detrimental effect on tumor progression and reflects the 
advantages of early tumor diagnosis with most favorable treatment options/effects. 
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Supplementary data 
Table SI: Genes and primersets 
Gene 
ID 
short Full name Forward primer 
Reverse 
primer 
Marker 
14433 GAPDH 
glyceraldehyde 3 
phosphate 
dehydrogenase 
CATGGCCTTCCGTGT
TCCTA 
GCGGCACGTCAG
ATCCA 
Reference 
15288 HMBS 
hydroxymethyl-bilane 
synthase 
AAG GGC TTT TCT 
GAG GCA CC 
AGT TGC CCA TCT 
TTC ATC ACT G 
Reference 
15452 HPRT 
hypoxanthine guanine 
phosphoribosyl 
transferase 
GTT AAG CAG TAC 
AGC CCC AAA 
AGG GCA TAT 
CCA ACA ACA 
AAC TT 
Reference 
66945 SDHA 
succinate 
dehydrogenase 
complex, subunit A 
CTTGAATGAGGCTGA
CTGTG 
ATCACATAAGCTG
GTCCTGT 
Reference 
11576 AFP alpha – fetoprotein 
AGCTTCCACGTTAGA
TTCCTCC 
ACAAACTGGGTA
AAGGTGATGG 
LPC 
16669 CK19 Cytokeratin 19 
GTTCAGTACGCATTG
GGTCAG 
GAGGACGAGGTC
ACGAAGC 
LPC 
11031
0 
CK7 Cytokeratin 7 
AGGAGATCAACCGA
CGCAC 
CACCTTGTTCGTG
TAGGCG 
LPC 
12505 CD44 CD44 antigen 
TCGATTTGAATGTAA
CCTGCCG 
CAGTCCGGGAGA
TACTGTAGC 
LPC 
19126 Prom1 Prominin 1 
CTCCCATCAGTGGAT
AGAGAACT 
ATACCCCCTTTTG
ACGAGGCT 
LPC 
17075 Epcam 
Epithelial cell adhesion 
molecule 
GCGGCTCAGAGAGA
CTGTG 
CCAAGCATTTAGA
CGCCAGTTT 
LPC 
16402 ITGAV Integrine alpha 5 
CAATTGCTGCTCCCT
ATGGT 
GATTTGAGATGG
CACCGAAT 
Metastasis 
17395 MMP9 
Matrix 
metalloproteïnase 9 
GAGACGGGTATCCCT
TCGAC 
TGACATGGGGCA
CCATTTGAG 
Metastasis 
16449 JAG1 Jagged 1 
ATGCAGAACGTGAAT
GGAGAG 
GCGGGACTGATA
CTCCTTGAG 
NOTCH 
18128 NOTCH1 Notch 1 
GATGGCCTCAATGGG
TACAAG 
TCGTTGTTGTTGA
TGTCACAGT NOTCH 
18129 NOTCH2 
Neurogenic locus notch 
homolog protein 2 
ATGTGGACGAGTGTC
TGTTGC 
GGAAGCATAGGC
ACAGTCATC 
NOTCH 
18131 NOTCH3 
Neurogenic locus notch 
homolog protein 3 
AGTGCCGATCTGGTA
CAAGTT 
CACTACGGGGTTC
TCACACA 
NOTCH 
15205 HES1 
Hairy enhancer of split 
1 
ACGTGCGAGGGCGT
TAATAC 
ACGTGCGAGGGC
GTTAATAC 
NOTCH 
22339 VEGFa 
Vascular endothelial 
growth factor A 
ACTCGGATGCCGACA
CGGGA 
CCTGGCCTTGCTT
GCTCCCC 
Hypoxia 
20525 Glut1 Glucose transporter 1 
GCT TAT GGG CTT 
CTC CAA ACT 
GT GAC ACC TCT 
CCC ACA TAC 
Hypoxia 
18642 Pfk Phosphofructokinase 
GCCGGCTCAGTGAG
ACAAG 
TGGCACCTTCAGC
AACAATG 
Hypoxia 
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1.7. Addendum/Corrigendum 
Materials and methods 
The number of mice per group should be added to the materials and methods 
(Table A1) 
TableA1: Total number of analysed mice/group 
22 weeks 27 weeks 
Saline Ctrl PBS Ctrl Early DMOG Int. DMOG Saline Ctrl PBS Ctrl Adv. DMOG 
8 8 6 5 7 6 5 
 
Official gene symbols were not consequently used in this manuscript, correct 
nomenclature of used abbreviations is provided in table A2. 
Table A2: Gene symbols 
Gene ID 
Gene 
symbol 
short Full name Marker 
14433 Gapdh GAPDH glyceraldehyde 3 phosphate dehydrogenase Reference 
15288 Hmbs HMBS hydroxymethyl-bilane synthase Reference 
15452 Hprt HPRT hypoxanthine guanine phosphoribosyl transferase Reference 
66945 Sdha SDHA succinate dehydrogenase complex, subunit A Reference 
11576 Afp AFP alpha – fetoprotein LPC 
16669 Krt19 CK19 Cytokeratin 19 LPC 
110310 Krt7 CK7 Cytokeratin 7 LPC 
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12505 Cd44 CD44 CD44 antigen LPC 
19126 Prom1 PROM1 Prominin 1 LPC 
17075 Epcam EPCAM Epithelial cell adhesion molecule LPC 
16402 Itga5 ITGAV Integrine alpha 5 Metastasis 
17395 Mmp9 MMP9 Matrix metalloproteïnase 9 Metastasis 
16449 Jag1 JAG1 Jagged 1 NOTCH 
18128 Notch1 NOTCH1 Notch 1 NOTCH 
18129 Notch2 NOTCH2 Neurogenic locus notch homolog protein 2 NOTCH 
18131 Notch3 NOTCH3 Neurogenic locus notch homolog protein 3 NOTCH 
15205 Hes1 HES1 Hairy enhancer of split 1 NOTCH 
22339 Vegfa VEGFa Vascular endothelial growth factor A Hypoxia 
20525 Slc2a1 Glut1 Glucose transporter 1 Hypoxia 
18642 Pfk Pfk Phosphofructokinase Hypoxia 
Results 
Y-Axes of graphs illustrating qPCR data show the normalised gene expression. 
The legend of Figure 2 should be adjusted to: 
Figure 2: General parameters. 
A: Liver/ bodyweight ratios for all groups. B: Representative images of Sirius 
red and reticulin staining showing cholangioma lesions in all DMOG groups 
except for PBS control after 22 weeks,  and HCC lesions in all DEN groups 
except for the Int. DMOG group. C: Prevalence of cholangioma and 
hepatocellular lesions, showing percentage of mice showing one or more 
cholangioma or (premalignant) HCC lesions. 
Scale bars: 200µm, *: p<0,05; **p<0,01 
DMOG: dimethyloxaloylglycine; DEN: diethylnitrosamine 
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2.1. Abstract 
Activation of the hypoxia-inducible factor (HIF)-pathway in hepatocellular carcinoma 
(HCC) induces therapy resistant tumours, characterized by increased liver 
progenitor cell (LPCs) characteristics and poor prognosis. We previously reported 
corresponding results in mice with HCC in which hypoxia was mimicked by prolyl 
hydroxylase domain (PHD) inhibition. Here, we aimed at investigating whether 
induction of LPC characteristics occurs during the onset of hepatocarcinogenesis 
and if this is associated with activation of Notch signalling. Dietheylnitrosamine 
(DEN) was used to induce hepatic tumours in PHD2 haplodeficient (PHD2+/-) mice 
which were euthanized at 5, 10, 15 and 17 weeks following DEN during neoplastic 
transformation, before tumour formation. Neoplasia and mRNA expression of LPC 
and Notch markers were evaluated by histology and qPCR on isolated livers. PHD2 
haplodeficiency resulted in enhanced expression of HIF target genes after 17 
weeks of DEN compared to wild type (WT) littermates but had no effect on the 
onset of neoplastic transformation. The mRNA expression of Afp and Epcam was 
increased at all time points following DEN whereas CK19, Prom1 and Notch3 were 
increased after 17 weeks of DEN, without difference between PHD2+/- and WT 
mice. MDR1 mRNA expression was increased in all DEN treated mice compared to 
saline control with increased expression in PHD2+/- compared to WT from 15 
weeks. These results indicate that the effects of PHD2 haplodeficiency on the 
expression of LPC and Notch markers manifest during tumour nodule formation 
and not early on during neoplastic transformation. 
2.2. Introduction 
With an estimated overall five year survival of less than 20%, liver cancer is the 2nd 
leading cause of cancer related death worldwide (1). Liver tumours often arise in a 
background of chronic liver disease characterised by inflammation, sinusoidal 
capillarisation and the formation of fibrous septa.  
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Moreover, when tumours outgrow their vascular supply, newly formed vasculature 
is often structurally and functionally anomalous during further tumour growth. These 
processes contribute to a reduced liver oxygenation early during tumour 
development and later, during tumour growth (2, 3).  
Insufficient oxygen supply results in hypoxia, a situation known to inhibit prolyl 
hydroxylase domain (PHD) enzyme activity, causing stabilisation of the hypoxia 
inducible factor (HIF). HIF stabilisation and its nuclear translocation results in the 
transactivation of genes involved in cell-survival by, amongst others, stimulating 
(neo-) angiogenesis (through induction of pro-angiogenic factors, such as the 
vascular endothelial factor or Vegf), and boosting the anaerobe glucose 
metabolism (via Glucose transporter 1 or Glut1, phospho-fructokinase or Pfk) (2, 4, 
5). Activation of the hypoxia inducible pathway is known as the ‘hypoxic adaptive 
response’ and has extensively been investigated in tumorigenesis as a mediator of 
tumour growth, therapy resistance and metastasis (6-8) 
Previous studies have shown that activation of the hypoxic pathway can induce 
therapy resistance and is related to poor prognosis in primary liver tumours (8-13).  
Furthermore, in humans, pre-operative trans-arterial chemoembolization, which has 
been shown to induce a hypoxic adaptive response, has been linked to higher 
recurrence rates and a phenotypic switch from hepatcellular carcinoma (HCC) to 
hepato-cholangiocarcinoma (HCC-CC), with increased expression LPC 
characteristics (14-16).  
In accordance, we previously reported that inhibiting PHDs, (using a pan-PHD 
inhibitor or PHD2 haplodeficient mice (PHD2+/-), in murine diethylnitrosamine 
(DEN)-induced hepatocellular carcinoma (HCC), results in a more aggressive 
mixed hepato-cholangiocarcinoma (HCC-CC) phenotype high in LPC 
characteristics, coinciding with increased expression of markers for metastasis and 
actors of the Notch signalling pathway (2, 4).  
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Possibly, PHD inhibition during carcinogenesis can readily prime future tumour 
cells to react differently to later hypoxic stimuli, and give rise to more aggressive 
mixed phenotype cancers, with increased LPC characteristics and an increased 
risk for therapy resistance and metastasis (5).  
LPCs are bipotential cells that reside in the canals of Hering in the liver, were they 
act as facultative adult stem cells (17). In healthy liver, loss of hepatocyte or 
cholangiocyte cell mass can easily be replaced by the immense self-replicative 
capacity of the parenchyma. However, in situations of severely reduced liver 
function, like in chronic liver disease, the progenitor cell compartment is activated 
(18).  
LPCs then proliferate and migrate to the site of injury where they differentiate to 
replenish the lost cell mass by a series of tightly organised interactions controlled 
by the Notch and Wnt signalling pathways. Activation of the Notch pathway drives 
LPC’s towards a cholangiocytic phenotype, while Wnt-induced inhibition of Notch 
signalisation results in hepatic differentiation (18).The Notch pathway not only plays 
a pivotal role in the cell-fate determination of LPCs, it is also shown to be an 
important mediator of hepatocarcinogenesis. Interestingly, activation or inhibition of 
the different Notch receptors can have both pro- and anti-oncogenic effects (19-22).  
In our previous studies, mRNA expression of actors of the Notch signalling pathway 
was increased in DEN-induced HCC in which PHDs were inhibited. The Notch 
pathway could thus play a role in PHD inhibition-mediated expression of LPC 
characteristics, which would be an attractive therapeutic target.  
Since we observed increased expression of LPC characteristics by inhibiting PHD 
proteins during HCC development, which was associated with increased mRNA 
expression of actors of the Notch pathway, we aimed to investigate if the effect of 
PHD2 haplodeficiency on liver tumour phenotype in advanced DEN-induced HCC 
is preceded by altered LPC and/or Notch expression at early stages of 
hepatocarcinogenesis.  
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A better understanding of the effect of hypoxic conditions early during tumour 
initiation and development, mimicked by PHD2 haplodeficiency, a situation readily 
present during chronic liver disease and tumour relapse, could allow us to pinpoint 
critical markers and events involved in the observed hypoxia-induced 
phenotypic switch, therapy resistance and metastasis. 
2.3. Materials and methods 
Induction of hepatocarcinogenesis in PHD2 haplodeficient mice 
PHD2+/- mice were obtained from the Vesalius Research Center (KUleuven, 
Leuven, Belgium). A heterozygous couple was used for breeding and offspring was 
genotyped using the following primers in a concentration of 10µM: 
ACCTATGATCTCAGCATTTGGGAG, TCAGGACAGTGAAGCCTAGAAACT and 
AAATTCTAATCGTAGCTGATGTGAGC (2). 
To investigate the effect of PHD2 haplodeficiency on early hepatocarcinogenesis in 
mice, 5 week old PHD2+/- and wild type (WT) littermates (129S6 background) 
received weekly intraperitoneal DEN injections (35mg/kg, Sigma –Aldrich, Bornem, 
Belgium).  
This induces microscopic neoplastic cells after 15 weeks, macroscopic nodule 
formation at 20 weeks and HCC after 25 weeks, which was previously reported by 
our group (23). These mice were euthanised after the 5th, 10th, 15th and 17th 
week of DEN, before HCC nodules could form (23). As we have previously shown 
that there is no difference between WT and PHD2+/- healthy mice (2), we 
administered weekly saline injections for 17 weeks to PHD2+/- mice as controls. 
Mice were euthanised at indicated time-points by cervical dislocation, the liver was 
prelevated and divided for histology and qPCR analysis, respectively submerged in 
4% formaldehyde (Klinipath, Olen, Belgium) for paraffin embedding and stored at -
80°C in RNA later (Ambion, Thermo Fisher scientific, Gent Belgium) for RNA 
extraction. 
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All experiments were approved by the ethical committee for animal experiments at 
the faculty of medicine and health sciences of Ghent University Belgium 
(ECD13/61). 
Histological evaluation 
General morphology of liver tissue was assessed using Haematoxylin-Eosin, Sirius 
Red and Reticulin stainings on 5µm sections of paraffin embedded tissue as 
routinely described. Neoplasticity was defined as enlarged cells with normal 
nucleus to cytoplasm ratio (n/c), small cells with increased n/c, enlarged 
pleomorphic nuclei, and binucleation, (pre) neoplastic hepatocytic lesions were 
identified by loss of reticulin staining and sirius red staining was performed to 
identify potential cholangiocytic lesions marked by cholangiofibrosis, as previously 
described (4).  
Cytokeratin 19 immunohistochemistry (1/200 in TBS, ab133496, 
RRID:AB_11155282, abcam, Cambridge, UK) was used to visualize structures of 
the cholangiocytic lineage as well as LPCs.  
Overall CK19 immunoreactivity was measured using Cell D software (Olympus 
Imaging Solutions, Münster, Germany) and to evaluate the LPC response, 5 portal 
areas were centred at a magnification of 400 and all CK19 positive single cells 
were counted.  
Quantitative real time PCR (qPCR) 
RNA was extracted from 20 mg of frozen liver tissue preserved in RNA-later, 
according to the manufacturer’s guidelines (Rneasy Mini Kit, Quiagen, Venlo, the 
Nederlands). 
cDNA was obtained from 1µg RNA using the iScript cDNA synthesis kit (Bio-Rad, 
Nazareth-Eke, Belgium) and quantitative PCR (qPCR) analyses were performed 
using a SYBR green mix (Sensifast Bioline Reagents Ltd, London, UK), using the 
primersets listed in table1. 
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All reactions were run in duplicate; the comparative Cq method was used to 
determine the gene expression which was normalised to reference genes that 
showed stable expression in all samples, as also previously described (2, 4).  
Table 1:primersets 
short Full name Forward primer Reverse primer 
Gapdh 
glyceraldehyde 3 phosphate 
dehydrogenase 
CATGGCCTTCCGTGTTCCT
A 
GCGGCACGTCAGATCCA 
Hmbs 
hydroxymethyl-bilane 
synthase 
AAGGGCTTTTCTGAGGCA
CC 
AGTTGCCCATCTTTCATCA
CTG 
Hprt 
hypoxanthine guanine 
phosphoribosyl transferase 
GTTAAGCAGTACAGCCCC
AAA 
AGGGCATATCCAACAACA
AACTT 
Sdha 
succinate dehydrogenase 
complex, subunit A 
CTTGAATGAGGCTGACTG
TG 
ATCACATAAGCTGGTCCT
GT 
Afp alpha – fetoprotein 
AGCTTCCACGTTAGATTCC
TCC 
ACAAACTGGGTAAAGGTG
ATGG 
CK19 Cytokeratin 19 
GTTCAGTACGCATTGGGT
CAG 
GAGGACGAGGTCACGAA
GC 
Prom1 Prominin 1 
CTCCCATCAGTGGATAGA
GAAC 
ATACCCCCTTTTGACGAG
GCT 
EpCam 
Epithelial cell adhesion 
molecule 
GCGGCTCAGAGAGACTGT
G 
CCAAGCATTTAGACGCCA
GTTT 
Mdr1 Multi drug resistance protein 1 
AGCCGTAAGAGGCTGAG
GCCG 
TCACGTGCCACCTCCGGG
TT 
Jag1 Jagged 1 
ATGCAGAACGTGAATGGA
GAG 
GCGGGACTGATACTCCTT
GAG 
Notch1 Notch 1 
GATGGCCTCAATGGGTAC
AAG 
TCGTTGTTGTTGATGTCAC
AGT 
Notch2 
Neurogenic locus notch 
homolog protein 2 
ATGTGGACGAGTGTCTGT
TGC 
GGAAGCATAGGCACAGTC
ATC 
Notch3 
Neurogenic locus notch 
homolog protein 3 
AGTGCCGATCTGGTACAA
GTT 
CACTACGGGGTTCTCACA
CA 
Hes1 Hairy enhancer of split 1 
ACGTGCGAGGGCGTTAAT
AC 
ACGTGCGAGGGCGTTAAT
AC 
Vegfa 
Vascular endothelial growth 
factor A 
ACTCGGATGCCGACACGG
GA 
CCTGGCCTTGCTTGCTCCC
C 
Glut1 Glucose transporter 1 
GCTTATGGGCTTCTCCAA
ACT 
GTGACACCTCTCCCACATA
C 
Pfk Phosphofructokinase 
GCCGGCTCAGTGAGACAA
G 
TGGCACCTTCAGCAACAA
TG 
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Statistical analysis 
Data were analysed using SPSS23 software (IMB corp, Armonk NY, USA) and 
graphs were illustrated using Graphpad prism 6 software (Graphpad software, inc; 
San Diego CA, USA). Kolmogorov-Smirnov test was used to test for normality. 
Student’s T-test was then performed in case of normality; the Mann-Whitney-U test 
was used for not normally distributed data. P-values ≤0.05 were considered 
significant. All data are presented as mean ±SEM.  
2.4. Results 
PHD2 haplodeficiency does not alter the onset of neoplastic transformation  
We first assessed the effect of PHD2 haplodeficiency on HIF stabilisation by 
assessing the activation of HIF target genes. In early hepatocarcinogenesis, we did 
not observe a significant activation of the hypoxic pathway compared to saline 
control mice, in either genotype. However, HIF downstream targets showed a peak 
RNA expression after 17 weeks of DEN compared to other time-points (Figure 1A, 
C) and in PHD2+/- mice compared to WT mice at the same time-point. (Figure 1B, 
C). To assess general morphology and neoplasia, haematoxylin-eosin, sirius red 
and reticulin stainings were performed.  
Neoplastic cells and reticulin free hepatocytic plates could be observed from 10 
weeks onwards (Figure S1) and neoplastic nodules were observed from 15 weeks 
onwards (Figure S1). Sirius red staining was evaluated as previously described (4), 
and showed no cholangiocytic lesions (Figure S1). No difference was observed 
between PHD2+/- and WT livers at the indicated time points. 
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Figure 1: mRNA expression of HIF target genes 
A. vascular endothelial growth factor alpha (Vegfa), B. phosphofructokinase (Pfk) and C. glucose 
transporter 1 (Glut1) in PHD2
+/-
 and WT mice, euthanised at different time points in 
hepatocarcinogenesis. 
°: p<0.05, °°: p<0.01 and °°°:p<0.001 compared to saline control mice 
*:p<0.05, **:p<0.01 and ***:p<0.001 
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Neoplastic transformation coincides with increased expression of LPC 
characteristics during early hepatocarcinogenesis  
To evaluate the effect of PHD2 haplodeficiency on the expression of LPC 
characteristics, we performed qPCR analysis of Cytokeratin 19 (CK19), Prominin 1 
(Prom1), Epithelial cell adhesion molecule (Epcam), Alpha fetoprotein (Afp) and 
multi drug resistance protein 1 (MDR1). In the early pathogenesis of DEN-induced 
HCC, the mRNA expression of Epcam and Afp was continuously upregulated in all 
DEN treated mice compared to saline control (Figure 2A,B), strengthening the 
evidence for these characteristics as good markers of carcinogenesis (24, 25). 
While no time dependent, PHD2 haplodefiency related effect could be observed 
concerning Epcam mRNA expression (Figure 2A), Afp expression was significantly 
increased after 15 weeks in PHD2+/- mice compared to WT livers. However, this 
increased expression was not maintained after 17 weeks of DEN induction (Figure 
2B). 
Like Afp and Epcam, MDR1 mRNA expression was increased in all groups that 
received DEN compared to saline control (Figure 2E). Furthermore, MDR1 
expression was significantly increased after 15 and 17 weeks of DEN, compared to 
all earlier time points in PHD2+/- mice and compared to WT counterparts, and 
differed significantly between 15 and 17 weeks of DEN in WT livers (Figure 2E). 
Comparison of CK19 immunopositivity between PHD2+/- and WT mice at different 
time points in hepatocarcinogenesis showed an increased number of central vein 
concentrated CK19+ single cells after 15 and 17 weeks of DEN (Figure 3A) and a 
tendency towards increased CK19 expression in PHD2+/- mice at week 15 and 17 
compared to earlier time points and compared to WT counterparts (Figure 3B). 
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Figure 2: mRNA expression of LPC markers 
A. epithelial cell adhesion molecule (Epcam), B. alpha feto-protein (Afp), C. cytokeratin 19 
(CK19),  
D. prominin 1 (Prom1) and E. multi drug resistance protein 1 (MDR1) in PHD2+/- and WT mice 
°: p<0.05, °°: p<0.01 and °°°:p<0.001 compared to saline control mice 
*:p<0.05, **:p<0.01 and ***:p<0.001 
Induction of the hypoxic adaptive response coincides with increased expression 
of Notch3 mRNA in early hepatocarcinogenesis 
The Notch pathway plays a pivotal role in the cell-fate determination of LPCs and 
could also play a role in the increased expression of LPC characteristics observed 
after PHD inhibition. We therefore investigated the mRNA expression of Notch 
markers in early DEN-induced hepatocarcinogenesis in PHD2+/- and WT 
counterparts. We performed qPCR analysis of Notch receptors Notch1, 2 and 3, 
Notch ligand Jagged 1 (Jag1) as well as the main Notch effector gene Hairy 
enhancer of split 1 (Hes1).  
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Figure 3: cytokeratin 19 immunohistochemistry 
A. CK19 immunopositive hepatocytes around the central vein after 15 week of DEN.B.percent 
immunopositivity and average number of CK19 positive cells per portal area in PHD2+/- and WT 
counterparts at different time points in hepatocarcinogenesis. 
CV: Central vein, P: Portal vein, Scale bars: 10µm 
*:p<0.05, **:p<0.01 and ***:p<0.001 
DEN treatment did not induce consistent effects on Notch1 and Notch2 mRNA 
expression (Figure 4A,B). Expression of Notch3, Hes1 and Jag1 mRNA was 
significantly upregulated compared to saline control after 17 weeks of DEN in both 
WT and PHD2+/- livers which coincides with increased expression of markers for 
hypoxia and HIF stabilisation (Figure 1, 4C,D,E). However, no difference could be 
observed between PHD2+/- and WT mice. After 17 weeks mRNA expression of 
Notch3 and Jag1 was also significantly upregulated in PHD2+/- livers compared to 
same genotype livers at earlier time points (Figure 4C,D). 
2.5. Discussion 
We have previously shown that in the DEN mouse model for hepatocarcinogenesis, 
PHD inhibition results in a mixed HCC-CC phenotype, high in LPC characteristics, 
which has been associated with a worse prognosis (2, 4).  
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In this study we aimed to investigate the effect of continuous PHD inhibition in early 
stages of hepatocarcinogenesis. We therefore used PHD2+/- mice that were 
euthanised at different time points to unravel the dynamics of PHD2 haplodeficiency 
during early hepatocarcinogenesis, before nodule formation.  
 
Figure 4: mRNA expression of Notch receptors and Notch target genes 
A. Notch1, B. Notch2, C. Notch3, D. jagged 1 (Jag1) and E.hairy transcriptor of split 1 (HES1) in 
PHD2+/- and WT mice, euthanised at different time points in hepatocarcinogenesis. 
°: p<0.05, °°: p<0.01 and °°°:p<0.001 compared to saline control mice 
*:p<0.05, **:p<0.01 and ***:p<0.001 
We observed that PHD2 haplodeficiency did not result in altered liver morphology 
or onset of neoplastic transformation compared to WT controls. After 17 weeks of 
DEN, we observed a peak expression of HIF target genes, which was more 
pronounced in PHD2+/- livers and coincided with the start of nodule formation as 
shown by histology.  
This allows the assumption that PHD haplodeficiency only affects gene expression 
of HIF target genes in the presence of hypoxia.  
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We found that Afp and Epcam mRNA expression was continuously upregulated, in 
all DEN treated mice, at all observed time points. Indeed, Afp and Epcam have 
been shown to be expressed in hepatocytes during embryogenesis and in cirrhotic 
and cancerous livers (24-28). 
The mRNA expression of CK19, Prom1 peaked after 17 weeks of DEN and 
coincided with increased expression of HIF target genes. Inherently to its 
microscopic structure, the liver can be divided in 3 zones, reflecting the level of 
oxygenation, with the hepatocytes around the central vein most prone to oxygen 
deprivation. The effects of PHD2 haplodeficiency will thus be most apparent in 
those cells. We did observe CK19+ hepatocytes around the central vein from 15 
weeks onwards, further indicating that expression of CK19 could be related to 
increased HIF stabilisation. While it is unclear if CK19 and Prom1 expressing cells 
are progenitor cell derived (29), or dedifferentiated hepatocytes (30), recent studies 
have shown that increased CK19 and Prom1 expression in HCC is related to 
prognosis (29, 31, 32) and recurrence (15, 32). 
Multi Drug resistance (MDR) proteins, which are inherently expressed by stem –
and progenitor cells (33) are drivers of therapy resistance and have been shown 
upregulated in hypoxic conditions (13, 34), attributing to the observed poor 
prognosis for liver cancer with an increased progenitor and/or hypoxic signature. 
Interestingly, MDR1 mRNA expression was increased in all DEN treated mice, 
compared to saline control and in PHD2+/- livers compared to WT counterparts from 
15 weeks onwards, indicating that MDR1 could possibly be a marker for decreased 
PHD activity in early hepatocarcinogenesis. mRNA expression of MDR1 has, to our 
knowledge, not yet been mapped over time in animal models for 
hepatocarcinogenesis and its value as a potential marker for ongoing 
tumorigenesis and increased hypoxic signalling has not yet been explored. 
Activation of the Notch signalling pathway has been shown to be involved in liver -
and other cancers, with contradictory proposed roles (20, 35, 36). 
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 Furthermore, while the distribution and prevalence of different Notch receptors 
have been reported in human healthy and diseased liver(37) and in a murine model 
for experimental HCC (21), little is known about the expression of different Notch 
receptors in relation to phenotype and prognosis in experimental or human liver 
cancer.  
Inhibiting Notch 2 decreased HCC cell proliferation (22) and tumour burden (21), 
while Notch 1 and 2 overexpression in the liver resulted in spontaneous HCC 
development with biliary or LPC characteristics (19, 36, 38).These observations are 
similar to the phenotype observed after PHD inhibition in HCC mice in previous 
studies (2, 4) and as in human tumours recurring after TACE treatment (14, 39). In 
this study we could not show altered Notch1 or 2 receptor mRNA expression during 
early hepatocarcinogenesis. Yet, we previously showed increased Notch2 mRNA 
expression, following PHD inhibition, associated with increased hepatocellular and 
cholangiocellular tumour burden at end stage DEN-induced carcinogenesis (2, 4). 
In PHD2+/- and WT mice, Notch3 expression peaked after 17 weeks of DEN, like 
CK19 and Prom1 mRNA expression, indicating that expression of these markers 
coincides with nodule formation. This is in line with previous data, were Notch3 
overexpressing HCC cells were shown to have increased aldehyde dehydrogenase 
activity (40), characteristic for LPCs (41) and inhibition was shown to overcome 
therapy resistance in HCC cells, increasing sorafenib toxicity(42).  
In conclusion, we used PHD2+/-mice to evaluate the effect of increased HIF 
stabilisation during early hepatocarcinogenesis. However, increased HIF signalling 
was only observed during nodule formation, coinciding with increased mRNA 
expression of LPC characteristics and Notch3. We hypothesise that previously 
observed effects of increased HIF signalling on tumour phenotype manifest during 
tumour growth rather than development and are not preceded by an early LPC or 
Notch signature.  
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Further elucidating possible mechanisms involved in this process could help to 
develop new therapeutic strategies to improve prognosis of patients with tumours 
growing in a fibrotic background, or receiving hypoxia- inducing therapies. 
Supplementary material 
 
FigureS1: representative images for Haematoxylin-Eosin, Reticulin and Sirius red stainings 
showing different groups at different time points. We observe neoplastic cells from 10 weeks 
onwards and loss of reticulin from 15 weeks onwards in PHD2+/- and WT livers. Sirius red 
staining showed no presence of cholangiocytic lesions. Scale bars 200µm 
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2.7. Addendum/Corrigendum 
Materials and methods 
Final primerconcentration for genotyping was 400nM 
A table showing the exact number of mice analysed for each group should be 
added to the materials and methods section (Table A1). 
Table A1: Total number of mice/group 
PHD2+/- Wild type 
Saline 5w 
DEN 
10w 
DEN 
15w 
DEN 
17w 
DEN 
5w 
DEN 
10w 
DEN 
15w 
DEN 
17w 
DEN 
11 8 8 8 7 5 5 6 8 
Official gene symbols were not consequently used in this manuscript, table A2 
provides the correct gene symbol for the used abbreviations. 
Table A2:gene symbols for used abbreviations 
short Gene symbol Full name 
Gapdh Gapdh glyceraldehyde 3 phosphate dehydrogenase 
Hmbs Hmbs hydroxymethyl-bilane synthase 
Hprt Hprt hypoxanthine guanine phosphoribosyl transferase 
Sdha Sdha succinate dehydrogenase complex, subunit A 
Afp Afp alpha – fetoprotein 
CK19 Krt19 Cytokeratin 19 
Prom1 Prom1 Prominin 1 
EpCam Epcam Epithelial cell adhesion molecule 
MDR1 Abcb1b Multi drug resistance protein 1 
Jag1 Jag1 Jagged 1 
Notch1 Notch1 Notch 1 
Notch2 Notch2 Neurogenic locus notch homolog protein 2 
Notch3 Notch3 Neurogenic locus notch homolog protein 3 
Hes1 Hes1 Hairy enhancer of split 1 
Vegfa Vegfa Vascular endothelial growth factor A 
Glut1 Slc2a1 Glucose transporter 1 
Pfk Pkf Phosphofructokinase 
Results 
Y-Axes of graphs illustrating qPCR data show the normalised gene expression. 
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3. GAMMA SECRETASE INHIBITION DAMPENS HYPOXIA-
INDUCED TUMOUR GROWTH AND DECREASES THE 
EXPRESSION OF LIVER PROGENITOR CELL 
CHARACTERISTICS IN HEPATOCELLULAR CARCINOMA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eliene Bogaerts, Annelies Paridaens,Anja Geerts, Hans Van 
Vlierbergheand Lindsey Devisscher  
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3.1. Abstract 
Background 
Treatment for advanced hepatocellular carcinoma is based on decreasing tumour 
vascularisation, thus reducing oxygenation, to dampen tumour growth. However, 
adaptive responses allow cells to respond to low oxygen tension by addressing a 
transcriptional cascade of pro-survival factors, something that has extensively been 
investigated in carcinogenesis. In hepatocellular carcinoma, increased hypoxic 
signalling has been related to increased expression of liver progenitor cell 
characteristics, associated with poor prognosis. Progenitor cell fate is regulated by 
the Notch signalling pathway and several reports have indicated that hypoxic and 
Notch signalling pathways cooperate in the induction of a more aggressive, therapy 
resistant phenotype, correlated with poor prognosis in cancer.  
Methods 
Our aim was to examine the effect of hypoxia on tumour growth, Notch and 
progenitor cell characteristics and the therapeutic potential of Notch inhibition to 
inhibit these effects. We therefore used a HepG2 xenograft mouse model, a 
hypoxic unit (10,5% O2) and a gamma secretase inhibitor. Tumour size and tumour 
expression of markers for hypoxia, proliferation, Notch activation and liver 
progenitor cell characteristics were assessed after 2 weeks of treatment, in 
normoxic and hypoxic conditions.  
Results 
Hypoxia, accompanied by an enhanced hypoxic gene signature, significantly 
increased tumour growth, Notch activation and cytokeratin 19 expression in HepG2 
xenografts. Treatment with the gamma secretase inhibitor decreased Notch 
activation and this was associated with reduced tumour growth in tumours grown in 
hypoxic conditions.  
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Gamma secretase inhibition was also associated with reduced expression of 
hypoxic and liver progenitor cell markers compared to control treatment, both in 
hypoxic and normoxic tumours.  
Conclusions 
Our data show that in vivo activation of the hypoxic adaptive response results in 
increased HCC tumour growth and cytokeratin 19 expression and that this is 
accompanied by Notch pathway activation. In addition, we provide promising pre-
clinical evidence for the therapeutic potential of gamma secretase inhibition as an 
adjuvant to counteract the potential side-effects of hypoxia inducing therapies. 
3.2. Introduction 
Growing tumours are often insufficiently vascularised, resulting in low intratumoural 
oxygen concentrations and activation of the hypoxic adaptive response (1), a 
cellular adaptation mechanism that allows cells to rapidly respond to changes in 
oxygen tension. Upon insufficient oxygen supply, the hypoxia inducible factors 1 
and 2 alpha (HIFα) are stabilised and migrate to the nucleus where a plethora of 
pro-survival genes are transactivated (2), which is crucial for many developmental 
and physiological processes (2, 3). However, in pathological conditions, like in 
carcinogenesis, activation of this hypoxic adaptive response can have detrimental 
effects on prognosis (2, 4). Indeed, in hepatocellular carcinoma (HCC), activation of 
the hypoxic adaptive response is linked to therapy resistance and increased 
invasive and metastatic potential (5). Furthermore, an increased hypoxic signature 
was linked to increased expression of liver progenitor cell (LPC) characteristics in 
primary liver tumours, which has been linked to worse prognosis (6-10).  
Several reports have shown that hypoxia-mediated effects on proliferation, 
migration, invasion and therapy resistance in cancer are moderated by interactions 
between the hypoxia inducible factor (HIF) and NOTCH signalling (11-13).  
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The NOTCH pathway is important in stem cell self-renewal, and plays a specific 
role in binary cell fate decisions (14). The role of NOTCH signalling has been 
studied in HCC (15, 16) and overexpression of NOTCH signalling has been shown 
to induce hepatic tumours with increased expression of LPC markers (17-20), 
which was linked to poor prognosis.  
There are 4 NOTCH receptors and 2 types of ligands described in mammals: the 
NOTCH 1, NOTCH 2, NOTCH 3 and NOTCH 4 receptors, and the jagged and 
Delta ligands. Ligand binding to the N-terminal extracellular domain of the receptor 
triggers cleavage of the C-terminal NOTCH intracellular domain (NICD) (14, 16, 21-
24). NICD cleavage is a two-step process; the second step is mediated by the 
presenilin-gamma-secretase complex. Upon its release into the cytoplasm, NICD 
migrates to the nucleus, binds to CSL (CBF1/Su(H)/Lag-1), and recruits co-
activators to induce NOTCH-dependent gene transcription, of which the 
transcription factor hairy and enhancer of split-1 (HES1) is one of the main target 
genes (14, 24).  
Importantly, primary hepatocytes and HCC cells have been shown able to 
dedifferentiate towards a more LPC-like phenotype in conditions of increased 
stress, like hypoxia (25-28). As current treatment strategies for advanced stage 
HCC are based on depriving the tumour from its oxygen supply, we investigated 
the effect of hypoxia on tumour growth, NOTCH activation and LPC characteristics 
and the therapeutic potential of decreasing NOTCH signalisation by gamma 
secretase inhibition (GSI) in HepG2 transplanted xenografts as a model for HCC 
growth. 
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3.3. Materials and methods 
Animal experiments 
HepG2 cells, derived from human HCC (ATCC, France), were cultured in 
dulbecco’s modified eagle medium (Life Technologies, Belgium) supplemented with 
10% foetal calf serum in 5% CO2 at 37°C and were passaged at ±80% confluency. 
32 homozygous Crl:NU-Foxn1nu nude mice (Charles river, France) were 
subcutaneously injected in the right flank with 7,5x106 HepG2 cells in 100 µL 
matrigel (BD, Belgium), 1/1 in DMEM. 
Tumour volume was measured throughout the experiment using a calliper and 
tumour volume was calculated using the formula
Major axis X Minor axis²
2
(25). 
When average tumour volume reached 300mm³, mice were divided into two 
groups, the first received daily intragastric treatment with a GSI (LY411,575, sigma 
Aldrich, Belgium) at 3mg/kg, as previously described (29, 30) in a 1% 
methylcellulose (MC, sigma, Belgium) solution. The other mice served as controls 
and received equal volumes of the 1% MC solution.  
Sixteen hours after the first GSI treatment, half the mice of each treatment group 
were placed in either the hypoxic unit, which was kept at 10,5% (3), by controlling 
the nitrogen inflow rate (continuously monitored by an oxygen sensor, Biospherix, 
United states), to obtain a hypoxic response, or at 21% O2 in normal airflow. We 
thus obtained 4 groups: 21% O2+MC, 21% O2+GSI, 10,5% O2+MC and 10,5% 
O2+GSI.  
Fourteen days after the first GSI treatment, mice were weighed and euthanized by 
cervical dislocation. Tumours were prelevated, weighed and divided for histological, 
RNA and protein analysis, as previously described (22). As GSI’s have been 
described to induce gastro-intestinal toxicity (31) we also sampled colon tissue, 
which was fixed in a 4% PBS buffered formaldehyde solution (klinipath, Belgium) 
and embedded in paraffin for histological analysis.  
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All animal experiments were approved by the Ethical Review Board for the use of 
experimental animals of Ghent University, faculty of medicine and health sciences 
(ECD approval 15/92). 
Protein analysis 
For histological analyses, hematoxilin-eosin (H&E) staining was performed on 5µm 
paraffin embedded sections as routinely described.  
Endoglin, a marker for endothelial cell activation, was used to evaluate tumour 
vascularisation (goat polyclonal anti mouse endoglin, 1/50, R&D systems, United 
Kingdom). The LSAB-horseradish peroxidase–mediated visualisation (Dako, 
Belgium) was used and overall intratumoural immunoreactivity was calculated 
using Cell D software (Olympus Imaging Solutions, Germany). 
Total protein extract was obtained by homogenizing tumour tissue in RIPA buffer 
(PBS, 0.5% NP-40, 0.5% sodium deoxycholate, 5.5% β-glycerophosphate, 0.1% 
sodium dodecyl sulfate, 1 mM dithiothreitol and complete protease and 
phosphatase inhibitors (Roche Diagnostics, Vilvoorde, Belgium). Total protein yield 
was determined using Bradford reagent (Biorad, Temse, Belgium).  
To evaluate NOTCH activation, we determined the amount of NICD in tumour 
lysates using the Pathscan Cleaved NOTCH1 (Val1744) Sandwich ELISA kit 
according to manufacturer’s instructions (Cell Signalling, The Netherlands), 
absorbance at 450nm was normalised to total protein concentration for each 
sample.  
Quantitative polymerase chain reaction (qPCR) 
RNA was extracted from frozen tumour tissue preserved in RNA-later, according to 
the manufacturer’s guidelines (Rneasy Mini Kit, Quiagen, Venlo, Nederland). cDNA 
was obtained from 1µg RNA using the iScript cDNA synthesis kit (Bio-Rad, 
Nazareth-Eke, Belgium) and real time quantitative PCR (RT-qPCR) analyses were 
performed using a SYBR green mix (Sensifast Bioline Reagents Ltd, London, UK).  
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Primer sets are listed in Table 1, their efficiency was calculated from the slope of a 
standard curve using the following formula: E=10(-1/slope)-1.  
All reactions were run in duplicate and normalized to reference genes that showed 
stable expression in all samples. The comparative Cq method was used to 
compare gene expression between different groups. 
Statistics 
Data were analysed using SPSS21 software (IMB corp, Armonk NY, USA). 
Kolmogorov-Smirnov test was used to test for normality. Student’s T-test was 
performed in case of normality; the Mann-Whitney-U test was used for not normally 
distributed data. P-values ≤0,05 where considered significant. All data 
arepresented as the mean of all cases from two independent experiments (n=6 - 
8/group) ±SEM. 
Table 1: Primersets 
Gene 
symbol 
Full name Forward prirmer Reverse primer 
GAPDH 
glyceraldehyde 3 phosphate 
dehydrogenase 
TGCACCACCAACTGCTTAGC 
GGCATGGACTGTGGTCATGA
G 
HMBS 
hydroxymethyl-bilane 
synthase 
GGCAATGCGGCTGCAA GGGTACCCACGCGAATCAC 
HPRT 
hypoxanthine guanine 
phosphoribosyl transferase 
TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 
SDHA 
succinate dehydrogenase 
complex, subunit A 
TGGGAACAAGAGGGCATCTG 
CCACCACTGCATCAAATTCAT
G 
SLC2A1 
(GLUT1) 
glucose transporter 1 AAATGCTTGTGGATTGAGGG GTCGAAGTCTAAGCCGTTGC 
VEGFA 
vascular endothelial growth 
factor alpha 
TCCTCACACCATTGAAACCA GATCCTGCCCTGTCTCTCTG 
PCNA 
proliferating cell nuclear 
antigen 
GCGTGAACCTCACCAGTATGT 
TCTTCGGCCCTTAGTGTAATG
AT 
KRT19 cytokeratin 19 AACGGCGAGCTAGAGGTGA 
GGATGGTCGTGTAGTAGTGG
C 
SOX9 
sex determining region Y 
(SRY)-box9 
CTCTGGAGACTTCTGAACGA TTGAAGATGGCGTTGGG 
EPCAM 
epithelial cell adhesion 
molecule 
ATAACCTGCTCTGAGCGAGTG 
TGCAGTCCGCAAACTTTTACT
A 
PROM1 prominin 1 AGTCGGAAACTGGCAGATAGC 
GGTAGTGTTGTACTGGGCCA
AT 
HES1 hairy and enhancer of split ACGTGCGAGGGCGTTAATAC GGGGTAGGTCATGGCATGA 
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3.4. Results 
Decreased oxygen tension enhances tumour growth, NOTCH signalization and 
expression of LPC characteristics in HCC xenografts 
We first analysed the effect of hypoxic housing on tumour growth. Relative tumour 
weight and mRNA expression of proliferating cell nuclear antigen (PCNA) were 
increased in mice housed in hypoxic conditions (Figure1A,B) and this was 
associated with increased expression of HIFtarget genes, vascular endothelial 
growth factor alpha (VEGFA) and Glucose transporter protein 1 (GLUT1) 
(Figure1C,D).  
 
Figure 1: activation of the hypoxic adaptive response, increased tumour growth and NOTCH 
activation in tumours from mice housed in hypoxic conditions. 
Relative tumour weight (A), and PCNA mRNA expression (B), HIF target genes: VEGFA (C), 
GLUT1 (SLC2A1, D) and NOTCH target gene HES1 (E) mRNA expression and NICD protein levels 
(F) in tumours grown in normoxic (21% O2) or hypoxic (10,5% O2) mice.  
*:P<0,05; **:p<0,01, ns: not significant). 
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The mRNA expression of HES1, the main NOTCH effector gene (14, 24), and 
NICD protein levels were increased in tumours from mice housed in hypoxic 
conditions, indicating NOTCH pathway activation (Figure 1E,F). 
Since both activation of the hypoxic response and increased NOTCH signalling 
have been related to increased expression of LPC characteristics in HCC, we also 
determined the mRNA expression of LPC characteristics in tumour tissue of mice 
housed in normoxic and hypoxic conditions. mRNA expression was significantly 
increased for cytokeratin 19 (KRT19) but  this increase was not significant for 
Prominin1 (PROM1), Epithelial cell adhesion molecule (EPCAM) and SRY-box9 
(SOX9) (Figure 2).  
In conclusion, hypoxic housing results in the development of tumours with 
increased growth, an increased hypoxic signature and higher expression of LPC 
characteristics. 
 
Figure 2: mRNA expression of LPC markers is increased in tumours grown in mice housed in 
hypoxic conditions 
mRNA expression of KRT19 (A), PROM1 (B), EPCAM (C) and SOX9 (D)(*:P<0,05 ) 
Gamma secretase inhibition reduces NOTCH pathway activation and tumour 
growth in mice housed in hypoxic conditions.  
To evaluate the therapeutic potential of NOTCH inhibition on the effects of hypoxic 
housing, we used daily GSI treatment.  
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This resulted in effective inhibition of the NOTCH pathway in tumours from mice 
housed in hypoxic conditions, as seen by significantly decreased expressions of 
HES1 mRNA and NICD protein levels (Figure 3A,B). Importantly, GSI treatment 
resulted in significantly smaller relative tumour sizes and decreased PCNA mRNA 
expression compared to MC-control treatment in hypoxic conditions (Figure 3C,D). 
This effect of GSI treatment on NOTCH inhibition and tumour reduction was not 
observed under normoxic conditions (Figure 3A-D). Taken together, this data 
shows that GSI treatment reduces Notch signalling and tumour growth in hypoxic 
but not normoxic conditions. 
 
Figure 3: GSI treatment decreases NOTCH signalling and reduces tumour growth in hypoxic 
conditions 
mRNA expression of HES1(A), protein levels of NICD (B), PCNA mRNA expression (C) and relative 
tumour weight (D) are significantly decreased in GSI treated tumours compared to control in 
the 10,5% O2 but not the 21% O2 groups. (*:P<0,05; **:p<0,01; ***:p<0,001) 
Since previous studies have reported GSI-induced gastro-intestinal toxicity (29, 31), 
we analysed body weight, as an indicator of general wellbeing, and evaluated H&E 
stained sections of colon tissue but did not observe any difference between MC 
and GSI groups after 14 days of treatment (Figure 4), indicating that the 
administered dose was not toxic. 
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Figure 4: GSI treatment was not toxic 
Bodyweight after 14 days of GSI treatment (A) and H&E sections of MC (B) and GSI (C) treated 
mice 
Gamma secretase inhibition decreases activation of the hypoxic adaptive 
response and expression of liver progenitor cell characteristics in HCC 
xenografts 
Since NOTCH and hypoxia are interconnected and have both been associated with 
an LPC-like phenotype in liver cancer, we analysed if the effect of GSI treatment 
also affected the expression of HIF target genes, endoglin and LPC markers in our 
xenograft model. The mRNA expression of GLUT1 and VEGFA and endoglin 
immunopositivity was lower in GSI compared to MC control treated tumours both 
under normoxic and hypoxic conditions (Figure 5A-E).  
LPC markers, KRT19 and SOX9, were also decreased in tumour tissue of GSI 
treated mice compared to control treated groups, in both hypoxic and normoxic 
conditions (Figure 5F,G). EPCAM and PROM1 mRNA expression was not 
significantly altered upon GSI treatment (Figure 5H,I).  
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Overall, GSI treatment appeared to decrease the expression of LPC characteristics 
and markers for hypoxia in both hypoxic and normoxic conditions. 
 
Figure 5: GSI treatment impedes activation of the hypoxic adaptive response, reduces tumour 
vascularisation and decreases expression of LPC markers.  
mRNA expression of GLUT1 (SLC2A1, A) and VEGFA (B), quantified percent of tumoural endoglin 
staining (C) and representative images of endoglin stained control (21%O2 +MC)(D) and GSI 
(10%O2+ GSI) treated tumour tissue (E). mRNA expression of KRT19 (F), SOX9(G), EPCAM (H) 
and PROM1 (I). (*:p<0,05; **p<0,01; ***:p<0,001) 
Results 
127 
3.5. Discussion 
In HCC, increased HIFα stabilisation has been linked to increased expression of 
LPC characteristics and poor prognosis (6, 7, 9, 22, 32, 33), and over activation of 
the NOTCH signalling pathway was shown to induce hepatic tumours with an LPC 
signature (16, 17, 20). Several reports have indicated that the HIF and NOTCH 
signalling pathways might cooperate in the induction of a more aggressive and 
therapy resistant phenotype, correlated with poor prognosis in cancer (11, 13, 34-
36). To examine the therapeutic potential of NOTCH inhibition to prevent hypoxia-
induced effects on tumour phenotype we used a HepG2 xenograft mouse model 
subjected to 10,5% O2 housing conditions.  
We observed an activation of the hypoxic adaptive response and increased relative 
tumour size and increased expression of LPC marker KRT19 in tumours from mice 
housed in hypoxic conditions. Our data of increased HES1 and NICD expression 
confirmed previous reports of increased expression of NOTCH receptors and target 
genes upon increased HIFα stabilisation (11, 13, 35, 36). Both HIF and NOTCH 
signalling have independently been associated with an enhanced LPC signature (8, 
17, 20, 22, 28). 
In human patients, hypoxia inducing transarterial chemoembolization treatment 
prior to transplantation was shown to induce an increased LPC signature in 
recurring tumours (8, 9, 33). Moreover, liver specific increased NOTCH signalling 
was shown to induce hepatic tumours with LPC characteristics (16). 
In a previous study we also observed increased expression of LPC characteristics 
in tumours with increased HIFα stabilisation, coinciding with a higher tumour 
burden and increased expression of NOTCH receptors and ligands (22). 
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The association of NOTCH pathway activation and expression of LPC 
characteristics upon increased hypoxic signalling aligns with our observations 
regarding tumour size, KRT19expression and NOTCH pathway activation in 
hypoxic mice. We therefore evaluated the therapeutic potential of NOTCH 
inhibition, using a GSI, known to inhibit the presenilin-gamma secretase complex, 
thereby inhibiting cleavage of NICD and subsequent activation of the NOTCH 
signalling pathway.  
GSI treatment resulted in significantly decreased HES1 and NICD expression, 
associated with impeded tumour growth in hypoxic mice. The expression of HIF 
downstream targets (VEGFA and GLUT) and LPC markers KRT19 andSOX9 were 
reduced upon GSI treatment, both under normoxic and hypoxic conditions. The 
previously reported gastro-intestinal toxicity upon GSI treatment (29, 31) was not 
observed in our treatment regime.  
In line with the proposed link between HIF and NOTCH, the NOTCH signalling 
pathway has previously been shown to be involved in neo-angiogenesis in tumours, 
with contradicting effects (37). We observed decreased endoglin expression in 
tumours from GSI treated mice in both hypoxic and normoxic conditions. As we did 
not observe significant effects of GSI treatment on NOTCH pathway activation in 
normoxia, the observations concerning HIF targets, LPC markers and endoglin 
expression could result from, perhaps more potent, off-target effects of GSI 
treatment.  
Indeed GSI’s have been shown to cleave/activate other membranous proteins 
involved in carcinogenesis, like the epithelial– and neuronal adhesion molecules 
(CDH1 and CDH2)(38). CDH1 is expressed by epithelial cells and is an important 
regulator of cell-cell contact to maintain tissue integrity. Adversely, CDH2 promotes 
cell- matrix contact, potentiating cell motility and invasion and is expressed by 
stem/progenitor cells (like LPCs), mesenchymal cells and cancer cells that 
underwent epithelial to mesenchymal transition (39). 
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Cleavage of the intracellular domain of cadherins releases β-catenin and activates 
the Wnt signalling pathway(39). Wnt signalling was shown to promote HCC growth 
and is activated in well differentiated HCC(34, 40). Interestingly, in hypoxic 
conditions, it was shown that HIFα can bind β-catenin to increase its stability, 
inhibiting the Wnt pathway, increasing HIF signalling and promoting cellular 
adaptation (41, 42). As Wnt signalling is also known to counteract the Notch 
signalling pathway in LPC differentiation (43), this could explain the observed 
discrepancies between the effects of GSI treatment in normoxic and hypoxic 
conditions. 
On the other hand, previous studies have shown that different NOTCH receptors 
and ligands can have antagonistic effects on tumour progression and angiogenesis 
(44-46). Thus, it is possible that the effects we observed in both hypoxia and 
normoxia result from inhibition of a different NOTCH receptor. Future research 
using receptor specific antibodies are necessary to further unravel this issue. 
3.6. Conclusions 
Our data show that in vivo activation of the hypoxic adaptive response results in 
increased HCC tumour growth and KRT19 expression and that this is accompanied 
by NOTCH pathway activation.  
Our data show the therapeutic value of GSI on the growth of HCC subjected to 
hypoxic threats, which might indicate that GSIs could serve as an adjuvant in HCCs 
with a (treatment-induced) increased hypoxic signature. 
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4. DEVELOPMENT OF A MOUSE MODEL FOR INDUCIBLE 
NOTCH1 OVER ACTIVATION IN THE BILIARY COMPARTMENT 
AND THE EFFECT ON LIVER INJURY 
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4.1. Introduction 
The Notch pathway is important in stem cell self-renewal, and plays a special role 
in the control of many binary cell fate choices in embryonic and adult cells (1). 
There are 4 Notch receptors and 2 types of ligands described in mammals: the 
NOTCH1, NOTCH2, NOTCH3 and NOTCH4 receptors and the jagged (JAG) and 
Delta ligands. In short, ligand binding to the N- terminal extracellular Notch domain 
triggers cleavage of the C- terminal Notch intracellular domain (NICD). Upon its 
release into the cytoplasm, NICD migrates to the nucleus, associates with the CSL 
(CBF1/Su(H)/Lag-1) transcription complex, and recruits co-activators, such as 
mastermind–like, to induce Notch-dependent gene transcription (1-3).  
The role of Notch signalling has been extensively studied in liver disease (3, 4). 
NOTCH1 and 2 have shown to be upregulated in the biliary compartment during 
cholestatic liver disease (5-7). Using a hepatocyte nuclear factor1β:Cre mouse, 
researchers also demonstrated that NOTCH2 overexpression in the biliary 
compartment induces severe ductular reactions, by increasing the proliferative 
capacity of the targeted cells (8). Furthermore, upregulation of Notch1 and Notch2 
in hepatocytes and hepatoblasts have been shown to induce hepatocellular 
tumours, high in biliary characteristics in mice (8-10). However, Notch1 inhibition 
drastically decreased HCC but increased the cholangiocellular burden in a mouse 
model for HCC, while Notch 2 inhibition only decreased the HCC load (11). These 
findings imply a different effect of Notch1 on the biliary and hepatocytic 
compartment.  
The biliary compartment consists of cholangiocytes and liver progenitor cells 
(LPCs). LPCs are bipotential stem cells that can differentiate towards hepatocytes 
and cholangiocytes (12-14). Upon severe acute or chronic injury, when hepatocytes 
and cholangiocytes can no longer restore liver function by self-replication, LPCs are 
activated.  
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The Notch signalling pathway plays a pivotal role in the regulation of the cell fate of 
LPCs, which is described by Boulter et al. (5). Cholangiocyte damage attracts 
portal myofibroblasts carrying JAG1 ligands, which activate the Notch signalling 
pathway in LPCs, resulting in biliary differentiation (5). However, during hepatocyte 
damage, macrophage produced WNT, induced by phagocytosis of hepatocytic 
debris, inhibits NOTCH signalling, and pushes LPCs towards the hepatocellular 
lineage (5). While interest in the role of LPCs in liver injury, disease and 
carcinogenesis has expanded in the last decade, the exact role for LPCs and of 
different Notch receptors in liver pathology has not yet been determined (15). 
In vitro, NOTCH 2 and 4 have been shown essential for LPC proliferation, while 
NOTCH 3 was shown to induce hepatocytic differentiation, but no NOTCH1 
mediated effects are described (16). As the aforementioned discrepancies between 
NOTCH 1 inhibition and upregulation studies could be caused by cell specific 
effects, we aimed to investigate the effect of NOTCH 1 upregulation in the biliary 
compartment, and the effect on liver injury and repair.  
4.2. Materials and methods 
Mouse strains 
For inducible Cre expression in the biliary compartment of the liver, transgenic mice 
carrying a tamoxifen inducible CRE (iCre) controlled by an Osteopontin (Opn) 
enhancer- promotor (17) were used. These mice were crossed with mice 
homozygously carrying the conditional Nicd1 and IRES coupled green fluorescent 
protein (GFP) sequence in the murine Rosa26 locus (Rosa26-LoxP-STOP-LoxP- 
Nicd1- GFP, from now on shortened as RosaNicd+/+,strain 008159, Jackson 
laboratory, Maine USA) to obtain OpnCre+;RosaNicd+/+ and OpnCre-; 
RosaNicd+/+  littermate control mice. Mice were genotyped using the following 
primers: CAGGATCTGCACACAGACAGG and GAAATTGCCCTTTTCCTTGC, in a 
final concentration of 200 nM,for the OpnCre construct, 
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and TAA GCC TGC CCA GAA GAC TC, GAA AGA CCG CGA AGA GTT TG and 
AAA GTC GCT CTG AGT TGT TAT, in a final concentration of 500nM, for the 
RosaNicd construct.  
Tamoxifen trial 
Tamoxifen was dissolved in corn oil and administered to 5 week old 
OpnCre+;RosaNicd+/+ and OpnCre-;RosaNicd+/+ (n=3 per group) mice 
intraperitoneally, thrice at a concentration of 250mg/kg with a 36hour interval. All 
mice were euthanized 2 weeks after the final tamoxifen injection. mRNA expression 
of the iCre-recombinase and GFP expression was evaluated to verify genotype and 
to determine efficient iCre-recombinase-mediated Lox excision. We also assessed 
the ratio of full length Notch1 to Nicd- mRNA and evaluated the mRNA expression 
LPC and cholangiocyte markers to further characterise the effect of biliary Nicd 
overexpression. 
Induction of liver injury 
3 week old male OpnCre+;RosaNicd+/+ and OpnCre-;RosaNicd+/+ mice received 
3 250mg/kg tamoxifen injections in 36-hour intervals. After 3 weeks, allowing time 
for full elimination of tamoxifen, mice received a diet containing 0,1% 3,5-
diethoxycarbonyl-1,4-dihydrocollidine (DDC), to induce cholestatic liver injury and 
an LPC response (18), for 3 weeks, after which they were euthanized 
(OpnCre+;RosaNicd+/+: n=8; OpnCre-;RosaNicd+/+: n=11)(Figure 1).  
 
Figure 1: Timeline for DDC- administration 
Tamoxifen injections occurred when mice were 3 weeks of age, 3 weeks after the first 
tamoxifen dose, the DDC diet was started for 3 weeks, after which mice were euthanized and 
sampled. 
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Sampling 
Mice were weighed and anaesthetised using ketamine (100mg/kg) and xylazine 
(10mg/kg). Blood was sampled from the ophthalmic vein and animals were then 
euthanized by cervical dislocation. The liver and spleen were excised and weighed 
and the liver was emerged in 4% PBS buffered formaldehyde (Klinipath, Olen, 
Belgium) for subsequent histological evaluation and in RNA later (ambion, Thermo 
Fisher scientific, Ghent, Belgium) for RNA extraction and qPCR analysis.  
Quantitative real time PCR (qPCR) 
RNA was extracted from 20 mg of frozen liver tissue, according to the 
manufacturer’s guidelines (Aurum total RNA kit, Biorad, Eke Belgium). 
cDNA was obtained from 1µg RNA using the sensifast cDNA synthesis kit (GC 
biotech Alphen aan den Rijn, The Nederlands) and real time quantitative PCR 
(qPCR) analyses were performed using a SYBR green mix (Sensifast Bioline 
Reagents Ltd, London, UK).All reactions were run in duplicate; the comparative Cq 
method was used to compare gene expression between different groups, which 
were normalised to reference genes that showed stable expression in all samples 
(19, 20). A list of all used primer sets is included in Table 1. 
Histology 
General morphology of liver tissue was assessed using Haematoxylin- Eosin and 
sirius red stainings on 5µm sections of paraffin embedded tissue. Cytokeratin 19 
immunohistochemistry (1/200 in TBS, ab133496, RRID:AB_11155282, abcam, 
Cambridge, UK) was used to visualize structures of the cholangiocytic lineage as 
well as LPCs as previously described (19).  
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Table 1: Primersets 
Gene 
Symbol 
Full name Forward primer Reverse primer 
Gapdh 
glyceraldehyde 3 phosphate 
dehydrogenase 
CATGGCCTTCCGTGTTCCTA 
GCGGCACGTCAGATCC
A 
Hmbs 
hydroxymethyl-bilane 
synthase 
AAG GGC TTT TCT GAG 
GCA CC 
AGT TGC CCA TCT TTC 
ATC ACT G 
Hprt 
hypoxanthine guanine 
phosphoribosyl transferase 
GTT AAG CAG TAC AGC CCC 
AAA 
AGGGCATATCCAACAA
CAAACTT 
Sdha 
succinate dehydrogenase 
complex, subunit A 
CTTGAATGAGGCTGACTGT
G 
ATCACATAAGCTGGTCC
TGT 
GFP green fluorescent protein 
AAGCTGACCCTGAAGTTCAT
CTGC 
CTTGTAGTTGCCGTCGT
CCTTGAA 
iCre inducible cre- recombinase TCGCCCTTCTGACTCCAATG 
GGTCTTGGTCCTGCCAA
TGT 
Krt19 cytokeratin 19 
GTTCAGTACGCATTGGGTCA
G 
GAGGACGAGGTCACGA
AGC 
Prom1 prominin 1 
CTCCCATCAGTGGATAGAG
AACT 
ATACCCCCTTTTGACGA
GGCT 
Epcam 
epithelial cell adhesion 
molecule 
GCGGCTCAGAGAGACTGTG 
CCAAGCATTTAGACGCC
AGTTT 
Notch1 Notch 1 
GATGGCCTCAATGGGTACA
AG 
TCGTTGTTGTTGATGTC
ACAGT 
Nicd Notch intracellular domain 
GGACATGCAGAACAACAAG
G 
CAGTCTCATAGCTGCCC
TCA 
Hes1 hairy enhancer of split 1 
ACGTGCGAGGGCGTTAATA
C 
ACGTGCGAGGGCGTTA
ATAC 
Acta2 alpha smooth muscle actin 
CCA GCA CCA TGA AGA 
TCA AG 
TGG AAG GTA GAC 
AGC GAA GC 
Tnf tumour necrosis factor alpha 
CATCTTCTCAAAATTCGAGT
GACAA 
TGGGAGTAGACAAGGT
ACAACCC 
Vcam1 
vascular cell adhesion 
molecule 
TGCCGAGCTAAATTACACAT
TG 
CCTTGTGGAGGGATGT
ACAGA 
 
Statistical analysis 
Data from DDC fed mice was analysed using SPSS23 software (IMB corp, Armonk 
NY, USA). Kolmogorov-Smirnov test was used to test for normality. Student’s T- 
test was then performed in case of normality; the Mann-Whitney-U test was used 
for not normally distributed data. P-values ≤0, 05 were considered significant. All 
graphs were illustrated using Graphpad prism 6 software (Graphpad software, inc; 
San Diego CA, USA), data are presented as mean ±SEM.  
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4.3. Results 
Successful tamoxifen-induced activation of the RosaNicd gene construct 
iCre- recombinase mRNA expression was higher in all OpnCre+ ;RosaNicd+/+ 
mice, compared to OpnCre-;RosaNicd+/+ mice (Figure2A) and GFP mRNA 
expression was induced in OpnCre+;RosaNicd+/+ livers only (Figure2B), indicating 
successful LoxP recombination and stop codon excision.  
This was also confirmed in the increased Nicd expression for unchanged full- 
length Notch1 expression (Figure 2C,D), which is better reflected by the decreased 
Notch1/Nicd ratio (Figure 2E) and increased expression of the major Notch target 
gene hairy enhancer of split 1 (Hes1) (Figure 2F). 
LPC markers prominin1 (Prom1) and cytokeratin 19 (Krt19) were also increased in 
OpnCre+;RosaNicd+/+ mice, compared to OpnCre-; RosaNicd+/+ mice upon 
tamoxifen administration. These data show that tamoxifen has successfully induced 
iCre mediated LoxP excision. 
 
Figure2:mRNA expression of iCre- recombinase, GFP, Notch and LPC markers in healthy 
OpnCre-;RosaNicd+/+ and OpnCre+;RosaNicd+/+ livers after tamoxifen injections. 
iCre (A)and GFP (B) mRNA expression show evidence of succesfull recombination. Gene 
expression of Nicd (C), Notch1(D), the Notch1/Nicd ratio (E)and Hes1(F)show increased Notch 
signallingin OpnCre+;RosaNicd+/+ livers.qPCR analysis of LPC makers Prom1 (G) and Krt19 (H) 
also show increased expression in OpnCre+;RosaNicd+/+ livers. 
no statistics were performed as n=3/group 
OpnCre+;RosaNicd+/+,  OpnCre-; RosaNicd+/+ 
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Effects of biliary Notch1 overexpression in mouse model for cholangiocyte injury  
To assess the effect of biliary Notch1 overexpression in cholangiocyte injury, 
tamoxifen injected mice were fed the DDC diet for 3 weeks. Body weight, liver and 
spleen weight at euthanasia revealed no significant differences between tamoxifen 
treated OpnCre-;RosaNicd+/+ and OpnCre+;RosaNicd+/+ mice (Figure 3 A,B,C). 
Successful iCre-mediated recombination in OpnCre+;RosaNicd+/+ mice was 
confirmed by increased iCre and GFP mRNA expression compared to OpnCre-
;RosaNicd+/+ mice. We could however not observe an altered Notch1 to Nicd ratio 
in full liver lysates (Figure 4F). 
 
Figure 3: general parameters of DDC treated OpnCre-;RosaNicd+/+ and OpnCre+;RosaNicd+/+ 
livers 
OpnCre+;RosaNicd+/+ mice did not differ from OpnCre-;RosaNicd+/+ mice in A. body weight, B. 
relative liver weight and C. relative spleen weight. D.iCre- recombinase and E. GFP mRNA nicely 
show GFP expression is induced in OpnCre+;RosaNicd+/+ mice upon tamoxifen induction. F. We 
did not observe any change in the Nicd/Notch1gene expression ratio. 
OpnCre+;RosaNicd+/+,  OpnCre-; RosaNicd+/+ 
Livers of OpnCre+;RosaNicd+/+ and OpnCre-;RosaNicd+/+ DDC fed mice were 
further evaluated histologically to determine the effect of increased biliary Nicd 
expression on disease progression. Haematoxylin- Eosin staining showed typical 
DDC-induced porphyrin plugs associated with a severe ductular reaction (Figure 4 
A, B) and sirius red staining showed fibrotic strands in these areas (Figure 4 C, D).  
No differences were observed between OpnCre-;RosaNicd+/+ and 
OpnCre+;RosaNicd+/+ mice.  
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These data show that, while we were able to confirm the induction of GFP mRNA in 
DDC fed OpnCre+;RosaNicd+/+ mice, the expected increased Nicd expression, nor 
any effects on general parameters and histology could be detected on whole liver 
compared to OpnCre-RosaNicd+/+ DDC fed mice. To verify that there was no 
difference in the level of fibrosis and hepatic stellate cell (HSC) activation, we also 
performed qPCR analysis for smooth muscle actin alpha (Acta2), a marker for 
activated HSCs and observed no significant difference in mRNA expression 
between both genotypes (Figure 5A).  
 
Figure 4: Histology of DDC treated OpnCre-;RosaNicd+/+ and OpnCre+;RosaNicd+/+ livers  
Top: heamatoxillin eosin staining did not show any difference between Cre+ and Cre- mice. 
Brown dots are porphyrin plugs. Middle: sirius red stained sections show no difference in 
fibrosis between iCre positive and iCre negative mice. Bottom: cytokeratin 19 immunopositivity 
is comparable between iCre+ and iCre- livers. Scale bars: 20µm 
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We next evaluated the mRNA expression of LPC characteristics: Prom1, Krt19 and 
epithelial cell adhesion molecule (Epcam) and an exploratory set of pro- 
inflammatory markers, which have previously been shown increased upon DDC 
feeding, vascular cell adhesion molecule (VCam1) and tumour necrosis factor-
alpha (Tnf). LPC marker Prom1 expression was significantly decreased while we 
did not observe any effects on the expression of LPC/cholangiocyte characteristics 
Epcam and Krt19 (Figure 5C,D) while in OpnCre+;RosaNicd+/+ compared to 
OpnCre-;RosaNicd+/+ controls (Figure 5B). Vcam1 mRNA (Figure 5E) expression 
was decreased in OpnCre+;RosaNicd+/+ mice, but no effect on Tnf mRNA 
expression was observed (Figure 5F). 
 
Figure 5: mRNA expression of markers for fibrosis, LPCsand inflammation in 
OpnCre+;RosaNicd+/+ and OpnCre+;RosaNicd+/+ DDC treated livers 
mRNA expression of A. Acta2, B. Prom1, C. Krt19, D. Epcam, E.Vcam1, and H. Tnf 
OpnCre+;RosaNicd+/+,  OpnCre-; RosaNicd+/+ 
In conclusion, LPC marker Prom1 and inflammatory marker Vcam1 were 
significantly downregulated in OpnCre+;RosaNicd+/+, which could point to a 
decreased ductular reaction. However, no effect could be observed on biliary 
markers (Epcam and Krt19) and inflammatory marker Tnf. 
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4.4. Discussion and future perspectives 
The liver distinguishes itself from other organs by its great regenerative capacity: in 
case of mild or moderate damage or cell – loss, hepatocytes and cholangiocyte can 
replicate to restore cell mass. However, in case of severe acute or chronic injury, 
the progenitor cell compartment is activated.  
These facultative stemcells can migrate to the site of injury and differentiate into the 
damaged cell type. Activation and differentiation of LPCs is tightly regulated by 
Notch and Wnt signalling: in case of severe cholangiocytic damage, the notch 
pathway is activated in LPCs and drives the differentiation towards a cholangiocytic 
phenotype. In case of hepatocytic injury, macrophage derived Wnt signalling 
opposes Notch activation in LPCs, resulting in hepatocytic differentiation (5). 
Generation of a mouse model for inducible biliary Notch1 overexpression 
In this study, we created a mouse model for inducible Nicd and GFP expression 
controlled by an osteopontin promotor enhancer sequence (17), resulting in 
continuous activation of the Notch1 signalling pathway and nuclear GFP expression 
in cells of the biliary lineage. The specificity of OpnCre mouse model we used for 
tamoxifen inducible Cre expression in the biliary lineage has previously been 
examined, using a Rosa26 – lox-stop-lox- yellow fluorescent protein (YFP) reporter 
sequence. YFP expression was shown restricted to LPCs and cholangiocytes and 
was not expressed in liver macrophages, stellate cells or hepatocytes. Efficiency of 
YFP expression was calculated as the ratio of cells co-expressing Sox9 and YFP 
and was 69 – 84%(17, 21).  
For our experiments, this OpnCre mouse was crossed to a RosaNicd mouse, in 
which the intracellular, transcriptionally active domain of the Notch1 receptor and a 
reporter GFP are (over)expressed upon excision of the LoxP flanked stop codon.  
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We first established a protocol for tamoxifen administration to induce GFP mRNA 
expression. Notch overexpression was less apparent, but present in whole liver 
lysates. Since the bulk of liver cells are hepatocytes, this could obscure a clear 
Nicd upregulation in the biliary compartment. 
Future experiments will further evaluate the efficiency of tamoxifen-induced iCre 
activity and the specificity of Nicd and GFP mRNA and protein overexpression by 
evaluating different cell types separately. 
Hepatocytes will first be isolated through density gradient centrifugation, and biliary 
cells can then be sorted from a rest- fraction (containing endothelial cells, 
leukocytes, stellate cells,…) through Epcam positivity using fluorescent- and/or 
magnetic- activated cell sorting (FACS and/or MACS) (22). The efficiency can be 
calculated by evaluating the percentage of Epcam positive cells that co-express 
GFP.  
Constitutive over-activation of Notch 1 signalling in both hepatocytes and 
cholangiocytes or hepatocytes only resulted in the formation of tumours with a 
cholangiocytic signature (9, 10), while antibody-mediated Notch1 inhibition 
decreased HCC burden in favour of cholangiocytic lesions (11).  
To determine if Notch1 signalling has cell-specific effects in the liver, and during 
hepatocarcinogenesis, we will further evaluate the effects of biliary Notch 1 
overexpression on liver physiology and it’s potential to induce hepatic tumours by 
evaluating liver structure of OpnCre+;RosaNicd+/+ mice for neoplastic 
transformation at different timepoints after tamoxifen induction. 
Effects of biliary Notch 1 overexpression on the LPC response in liver injury 
While the involvement of LPCs has been shown in different liver diseases, their 
exact role in the pathogenesis of chronic liver injury has not yet fully been 
unravelled. It is possible that, in case of chronic injury, the LPC-mediated repair can 
go haywire, as seen in the ductular reaction, attributing to disease progression.  
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To further investigate the role of LPCs in disease progression, mice overexpressing 
Nicd in the biliary lineage were submitted to the DDC diet, resulting in a 
cholangiocyte damage-mediated LPC response.  
While histology and mRNA expression of markers for both LPCs and 
cholangiocytes, Epcam and Krt19, showed no effect of increased biliary Notch 
signalling, we did observe decreased expressions of Prom1 and pro- inflammatory 
marker Vcam1. Further analyses should confirm or refute a pro-inflammatory 
response in Cre+ mice.  
Possibly, increasing Notch signalling accelerates the differentiation towards a 
cholangiocytic phenotype, resulting in a faster depletion of Prom1 expressing 
progenitor cells, in favour of cholangiocytes. During liver injury, the liver progenitor 
cell niche contains HSCs and inflammatory cells, contributing to disease 
progression and fibrogenesis. Several studies have shown that reduced pro-
inflammatory signalling attenuates the LPC- response (23-25), and it has been 
suggested that inhibiting proliferation of LPCs also reduces the pro-inflammatory 
response, in turn attenuating the progression of liver disease (26).  
If targeted increased Notch1 signalling can reduce the severity of the LPC 
response, by inducing faster differentiation, and/or decrease the inflammatory 
response, this could thus have implications with regards to disease progression 
and fibrogenesis in cholestatic liver disease. 
To determine whether biliary Nicd overexpression-mediated reduced mRNA 
expression of pro- inflammatory markers and Prom1 affect disease progression, we 
should further investigate the effects at later timepoints in DDC-induced injury.  
However, since the Notch pathway is already over-activated in LPCs in case of 
biliary damage, further increasing Nicd expression might not affect the 
pathogenesis of DDC- feeding-induced damage and/or repair.  
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On the contrary, differentiation of LPCs towards the hepatocyte lineage requires 
inhibition of Notch signalling. Therefore, we can assume that, in mice with 
continuously activated Notch signalling in LPCs, the contribution of these LPCs in 
resolving hepatocytic injury will be impeded. 
As there is some controversy to the importance of the LPC response in the 
progression of liver disease vis-à-vis simply replacing damaged hepatocytes (27, 
28), we will further investigate the role of the LPC response in resolving severe 
hepatocyte injury by using the choline deficient, ethionine supplemented (CDE) diet 
in OpnCre+;RosaNicd+/+ and OpnCre-RosaNicd+/+ mice. These mice will receive 
tamoxifen injections at week 3, and CDE diet will start at week 5 after birth. We will 
investigate the liver after 2 and 4 weeks of CDE diet, and after 2 weeks of recovery. 
We will then evaluate disease progression through histology, and evaluate mRNA 
and protein expression of LPC and inflammatory markers. 
To summarise, we have shown that our tamoxifen regimen successfully induces 
continuous Nicd and GFP expression in the liver, however efficiency and specificity 
are being investigated further. Next we have shown that Nicd overexpression in 
osteopontin expressing cells has no effect on early pathogenesis of cholestatic liver 
disease evaluated by histology. 
However, we did observe a small decrease in stem cell marker Prom1 and pro- 
inflammatory marker mRNA expression, which could result in a decreased time- to- 
progression in DDC-mediated biliary disease and should be further investigated. To 
evaluate the role of LPCs in hepatocyte-mediated liver injury, we will compare the 
effect of CDE feeding in OpnCre+;RosaNicd+/+ and OpnCre-;RosaNicd+/+ 
tamoxifen-induced mice.  
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1. THE EFFECT OF PROLYL HYDROXYLASE DOMAIN INHIBITION 
ON THE EXPRESSION OF LPC CHARACTERISTICS IN THE 
PATHOGENESIS OF HEPATOCELLULAR CARCINOMA 
Liver tumours often arise in a background of chronic liver disease and when 
tumours outgrow their vascular supply, newly formed vasculature is often 
structurally and functionally anomalous. Furthermore, current therapeutic options 
mostly aim at decreasing oxygen and nutrient supply to decrease tumour growth. 
These factors can all contribute to reduced liver oxygenation and activation of 
hypoxic adaptive response in HCC. Increased expression of markers for hypoxia 
has been correlated to increased invasive and metastatic potential, augment 
therapy resistance and induce increased expression of liver and progenitor cell 
characteristics, related to poor prognosis in HCC(1).  
We first aimed to investigate the effect of increased HIFα stabilisation at different 
timepoints of hepatocarcinogenesis on the expression of LPC characteristics and 
prognosis in a mouse model for HCC, as described in chapter 3.1(2). 
Increased HIFα stabilisation at advanced stages of tumourigenesis resulted in 
severely increased expression of LPC characteristics. However, markers of Notch 
signalling and metastasis were not increased at this timepoint. Conversely, HIFα 
stabilisation at intermediate stages of DEN-induced hepatocarcinogenesis 
appeared to have the least detrimental effect on tumour progression and 
phenotype, underlining the importance of early detection and treatment in HCC. 
Interestingly, we show that early hypoxic stimuli have detrimental effects on tumour 
progression, resulting in tumours with an HCC-CC phenotype and increased 
expression of LPC characteristics and markers for metastasis indicating poor 
prognosis (3).  
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This phenotype coincided with increased expression of Notch- related markers that 
were not observed after DMOG treatment at intermediate or advanced stages. 
These results show that tumour cells can possibly be primed by hypoxic conditions 
early on, causing them to be more resistant to growth-or treatment-induced hypoxic 
conditions at later stages. 
Previous studies in our research group have also shown an increased prevalence 
of the more aggressive mixed HCC-CC phenotype, with increased expression of 
LPC characteristics, after DEN-induced HCC in PHD2+/- mice (4). As this 
phenotype strongly resembles the mixed phenotype observed in patients with 
tumours recurring after resection preceded by hypoxia inducing TACE treatment (5, 
6), we wanted to further evaluate early hepatocarcinogenesis in this mouse model, 
to identify possible predictive markers and characterise events leading to the 
developments of mixed phenotype tumours at later stages. We therefore analysed 
DEN-induced HCC in PHD2+/- and WT littermates at early timepoints, before 
nodule formation in chapter 3.2.  
PHD2+/- mice are haplodeficient for the main hepatic oxygen sensor PHD2 (4), 
resulting in a reduced capacity for HIFɑ hydroxylation in normoxic conditions. 
However, data presented show that PHD2 haplodeficiency did not lead to 
increased activation of the hypoxic adaptive response at early timepoints.  
Interestingly, at week 17 the expression of markers for hypoxia peaked in both 
genotypes and expression was higher in PHD2+/- livers compared to WTs. This 
peak expression of markers for hypoxia coincided with increased expression of 
LPC markers KRT19 and Prom1, without differences between PHD2+/- and WT 
mice (3).  
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We also found increased expression of Notch3 at this time points, which aligns with 
results from a previous study, where Notch3 overexpressing HCC cells were shown 
to have increased aldehyde dehydrogenase activity (7), characteristic to LPCs (8). 
We thus concluded that the observed “hypoxia”-induced phenotypical switch we 
previously described at later timepoints is not preceded by an early LPC or hypoxic 
signature.  
Interestingly, Notch1 and 2 mRNA expression was decreased compared to WT 
DEN mice at several timepoints in PHD2+/- mice.As we did not observe any effects 
of this decreased Notch1 and 2 mRNA expression on downstream marker Hes1, it 
is possible that the stability of the intracellular domains of these receptors was 
increased through interaction with HIF1α. Indeed previous studies have shown that 
interaction between HIF1α and the intracellular domain of Notch receptors can 
increase their transcriptional activity, thus increasing Notch signalling without 
increasing the amount of receptors(9, 10). This theory should be tested by 
examining Nicd protein concentrations. 
Moreover, the possibility of a negative feedback loop, decreasing the transcription 
of Notch1 and Notch 2 upon increased Nicd stability should be further explored. 
Especially since we did observe increased Notch1 and 2 mRNA expression, 
following early PHD inhibition in chapter 3.1, and increased Notch2 mRNA 
expression in a previous study using PHD2+/- mice, both associated with increased 
hepatocellular and cholangiocellular tumour burden at later timepoints after DEN-
induced HCC (2, 4). 
Possibly, during nodule formation the suggested negative feedback loop is 
somehow overruled in tumours with increased hypoxic signalling, resulting in 
increased Notch receptor expression and a peak in Notch signalling, which could, 
with respect to our hypotheses, potentially drive the phenotypic changes we have 
previously described.  
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While the distribution and prevalence of different Notch receptors has been 
mapped in human healthy liver, primary sclerosing cholangitis, primary biliary 
cirrhosis and alcoholic liver disease (11) and a murine model for experimental HCC 
(12), little is known about the expression of different Notch receptors in relation to 
phenotype and prognosis in experimental or human liver cancer. Further research 
should thus focus on determining the possibility of a negative feedback loop, 
decreasing the transcription of Notch receptors 1 and 2. A better understanding of 
the mechanisms driving these observations could provide important insights in the 
observed phenotypic switch. 
In this observational study, we could not detect an altered LPC signature in 
PHD2+/- livers before nodule formation as the early neoplastic liver had not yet 
established the more malignant phenotype at early timepoints. Further research 
unravelling the events and pathways involved in the phenotypic switch, like 
studying the involvement of the Notch signalling pathway, could lead to new 
therapeutic targets and strategies to prevent the hypoxia-induced effects on 
prognosis in HCC.  
Using the DEN mouse model has the important advantage that tumours develop in 
a background of inflammation and fibrosis (13), which is similar to most human 
cases of HCC. However, in our study, we did not observe the previously reported 
F2 fibrosis (13); our model could be improved by combining the DEN injections with 
carbon tetrachloride injections, to induce a more fibrotic background (14), more 
adequately mimicking the human situation.  
Furthermore, the pan-PHD inhibitor DMOG was administered intraperitoneally, 
while this ensures fast delivery to the liver via the portal vein, the compound did not 
just act on liver tumour cells, but healthy hepatocytes and stroma alike.  
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It has been shown that PHD inhibition in tumour stroma cells can adversely 
decrease the invasive and metastatic potential of tumours (15). This could help 
explain why expression of markers for metastasis was not increased in tumours 
treated at advanced stages, as we also observed increased expression of HIF 
downstream markers in healthy liver upon DMOG administration. Interestingly, we 
did not observe this effect on downstream HIF targets in PHD2 haplodeficient mice 
until the hypoxic response was activated in both genotypes. For our studies, using 
the haplodeficient mice thus provided the advantage, over chemically induced HIFα 
stabilisation, that only hypoxic (cancer) cells were affected. 
Our results further elucidate the role and dynamics of hypoxia and increased 
stabilisation of HIFα in HCC. We confirm that the induction of the hypoxic adaptive 
response in HCC is related to increased expression of LPC characteristics (2, 3, 
16) and poor prognosis (2). Moreover, the timing at which a hypoxic stimulus is 
introduced could determine the outcome (2), and the observed increased 
expression of biliary characteristics in DEN-induced tumours is not preceded by an 
early LPC or hypoxic signature, but most likely occurs during tumour growth and 
progression (3). These observations can fuel further research to unravel the exact 
mechanism by which HIFα stabilisation affects prognosis and phenotype, to 
discover new therapeutic targets and/or to optimise current strategies. 
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2. NOTCH AS A THERAPEUTIC TARGET AGAINST HYPOXIA-
INDUCED TUMOUR GROWTH AND EXPRESSION OF LPC 
CHARACTERISTICS IN HEPATOCELLULAR CARCINOMA 
The Notch signalling pathway is involved in liver -and other cancers (17-19). Liver 
specific overexpression of Notch signalling was shown to induce HCC with 
increased expression of biliary and LPC markers (18, 20-22), as also observed in 
HCC with an increased hypoxic signature upon pharmacological or physiological 
activation of the hypoxic pathway (4-6, 10, 23, 24). Furthermore, several reports 
have indicated that hypoxia-mediated effects on proliferation, migration, invasion 
and therapy resistance in cancer are mediated by interactions between HIF and 
Notch signalling (1, 10, 25-28).Interestingly, previous studies have also shown that 
Notch 1 and 2 overexpression in hepatocytes results in the development of HCC 
with a strong LPC signature(18, 20, 29), similar to the phenotype we observed after 
early or continuous PHD inhibition in HCC mice (2, 4) and as in human tumours 
recurring after TACE treatment (5, 6).  
As the Notch signalling pathway is suggested to be involved in HIF-mediated 
effects on prognosis, and we, and others, have shown increased expression of 
Notch receptors, ligands and downstream targets coinciding with increased hypoxic 
stimuli, we wanted to explore the therapeutic potential of inhibiting the Notch 
signalling pathway to prevent HIF-mediated effects on growth, prognosis and 
expression of LPC characteristics. A major downside to our first two studies is that 
we used PHD inhibition to mimic a hypoxic response, which, as seen in the first 
study (3), does not always adequately increases HIFα stabilisation and, as seen in 
the second study (2), can result in a, probably compensatory, decreased HIF 
signalling after the effects of the inhibitor wear off.  
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Therefore, in chapter 3.3, we aimed to induce a hypoxic response by decreasing 
the environmental oxygen pressure (16). Taking animal ethics into account, we 
used a xenograft mouse model to investigate the therapeutic potential of Notch 
inhibition, using a GSI, to inhibit the hypoxia-induced effects on tumour prognosis in 
HCC. 
We found that hypoxia-induced a hypoxic adaptive response in HepG2 tumours 
and resulted in increased tumour growth and activation of the Notch signalling 
pathway (16). In line with results from PHD inhibition experiments, these tumours 
also had a higher expression of LPC characteristics (16). GSI treatment decreased 
relative tumour size and Notch pathway activation in hypoxia and decreased mRNA 
expression of LPC characteristics and HIF target genes in tumours in both hypoxia 
and normoxia. These pre-clinical results are promising for the use of GSI’s as an 
adjuvant for tumours with a hypoxic and/or LPC signature, but its merit should be 
tested further in orthotopic chemical/genetic mouse models for HCC.  
There are two major hypotheses concerning the interaction between Notch and 
HIF: i) activation of the hypoxic pathway increases Notch signalling by stimulating 
expression of Notch ligands, receptors and target genes (10, 25, 27), by increasing 
the activity of the gamma secretase complex (30, 31) and/or by stabilising the NICD 
protein (10) and ii) HIFα requires Notch signalling pathway activation to exert its 
effects on tumour prognosis (10, 32). 
The data presented in chapters 3.1 and 3.2support the first hypothesis. As Notch 
pathway activation was higher in tumours grown in hypoxic compared to normoxic 
mice, and GSI inhibition decreased the expression of HIF target genes (and LPC 
characteristics) in both normoxic and hypoxic conditions, this study shows that both 
hypotheses have merit (16). 
However, while the GSI treatment successfully suppressed both Hes1 and NICD 
expression in tumours from mice housed in hypoxia, it resulted in increased NICD 
protein expression in tumours from normoxic mice (16). 
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Further research could help determine whether this is due to poor GSI activity or a 
compensatory increased NICD, Notch receptor or ligand stabilisation or expression 
or caused by off target interactions. Moreover, while HepG2 tumours from mice 
treated with the GSI were significantly smaller compared to vehicle treated mice 
when housed in hypoxia, GSI treatment tended to (non-significantly) increase 
tumour size in normoxia (16). This suggests that the effect of GSI on tumour growth 
might be HIF dependent, which could help to explain the controversial results 
concerning Notch pathway inhibition in cancer (19, 33, 34). These result implicate 
that measuring tumour oxygenation could be a marker for the effectiveness of 
GSI’s (as an adjuvant) in the treatment of HCC, and possibly other solid tumours in 
which a strong Notch signature has been observed, like breast, cervical, 
pancreatic, ovarian and colon cancer (25, 27, 35, 36). A schematic overview of all 
findings is shown in Figure 1.  
 
Figure 1: schematic overview of different interactions we observed in this thesis. 
Black arrows present events we studied in hepatocarcinogenesis, blue arrows present the 
effects of increased HIFɑ stabilisation, purple arrows display the effects of the GSI we used.  
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3. FUTURE PERSPECTIVES 
To unravel the effects of HIF signalling in the pathogenesis of HCC, we first used a 
PHD inhibitor at different timepoints in hepatocarcinogenesis and found that 
administering hypoxia- mimicking treatment in early or advanced stages of HCC 
resulted in tumours with increased expression of LPC characteristics (2). We next 
used PHD2+/-mice to evaluate the effect of increased HIFα stabilisation during 
early hepatocarcinogenesis(3). Interestingly, we found that HIF signalling was not 
increased in PHD2+/- mice until week 17, during nodule formation, when it also 
peaked in WT mice, coinciding with increased mRNA expression of LPC 
characteristics (3). We concluded that previously observed effects of PHD inhibition 
on tumour phenotype manifest during tumour growth and progression rather than in 
early development and are not preceded by an early LPC or Notch signature(3). 
Inhibiting different down-stream mediators in the presence of hypoxia and/or adding 
recombinant proteins possibly involved in HIF-mediated effects, like actors of the 
notch signalling pathway, in the absence of hypoxia in an in vitro setting could help 
elucidate possible mechanisms contributing to our observations. Continuing 
research focussing on the interactions at play in HIF-mediated effects on tumour 
characteristics could help to develop new therapeutic strategies to improve 
prognosis of patients with tumours growing in a fibrotic background, or receiving 
hypoxia- inducing therapies. 
We have shown increased expression of Notch receptor mRNA in the pathogenesis 
of DEN-induced HCC in mice with increased HIFɑ stabilisation (2-4) and inhibiting 
the Notch signalling pathway resulted in decreased tumour size and LPC mRNA 
expression in a Xenograft mouse model (16).  
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We could thus also evaluate the therapeutic potential of Notch inhibition in DEN 
mice, in which PHDs are inhibited to evaluate its potential to decrease tumour 
burden and expression of LPC characteristics in an orthotopic model for HCC with 
biliary characteristics. Furthermore, these long term studies could provide more 
information concerning GSI safety and, in line with previous studies, this setup 
would also allow to investigate the effects of the GSI treatment at different 
timepoints in hepatocarcinogenesis. 
The use of gamma secretase inhibitors is accompanied by several adverse effects 
of which (severe) gastro-intestinal toxicity, resulting in diarrhoea, mostly resulting 
from off target Notch inhibition (36). Furthermore, GSI’s have been shown to cleave 
other membranous proteins like E-cadherin and N-cadherin, which are also 
involved in tumourigenesis (37). This lack in specificity not only contributes to the 
many side effects, it also increases the urge to improve our understanding of the 
role of different Notch receptors, to enable more specific inhibition of Notch 
receptors involved in cancer processes only. Indeed, previous studies using 
specific antibodies in a transgenic model for HCC and an LPC cell line have shown 
distinct roles for each receptor (12, 38). We too have shown that the mRNA of 
different Notch receptors is upregulated at different timepoints in the pathogenesis 
of HCC, and after the shift to a more biliary phenotype.  
While the distribution and prevalence of different Notch receptors has been 
mapped in human healthy liver, primary sclerosing cholangitis, primary biliary 
cirrhosis and alcoholic liver disease (11) and a murine model for experimental HCC 
(12), little is known about the expression and activation of different Notch receptors 
in relation to phenotype and prognosis in experimental or human liver cancer.  
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To further investigate the role of these different receptors in the pathogenesis of 
HCC, and their role in hypoxia-mediated effects on prognosis and phenotype, we 
could use antibodies to specifically inhibit one or more receptors, as it was 
previously shown that inhibiting different Notch receptors had distinct effects on 
tumourigenesis in a mouse model for HCC driven by V-AKT and N-RAS mutations 
(12). Their use in different tumour models and in combination strategies with 
hypoxia inducing compounds like sorafenib or TACE, will allow us to further 
evaluate their potential to inhibit hypoxia-induced therapy resistance, metastasis 
and phenotypic switch(10, 25-27). 
Upregulation of Notch1 and Notch2 in hepatocytes and hepatoblasts have been 
shown to induce hepatocellular tumours, high in biliary characteristics (18, 29, 39). 
However, Notch1 inhibition drastically decreased HCC but increased the 
cholangiocellular burden in a mouse model for HCC, while Notch 2 inhibition only 
decreased the HCC load (12). These findings imply a differential effect of Notch1 
on the biliary and hepatocytic compartment. As Notch1 pathway activation was also 
suggested to be a mediator of HIF-induced effects in tumourigenesis (26, 32), 
further unravelling the role of Notch1 signalling on the biliary compartment is crucial 
for the development of targeted Notch inhibition strategies, to overcome hypoxia-
mediated effects with minimal adverse effects.  
This could be assessed using Notch1 inhibition (using antibodies or shRNA), and/or 
recombinant NICD proteins in HCC, iCC and LPC cell lines in vitro (25, 27). While 
in vivo, this could be approached by upregulating or knocking out Notch1 in specific 
cell types of the liver (18, 29, 40). 
To this effect, we have started the validation of a mouse model for biliary specific 
increased Notch1 signalling in chapter 3.4. 
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 The specificity of OpnCre mouse model we used for tamoxifen inducible Cre 
expression in the biliary lineage has previously been examined, using a Rosa26–
loxP-stop-loxP-YFP reporter sequence and was shown restricted to LPCs and 
cholangiocytes in the liver (41). Efficiency of YFP expression was calculated as the 
ratio of cells co-expressing Sox9 and YFP, and was 69 – 84% (41, 42).  
For our experiments, this OpnCre mouse was crossed to a RosaNicd mouse, in 
which the intracellular, transcriptionally active domain of the Notch1 receptor and a 
reporter GFP are (over)expressed upon excision of the LoxP flanked stop codon 
(43). We first established a protocol for tamoxifen administration to induce GFP 
mRNA expression. Previously shown specificity will be verified by GFP positivity on 
sorted cells using MACS and/or FACS. Efficiency can then be calculated by 
evaluating the percentage of Epcam positive cells that co-express GFP.  
Once this mouse model is fully validated, it can be used to further evaluate and 
characterise the effect of biliary Notch1 overexpression in liver disease and cancer. 
We have performed a preliminary study to assess the effect of increased Notch1 
signalling in LPCs and cholangiocytes in cholestatic liver disease, using the DDC 
diet. While we did not observe altered histological features after 3 weeks, we did 
observe decreased expression of stem cell marker Prom1 and pro- inflammatory 
marker Vcam1, which was previously found upregulated in the pathogenesis of 
DDC-mediated liver injury (44). To assess the effect of this altered gene expression 
on the pathogenesis of cholestatic liver disease, we suggest evaluating the effect of 
increased biliary Notch1 signalling at later timepoints in the DDC feeding regimen, 
and after a period of recovery.  
As inhibition of Notch signalling in LPCs is crucial for differentiation to hepatocytes, 
we expect decreased potential for hepatocytic differentiation; we will therefore use 
our mouse model to investigate the role of LPCs in hepatocyte-mediated injury by 
evaluating the effect of increased Notch1 signalling in the biliary compartment on 
CDE diet-induced liver injury.  
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These experiments have been set up in cooperation with the VUB LIVR lab and 
results are currently being analysed. 
Lastly, as it has been proposed that increased HIFɑ stabilisation affects tumour 
cells through activation of the Notch signalling pathway, we should evaluate the 
effect of biliary Notch1 overexpression in the pathogenesis of hepatocellular 
carcinoma. Increased Notch1 expression promoted by an Afp or Albpromoter (thus 
hepatocytes and cholangiocytes, or hepatocytes alone respectively) resulted in 
spontaneous formation of HCC tumours with biliary/LPC features (18, 29). 
Adversely, antibody-mediated Notch1 inhibition resulted in an increased iCC load in 
a different study (12). Investigating the effect of increased Notch1 signalling in 
LPCs and cholangiocytes in the pathogenesis of HCC, and comparing it to the 
previously described effects of Notch1 overexpression in hepatocytes will allow us 
to determine if there is a cell specific effect of Notch1 signalling in the liver. 
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1. SUMMARY 
Liver cancer is the 5th most common cancer and the second most common cause 
of cancer related death worldwide. Hepatocellular carcinoma (HCC) is the most 
common form of primary liver cancer, which is derived from hepatocytes. Liver 
tumours often arise in a background of chronic liver disease and when tumours 
outgrow their vascular supply, the newly formed vasculature is often structurally 
and functionally anomalous resulting in decreased oxygenation or hypoxia. In 
addition, current therapeutic options also aim at decreasing oxygen and nutrient 
supply to inhibit tumour growth, which aggravates the reduced tumour oxygenation 
and might result in an aberrant activation of adaptive responses.  
Indeed, in conditions of reduced oxygen tension, the prolyl hydroxylase domains 
(PHDs) can no longer hydroxylate the hypoxia inducing factor alpha (HIFɑ), 
causing HIFɑ stabilisation and migration to the nucleus were it transactivates 
several pro-survival genes. This is called the hypoxic adaptive response. Not 
surprisingly, expression of key markers of the hypoxic adaptive response is related 
to increased therapy resistance, higher potential for invasion and metastasis and 
increased expression of liver progenitor cell (LPC) characteristics, all related to 
poor prognosis in HCC. 
Since therapy for HCC inhibits the tumoural oxygen supply, our first aim was to 
elucidate the timepoints at which activation of the hypoxic response pathway has 
detrimental effects with respect to tumour outcome, which may allow us to 
anticipate and adapt current therapeutic strategies. In chapter 3.1, we used a pan-
PHD inhibitor, to induce the hypoxic adaptive response at different timepoints in 
diethylnitrosamine (DEN)-induced hepatocarcinogenesis in mice.   
We observed that increased HIFɑ stabilisation upon pan-PHD inhibition in 
advanced stage HCC resulted in increased expression of LPC characteristics, 
which has been shown associated with poor prognosis.  
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However, pan-PHD inhibition at intermediate stages did not result in increased 
expression of these LPC characteristics and decreased the HCC tumour burden. 
This implies a possible safe window for hypoxia inducing treatments for early- and 
intermediate stage HCC, highlighting the importance of early detection.  
Interestingly, increased HIFɑ stabilisation at the onset of tumour development had 
detrimental effects on tumour progression, with the development of the mixed HCC- 
cholangiocellular (HCC-CC) phenotype and increased expression of LPC 
characteristics, Notch related genes and markers for metastasis. This might imply 
that increased HIFɑ stabilisation during tumour initiation, like in tumours arising in a 
fibrotic liver, can prime future tumour cells to react more aggressively at later 
stages. 
As PHD2 is the main oxygen sensor in the liver, we were interested in the role of 
PHD2 in the observed effects of early pan-PHD inhibition. Indeed, previous studies 
in our lab have shown that DEN induction in PHD2 haplodeficient mice also results 
in the development of the more aggressive mixed HCC-CC phenotype. In chapter 
3.2, we therefore aimed to further evaluate the effects of PHD2 haplodeficiency in 
early DEN-induced hepatocarcinogenesis to characterise the events leading to this 
more aggressive phenotype.  
We found that the hypoxic adaptive response was not activated until tumours 
began to form, at which time mRNA expression of HIF downstream markers, LPC 
characteristics and Notch3 was increased, however without effect of PHD2 
haplodeficiency. We concluded that the PHD2-mediated effects on tumour 
phenotype we previously observed at later timepoints, are not preceded by an early 
LPC signature.  
Hypoxia-mediated effects can be potentiated by interactions between HIF and 
Notch signalling.  
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As we observed increased expression of Notch markers, coinciding with increased 
HIF signalling in our first 2 studies, we next aimed to investigate a potential 
therapeutic role for Notch inhibition to counter the effects of increased hypoxic 
signalling in HCC. In chapter 3.3, we evaluated tumour growth and expression of 
LPC characteristics in HCC xenograft mice, housed in hypoxic conditions and 
treated with a Notch inhibitor (gamma secretase inhibitor, GSI).  
We found that Notch pathway activation and mRNA expression of LPC markers 
were higher in tumours of mice housed in hypoxic conditions and that this was 
associated with increased tumour growth. Importantly, these hypoxia-induced 
effects were reduced upon GSI treatment. Moreover, GSI also decreased mRNA 
expression of HIF target genes and LPC characteristics in normoxic conditions. 
These pre-clinical results are promising for the use of GSI’s as an adjuvant in 
patients who have developed a tumour in a background of fibrosis (characterised 
by hypoxia) and/or receiving oxygen depriving treatment. 
Lastly, to gain further insight in the role of Notch signalling in liver disease and 
cancer, we initiated the validation of a mouse model for inducible, biliary specific 
Notch 1 over-expression, in chapter 3.4, which will allow us to further define the cell 
-and receptor specific effects of Notch signalling in liver disease and cancer. 
In our study, we have shown that hypoxia and Notch signalling are involved in the 
expression of LPC characteristics in mouse models for HCC. We show that 
activation of the hypoxic response is related to increased expression of LPC 
markers, and increased tumour growth which are linked to poor prognosis. 
 Inhibiting the Notch signalling pathway showed promising therapeutic potential to 
inhibit hypoxia-induced effects in a xenograft mouse model for HCC. However, the 
roles of different Notch receptors and their potentially differential effects on various 
cell-types in liver disease and cancer should be further investigated. 
Chapter 5 
172 
2. SAMENVATTING 
Primaire leverkanker is de 5e meest prevalente kanker en de 2e meest dodelijke 
kanker wereldwijd. Kanker van de hepatocyten of hepatocellulair carcinoma (HCC) 
ontstaat meestal in patiënten met chronische leverziekte veroorzaakt door, onder 
andere hepatitis B, hepatitis C, chronisch alcoholisme en leververvetting. Deze 
gaan allen gepaard met verhoogde bindweefselafzetting en dus de vorming van 
fibrose, waardoor de doorbloeding van de lever bemoeilijkt wordt, en de 
zuurstoftoevoer belemmerd wordt. Bovendien steunt de behandeling van HCC 
voornamelijk op het verminderen van de toevoer van nutriënten en zuurstof naar de 
tumor, om zo tumorgroei te vertragen en overleving te verlengen.  
Wanneer cellen verlaagde zuurstofspanning of hypoxie ondervinden, kunnen de 
prolyl hydroxylase domeinen (PHD) de hypoxie induceerbare factor alpha (HIFɑ) 
niet langer hydroxyleren waardoor deze gestabiliseerd wordt en in de nucleus de 
transcriptie van genen betrokken bij cel overleving stimuleert. Dit proces wordt de 
hypoxische adaptieve respons genoemd en de expressie van merkers voor dit 
proces is gerelateerd aan slechte prognose door verhoogde kans op metastase, 
therapieresistentie en expressie van lever progenitor cel (LPC) kenmerken in HCC. 
Aangezien behandeling bij HCC steunt op het induceren van hypoxische 
omstandigheden, gingen we na of het tijdstip waarop verhoogde HIFɑ stabilisatie 
optreedt effect heeft op tumor progressie en karakteristieken. In hoofdstuk 3.1 
gebruikten we een PHD inhibitor om verhoogde HIFɑ stabilisatie te induceren op 3 
tijdstippen: vroeg, intermediair en laat in de pathogenese van HCC.  
Hier observeerden we dat PHD inhibitie op een laat tijdstip, na het ontwikkelen van 
tumor noduli, een verhoogde expressie van LPC merkers uitlokt, terwijl HIFɑ 
stabilisatie op een intermediair tijdstip, tijdens de vorming van tumor noduli, geen 
effect had op de expressie van LPC kenmerken en leidde tot minder HCC 
ontwikkeling in muizen. 
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Deze bevindingen ondersteunen de hypothese dat er mogelijks een “veilig” 
tijdskader voor hypoxie inducerende behandelingen bestaat wanneer het ontstaan 
van neoplastische laesies tijdig gedetecteerd wordt.  
Daarnaast resulteerde activatie van de hypoxische adaptieve respons tijdens 
tumorinitiatie expressie van tot verhoogde LPC karakteristieken, Notch merkers en 
een verhoogde HCC-tumorlast na het ontwikkelen van tumoren. Het is dus mogelijk 
dat verhoogde HIFɑ stabilisatie tijdens tumorinitiatie, zoals kan verwacht worden 
voor tumoren die ontstaan in een fibrotische lever, toekomstige tumorcellen kan 
voorbereiden om later een meer agressief fenotype te ontwikkelen.  
Omdat PHD2 de belangrijkste zuurstofsensor is, wilden we vervolgens nagaan of 
de effecten van PHD- inhibitie voornamelijk PHD2- gemedieerd waren. Inderdaad, 
eerdere studies in ons labo toonden al aan dat HCC inductie in PHD2 
haplodeficiente muizen ook leidt tot verhoogde tumorlast en expressie van LPC 
kenmerken.  
Om meer inzicht te krijgen in de mechanismen die bij de ontwikkeling van dit meer 
agressieve fenotype betrokken zijn, gingen we vervolgens de expressie van HIF, 
LPC en Notch merkers in de vroege tumor- ontwikkeling van deze PHD2 
haplodeficiente muizen na in hoofdstuk 3.2. Hierbij werd geen vroegtijdige 
verhoogde expressie van LPC of hypoxie- gerelateerde kenmerken vastgesteld op 
vroege tijdstippen. Op het laatst bestudeerde tijdspunt, net voor de vorming van 
HCC noduli, observeerden we een sterk verhoogde expressie van HIF, LPC en 
Notch3 merkers. Op dit tijdspunt was er geen verschil in de expressie van LPC 
kenmerken en Notch3 tussen PHD2 haplodeficiente en wild type muizen. We 
concluderen dat de effecten van verminderde PHD expressie waarschijnlijk 
plaatsvinden tijdens vorming van tumornoduli en niet voorafgegaan worden door 
een veranderde expressie van LPC of Notch merkers. 
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Activatie van de Notch signalisatieweg werd al uitvoerig beschreven in HCC, en 
werd vooropgesteld als de effector van HIF gemedieerde effecten op de prognose 
van verschillende kankers. In onze PHD- inhibitie studies observeerden we 
inderdaad een verhoogde mRNA expressie van Notch merkers waardoor we 
vervolgens het therapeutisch potentieel van Notch inhibitie met behulp van een 
gamma secretase inhibitor (GSI) wilden nagaan in hoofdstuk 3.3. Om een 
hypoxische adaptieve respons te induceren werden HCC-xenograft muizen in een 
hypoxische kamer geplaatst. Hier toonden we aan dat tumoren van hypoxische 
muizen groter waren en gekenmerkt waren door verhoogde Notch signalisatie en 
expressie van LPC merkers.  
Belangrijk was dat GSI behandeling deze hypoxie gemedieerde effecten op 
tumoren kon onderdrukken. Bovendien was de behandeling niet toxisch en kon 
gamma secretase inhibitie ook bij normoxie de mRNA expressie van HIF en LPC 
merkers verminderen. Deze preklinische resultaten zijn een belangrijke stap in de 
richting van het gebruik van Notch inhibitoren als bijkomende therapie in 
hypoxische tumoren en/of in combinatie met huidige behandelingen, om nadelige 
effecten van zuurstoftekort in de behandeling van HCC tegen te gaan.  
Om eventuele Notch – inhibitie therapieën verder te optimaliseren moet verder 
inzicht verworven worden in de precieze invloed van verschillende Notch 
receptoren op verschillende celtypes in de evolutie van leverziekte en kanker. 
Daarvoor werd in hoofdstuk 3.4 een muismodel voor induceerbare verhoogde 
Notch1 signalisatie in de biliaire lijn ontwikkeld, waarbij de eerste stappen naar de 
validatie gezet zijn.  
In dit onderzoek werd aangetoond dat hypoxie- en Notch signalisatie betrokken zijn 
bij de expressie van LPC kenmerken in muismodellen voor HCC. We tonen aan dat 
activatie van de hypoxische adaptieve respons gepaard gaat met verhoogde 
expressie van LPC merkers en tumorgroei, beide gerelateerd aan een slechtere 
prognose.  
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Bovendien tonen we aan dat inhibitie van de Notch signalisatieweg veelbelovend 
therapeutisch potentieel biedt om de hypoxie geïnduceerde effecten tegen te gaan 
in een xenograft model voor HCC. Echter, de specifieke rol van verschillende Notch 
receptoren in leverziekte en kanker dient nog verder onderzocht te worden. 
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(2014) 
EASL Young investigator bursary 
Granted by the European association for the study of the liver for participation to 
the EASL monothematic conference in Geneva (2014) 
VVGE aanmoedigingsbeurs 
Granted by the Vlaamse vereniging voor gastro-enterologie for research proposal 
(2013) 
Emmanuel van der Schueren grant 
Granted by the flemmish league against cancer (VLK) for research proposal (2012) 
Research Communication 
Eliene Bogaerts, Femke Wulgaert, Yves-Paul Vandewynckel, Petra 
Vanwassenhove, Xavier Verhelst,  Anja Geerts, Peter Carmeliet, Lindsey 
Devisscher and Hans Van Vlierberghe; The effect of prolyl hydroxylase domain-2 
haplodeficiency on liver progenitor cell markers in early hepatocarcinogenesis. 
POSTER presentation and ORAL poster champ session at United European 
Gastroenterology week, Barcelona, Spain, 2015 
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Eliene Bogaerts, Femke Heindryckx, Lindsey Devisscher, Annelies Paridaens, 
YvesPaul Vandewynckel, Anja Van den Bussche, Xavier Verhelst, Louis Libbrecht, 
Leo A. van Grunsven, Anja Geerts and Hans Van Vlierberghe; Time-Dependent 
Effect of Hypoxia on Tumor Progression and Liver Progenitor Cell Markers in 
Primary Liver Tumors. ORAL presentation at the spring meeting of the Belgian 
Society of Physiology and Pharmacology, Brussels, Belgium, 2015 
Eliene Bogaerts, Femke Heindryckx, Lindsey Devisscher, Annelies Paridaens, 
Yves-Paul Vandewynckel, Anja Van den Bussche, Xavier Verhelst, Louis Libbrecht, 
Leo A. van Grunsven, Anja Geerts and Hans Van Vlierberghe; Time-Dependent 
Effect of Hypoxia on Tumor Progression and Liver Progenitor Cell Markers in 
Primary Liver Tumors. ORAL bullet presentation, Science day Ghent University, 
Ghent, Belgium, 2015 
ElieneBogaerts, Femke Heindryckx, Annelies Paridaens, Yves-Paul Vandewynckel, 
Anja Geerts, Hans Van Vlierberghe; Time dependent effects of hypoxia on liver 
progenitor cell activation in a mouse model for hepatocellular carcinoma. ORAL 
storm presentation at oncopoint, Ghent , Belgium, 2014 
Eliene Bogaerts, Femke Heindryckx, Anja Van den Bussche, Anja Geerts and Hans 
Van Vlierberghe; Hypoxia induces an increased number of progenitor cells in late 
but not in early stages of hepatocellular carcinoma. ORAL presentation presented 
at the Belgian week of gastroenterology, La Hulpe, Belgium, 2014 
Eliene Bogaerts, Aurelie Comhaire , Femke Heindryckx, Annelies Paridaens , 
Yves-Paul Vandewynckel, Peter Carmeliet,  Anja Geerts, and Hans Van 
Vlierberghe; The role of hypoxia on liver progenitor cell activation in a mouse model 
for hepatocellular carcinoma. ORAL presentation presented at the Belgian week of 
gastroenterology, La Hulpe, Belgium, 2014 
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Eliene Bogaerts, Femke Heindryckx, Anja Van den Bussche, Anja Geerts and Hans 
Van Vlierberghe; Hypoxia induces an increased number of progenitor cells in late 
but not in early stages of hepatocellular carcinoma. POSTER presented at EASL 
HCC SUMMIT, Geneva, Switzerland 2014 
Eliene Bogaerts, Aurelie Comhaire, Femke Heindryckx, Annelies Paridaens, Yves-
Paul Vandewynckel, Peter Carmeliet, Anja Geerts and Hans Van Vlierberghe; The 
role of hypoxia on liver progenitor cell activation in a mouse model for 
hepatocellular carcinoma. POSTER presented at EASL HCC SUMMIT, Geneva, 
Switserland 2014 
Student supervision and training 
Aurélie Comhaire:  Influence of hypoxia on differentiation of liver progenitor 
cells in the liver -Master in biomedical sciences (2013) 
 Promotor: Prof. Dr. Hans Van Vlierberghe 
Femke Wulgaert:  The role of hypoxia on expression of liver progenitor cells 
at different timepoints during hepatocarcinogenesis - 
Master in biomedical sciences (2015) 
 Promotor: Prof. Dr. Hans Van Vlierberghe 
Sander Lefere: Biliary Notch1 signalisation in the pathogenesis of fatty 
liver disease - Master of Medicine in Medicine (2015) 
 Promotor: Prof. Dr. Anja Geerts 
Joyca De Temmerman:  The role of correct activation and differentiation of liver 
progenitor cells in different mouse models for liver 
damage – Master in biomedical sciences (2016) 
 Promotor: Prof. Dr. Hans Van Vlierberghe 
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Publication in Journals with peer review 
E. Bogaerts, A. Paridaens, A. Geerts, H. Van Vlierberghe, L. Devisscher. ”Gamma 
secretase inhibition dampens hypoxia-induced tumour growthanddecreases 
expression of liver progenitor cell characteristics in hepatocellular carcinoma in 
vivo” Manuscript in preparation(2016) 
A. Paridaens, S. Raevens, L. Devisscher, E. Bogaerts, X. Verhelst, A. Hoorens, H. 
Van Vlierberghe, L. A. van Grunsven, A. Geerts, I. Colle.“Modulation of the 
unfolded protein response by tauroursodeoxycholic acid counteracts apoptotic cell 
death and fibrosis in a mouse model for secondary biliary liver fibrosis” Accepted to 
international journal of molecular sciences (2016) 
E. Bogaerts, A. Paridaens, X. Verhelst, A. Geerts, P. Carmeliet, H. Van 
Vlierberghe, L. Devisscher.“Effect of prolyl hydroxylase domain 2 haplodeficiency 
on liver progenitor cell characteristics early in mouse hepatocarcinogenesis” Excli 
Journal (2016, nov 11; 15; 687-698; doi: 10.17179/excli2016-607) 
A. Paridaens, S. Raevens, I. Colle, E. Bogaerts, Y.P. Vandewynckel, X. Verhelst, 
A. Hoorens, L.A. van Grunsven, H. Van Vlierberghe, A. Geerts, L. Devisscher. 
“Combination of tauroursodeoxycholic acid and N-acetylcysteine exceeds standard 
treatment for acetaminophen intoxication.” Liver international (2016, Oct 5; doi: 
10.1111/liv.13261. [Epub ahead of print]) 
Y. P. Vandewynckel, C. Coucke, D. Laukens, L. Devisscher, A. Paridaens, E. 
Bogaerts, A. Vandierendonck, S. Raevens, X. Verhelst, C. Van Steenkiste,  L. 
Libbrecht, A. Geerts, H. Van Vlierberghe.“Next-generation proteasome inhibitor 
oprozomib synergizes with modulators of the unfolded protein response to 
suppress hepatocellular carcinoma.” Oncotarget(2016 Jun 7;7(23):34988-5000. doi: 
10.18632/oncotarget.9222) 
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Y. P.Vandewynckel, D. Laukens, L. Devisscher, E. Bogaerts, A. Paridaens, A. Van 
den Bussche, S. Raevens, X. Verhelst, C. Van Steenkiste, B. Jonckx, L. Libbrecht, 
A. Geerts, P. Carmeliet, H. Van Vlierberghe. "Placental growth factor inhibition 
modulates the interplay between hypoxia and unfolded protein response in 
hepatocellular carcinoma." Bmc Cancer(2016 Jan 11;16:9. doi: 10.1186/s12885-
015-1990-6) 
E. Bogaerts., F. Heindryckx, L. Devisscher, A. Paridaens, Y. P. Vandewynckel, A. 
Van den Bussche, X. Verhelst, L. Libbrecht, L. A. van Grunsven, A. Geerts, H. Van 
Vlierberghe (2015). "Time-Dependent Effect of Hypoxia on Tumor Progression and 
Liver Progenitor Cell Markers in Primary Liver Tumors."Plos One(2015 Mar 
20;10(3):e0119555. doi: 10.1371/journal.pone.0119555) 
Y-P. Vandewynckel, D. Laukens, E. Bogaerts, A. Paridaens, A. Van den Bussche, 
X. Verhelst, C. Van Steenkiste, B. Descamps, C. Vanhove, L. Libbrecht, R. De 
Rycke, B. N. Lambrecht, A. Geerts, S. Janssens, H. Van Vlierberghe. "Modulation 
of the unfolded protein response impedes tumor cell adaptation to proteotoxic 
stress: a PERK for hepatocellular carcinoma therapy." Hepatology 
International(2014 Oct 1;9(1):93-104. doi: 10.1007/s12072-014-9582-0) 
Y-P. Vandewynckel, D. Laukens, L. Devisscher, A. Paridaens, E. Bogaerts, X. 
Verhelst, A. Van den Bussche, S. Raevens, C. Van Steenkiste, M. Van Troys, C. 
Ampe, B. Descamps, C. Vanhove, O. Govaere, A. Geerts, H. Van Vlierberghe. 
"Tauroursodeoxycholic acid dampens oncogenic apoptosis-induced by 
endoplasmic reticulum stress during hepatocarcinogen exposure." Oncotarget(2015 
Sep 29;6(29):28011-25. doi: 10.18632/oncotarget.4377) 
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Y-P.Vandewynckel, D. Laukens, A. Geerts, C. Vanhove, B. Descamps, I. Colle, L. 
Devisscher, E. Bogaerts, A. Paridaens, X. Verhelst, C. Van Steenkiste, L. 
Libbrechte, B. N. Lambrecht, S. Janssens, H. Van Vlierberghe (2014)“Therapeutic 
effects of artesunate in hepatocellular carcinoma: repurposing an ancient 
antimalarial agent.” European journal of gastroenterology and hepatology (2014 
Aug;26(8):861-70. doi: 10.1097/MEG.0000000000000066) 
E. Bogaerts., F. Heindryckx, Y. P. Vandewynckel, L. A. Van Grunsven, H. Van 
Vlierberghe (2014). "The roles of transforming growth factor-beta, Wnt, Notch and 
hypoxia on liver progenitor cells in primary liver tumours (Review)." International 
Journal of Oncology (2014 Apr;44(4):1015-22. doi: 10.3892/ijo.2014.2286) 
Y-P.Vandewynckel, R. De Rycke, E. Bogaerts, H. Van Vlierberghe 
(2014)."Intestinal metaplasia in an orthotopic mouse model for hepatocellular 
carcinoma."Digestive and Liver Disease(2014 Dec;46(12):e17. doi: 
10.1016/j.dld.2014.07.003) 
Y-P. Vandewynckel., D. Laukens, A. Geerts, E. Bogaerts, A. Paridaens, X. 
Verhelst, S. Janssens, F. Heindryckx, H. Van Vlierberghe (2013). "The Paradox of 
the Unfolded Protein Response in Cancer."Anticancer Research (2013 
Nov;33(11):4683-94) 
F. Heindryckx, E. Bogaerts, S. Coulon, H. Devlies, A. Geerts, L. Libbrecht, J. M. 
Stassen, P. Carmeliet, I. Colle, H. Van Vlierberghe (2012). "Inhibition of the 
placental growth factor decreases burden of cholangiocarcinoma and 
hepatocellular carcinoma in a transgenic mouse model." European Journal of 
Gastroenterology & Hepatology (2012 Sep;24(9):1020-32. doi: 
10.1097/MEG.0b013e3283554219)
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Het is zover, ik mag eindelijk iedereen bedanken die me de voorbije -iets meer dan- 
4 jaar heeft geholpen met het uitwerken en neerschrijven van deze 
doctoraatsthesis en/of voor me klaarstond om mee te juichen als het goed ging (of 
mopperen als het minder goed ging). Jullie hebben mij en deze doctoraatsthesis 
mee vormgegeven en daarvoor ben ik jullie dankbaar. 
Vooreerst wil ik mijn promotor Hans Van Vlierberghe bedanken. Jij kon me steeds 
inspireren en motiveren en wist precies wanneer ik een schouderklopje of net een 
duwtje in de rug nodig had. Bedankt voor het vertrouwen, je gaf me de vrijheid om 
het project op mijn eigen manier uit te werken waardoor ik na onze meetings 
steeds met een goed gevoel (en een heleboel werk) verder kon. 
Mijn copromotoren, Leo van Grunsven en Lindsey Devisscher wil ik ook heel graag 
bedanken. Leo, voor de fijne samenwerking. Jij stond altijd klaar om mij op weg te 
hepen, jouw praktisch inzicht in de experimenten die we samen uitvoerden en 
kritische hulp bij het schrijven van papers en dit doctoraat hebben er mee voor 
gezorgd dat alles van start tot finish vlot verlopen is. Lindsey, jouw energie en 
engagement zijn een voorbeeld, je zegt waar het op staat, werkt actief mee aan 
een oplossing en blijft vooral doorgaan en motiveren tot het goed is. Zonder jou 
was dit werk niet geweest wat het nu is. MERCI!!!  
Dear members of the examination committee, I would like to thank you for the time 
you have invested in the critical evaluation of this doctoral thesis. Your comments 
and questions have made a substantial contribution to the quality of this work.Prof. 
Johan Vandevoorde, Prof. Hendrick Reynaert, Prof. Anne Hoorens, Prof. Debby 
Laukens, Prof. Inge Mannaerts and Dr. Francesca Fornari, I am gratefull for your 
willingness to participate in the evaluation and the defence of this dissertation.  
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Femke Heindryckx, jij hebt me tijdens mijn masterproef begeleid, jouw 
enthousiasme is besmettelijk en voor ik het goed en wel besefte waren we samen 
projecten aan het schrijven. Ik ben je dankbaar voor de tijd die je in mij hebt 
geïnvesteerd,. Je doet het schitterend daar in Zweden maar ik kijk toch altijd uit 
naar je bezoekjes aan België .  
Annelies Paridaens, met jou heb ik de meeste tijd in onze bureau in Blok B 
doorgebracht, als er iets niet goed ging, of net wel was jij vaak de eerste die dat 
hoorde en dan klaar stond met een beetje perspectief en nuance om terug rust te 
brengen. We hebben de laatste 4 jaar veel over en van elkaar geleerd en vooral 
veel problemen, rare resultaten en mislukte experimenten samen uitgeplozen en 
opgelost. Merci ! Ik wens je volgende maand heel veel succes op jouw  
verdediging, en natuurlijk een mooie toekomst!  
Aan de andere Hepato-ers, merci voor het gezelschap, de vriendschap en jullie 
bereidheid om steeds te helpen als dat even nodig was. Sarah en Sander, ik wens 
jullie veel succes met de volgende etappe van jullie doctoraat en ben overtuigd dat 
het goed komt. Astrid en Sanne, er staat jullie nog heel wat te wachten, ik wens 
jullie heel veel succes, en verwacht nog een paar uitnodigingen voor schitterende 
hepato- doctoraatsverdedigingen de komende 4 jaar . 
Ook een dikke merci aan iedereen van de Gastro, ik heb vele uren doorgebracht in 
het labo en ik wil jullie, Sophie, Sarah, Lien en Tom bedanken voor de leuke 
lunches, drinks, uitstapjes en fijne babbels tijdens de zoveelste incubatiestap.  
In het bijzonder wil ik de laborantes bedanken, Petra, Griet en Hilde. Jullie staan 
steeds klaar om ons te helpen waar nodig, om samen proefopstellingen uit te 
werken en ons geduldig nieuwe technieken aan te leren. Bedankt om als het extra 
druk was een beetje (of veel) werk over te nemen, zonder jullie hulp was ik er niet 
geraakt. 
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Ook bedankt aan alle collega’s die ondertussen elders aan het werk zijn: 
Christophe, Bram, Stephanie, Muhammed, Evi, Hugo en Yves-Paul, jullie hebben 
allemaal bijgedragen aan de leuke sfeer die in Blok B en MRB2 heerst. 
Anja Geerts en Xavier Verhelst, Bedankt voor jullie steun en bijdrage op de 
maandelijkse labovergaderingen.  
In blok B zitten ook nog vele andere groepen, merci aan VRU-ers Charlotte, Lies 
en Laura voor de leuke sfeer in de gang en de toffe lunches. Bart, jij bent vaak een 
klankbord geweest, merci voor je inzichten in kleine en grotere problemen, voor de 
leuke babbels en de vriendschap! Ook voor het TOWO-trio: Tom, Diego en Sam bij 
wie ik steeds terecht kon met kleine of grote technische of computer gerelateerde 
probleempjes, is een extra bedankje op z’n plaats.  
De studenten die ik de voorbije jaren heb mogen begeleiden: Aurelie, Femke en 
Joyca, bedankt voor jullie enthousiasme, hulp en kritische blik op de projecten die 
jullie tot een goed einde hebben gebracht.  
Er zijn ook nog heel wat andere mensen die me naast het werk hebben bijgestaan 
en voor de nodige ontspanning hebben gezorgd. 
Anja, Hanne, Merel, Tacco, Amber, Jelle en Frank, bedankt voor de gezellige 
avonden, de uitstapjes en bierproeverijen. We hebben samen verdriet en blijdschap 
gedeeld en ik ben blij dat ik dit ook met jullie mag delen. YES, YES, YES  
Reisjes, lekker eten (en drinken), geocachen, lange telefoongesprekken, en vooral 
heel veel plezier, Stefanie, ik wens jou heel veel succes met het nieuwe 
appartement, je huisje en Jerzy. Samen koken, marvelmarathons en urenlang 
kletsen over alles en niks, Patricia, jij wordt heel binnenkort mama, en ik kan alleen 
maar zeggen dat kindje van jullie een gelukzak is! Ik kan moeilijk onder worden 
brengen hoeveel jullie voor mij betekenen, ik zie jullie graag!  
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Dries, Liefje, je was er niet bij vanaf het begin van mijn doctoraat, maar ik ben er 
zeker van dat ons verhaal pas begonnen is. Je hebt me dit laatste jaar keihard 
gesteund (en ik heb het je niet altijd gemakkelijk gemaakt), je luistert geduldig naar 
m’n (soms bizarre) gedachtenspinsels, problemen en zorgen. Bij jou vind ik rust. 
Als laatste wil ik mijn familie bedanken. Ik heb het geluk om deel uit te maken van 
een warm nest waar alles bespreekbaar is. Mama & Papa, het maakt jullie niet uit 
wat we doen, zolang het ons gelukkig maakt. Ik denk dat we daar tot nu toe alle 
drie goed in geslaagd zijn. Mijn liefste zusjes (Eefje en Lisa) en schoonbroers 
(Yanick en Timothy), mijn activiteiten op het labo waren voor jullie grotendeels een 
mysterie, maar jullie hebben me toch steeds gesteund. Als laatste wil ik ook mijn 
metekindje Jolien en mijn neefje Loewie bedanken voor hun kinderlijke vrolijkheid 
en optimisme waardoor jullie er steeds weer in slagen om mijn hart te stelen .  
